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When the Emperor Joseph II first listened to The Abduction from the Seraglio, he 
reportedly said, “My dear Mozart, that is too fine for my ears; there are too many 
notes.” When viewing the dauntingly expanding list of focal-adhesion components, it is 
also easy to conclude that there are too many molecular domains in cell–matrix 
adhesions. However, to continue the story, Mozart replied, “I ask your Majesty’s 
pardon, but there are just as many notes as there should be.” 
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The global aim of this thesis was to study the use of microarray technology for the 
screening and identification of biocompatible polymers, to understand physiological 
phenomena, and the design of biomaterials, implant surfaces and tissue-engineering 
scaffolds. This work was based upon the polymer microarray platform developed by the 
Bradley group.   
Polymer microarrays were successfully applied to find the best polymer supports for:  
(i) mouse fibroblast cells and used to evaluate cell biocompatibility and cell 
morphology. Fourteen polyurethanes demonstrated significant cellular adhesion.  
(ii) Analysis of the adhesion of human erythroleukaemic K562 suspension cells onto 
biomaterials with particular families of polyurethanes and polyacrylates identified. A 
DNA microarray study (to access the global gene expression profiles upon cellular 
binding) demonstrated that interactions between cells and some polyacrylates induced a 
number of transcriptomic changes. These results suggested that, during these 
interactions, a chain of cellular changes is triggered, most notably resulting in the down-
regulation of membrane receptors and ligands.  
(iii) Identification of polymers with potential applications in the field of stem cell 
biology. Polymers were identified that showed attachment, promotion and stabilisation 
of hepatocyte-like cells. A polyurethane support (PU-134) was pinpointed, which 
significantly improved both hepatocyte-like cell function and “lifespan”. A second 
project investigated biomaterials that promoted adhesion, growth and function of 
endothelial progenitor cells. A new polymer matrix was identified which contained the 
necessary signals to promote endothelial phenotype and function. This has potential 
application in the creation of blood vessels and the endothelialisation of artificial vessel 
prostheses and stent coatings for improving angioplasty therapy.  
(iv) The study of bacterial adhesion, focusing on the adhesion of food-borne pathogenic 
bacterium Salmonella enterica serovar typhimurium, strain SL1344, and the commensal 
bacterium Escherichia coli, strain W3110. Several polymers were found to support 
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The concept of a biomaterial has been defined as “any substance (other than a drug) 
or a combination of substances, synthetic or natural in origin, which can be used for 
any period of time, as a whole or as part of a system which treats, augments, or 
replaces any tissue, organ, or function of the body”.1 This definition was later refined 
as: “a material conceived to interface with biological systems to evaluate, treat, 
augment or replace any tissue, organ or function of the body”.2 
 
The use of man-made materials for the replacement of body parts dates back to well 
before Christianity, with metals such as gold being used extensively in dentistry.3 “It 
is intuitive to think that, throughout history, anyone who had the misfortune to suffer 
a seriously debilitating injury would have tried to provide themselves with a 
prosthesis adapted to compensate for the anatomical and functional damage sustained, 
and consequently to remedy, at least in part, their incapacity by profiting from such a 
device”.4 As might be expected, evidence of use of biomaterials as prostheses from 
the classical period are scarce, as indeed it is in the early part of the Middle Ages. 
However, there are several representations of prostheses used by disabled and lepers 
dating from the thirteenth to fifteenth centuries, as is shown, for example, in some 
frescoes in the baptisteries of Parma and Florence, and in various works by Brueghel, 
Cornelius, Mastys and Hieronymous Bosch.5 It was only in the sixteenth century, 
however, that the disabled were accorded a new interest, which removed them from 
the isolation to which they had been confined.  
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One of the most important historical studies is found in the work of Ambroise Paré, 
titled “Treatise on Surgery”, in which, for the first time, the problem of prosthetic 
intervention became a medical problem, even if the doctor had recourse only to the 
blacksmith for practical solutions. In this same work, a series of prostheses are 
discussed, such as artificial eyes made of gold, dental prostheses, palatal prostheses, 
prostheses for the tongue, for the outer ear, for the genito-urinary tract and so on.6 
For centuries, iron, wood and leather were the dominant materials used in such 
applications – the use of, for instance, noble metals was rare. In the modern sense, 
biomaterials hardly existed – these materials were simply confined to use outside of 
the organism.4 The advance towards true biomaterials was essentially the result of an 
imaginative leap; people such as Lister, Pasteur, Klebs and Koch who opened a new 
chapter in medicine and indirectly created new hypotheses, because the ‘insides’ of 
the human body became a new territory to be conquered by technology.7 
The use of biomaterials grew rapidly from the end of the nineteenth century, in 
particular after the advent of antiseptic surgical techniques developed by Lister in 
1860.8 The first metal devices for correcting bone fractures were introduced at the 
beginning of the twentieth century; the first replacement prosthesis for an entire hip 
bone was implanted by Wiles in London in 1938,9 and between 1950 and 1960 
polymers were introduced for the replacement of the cornea and blood vessels.10 
In many cases, biomaterials did not begin as materials destined for medical 
applications, but were originally used in other fields, and their entry into the 
biomedical field came as a result of the attempt to solve specific clinical and surgical 
problems. For instance, many new materials were developed in the 1940s and ‘50s as 
a response to military and aerospace needs, and these materials were subsequently 
found to have applications in the field of biomedicine.11 In the 1960s, with advances 
in the fields of chemistry, biology and physics, an entirely new, collaborative area of 
research was initiated purposely for the design of new biomaterials with improved 
biological performance.12 Biomaterials have now contributed to improved quality of 
life for millions of people.3, 4, 12 Over the past two decades focus has shifted 
gradually to generating materials that are considered “bioactive” and elicit a 
controlled response. Current applications include: (a) prostheses for functional 
replacement; (b) supportive scaffolds for guided tissue growth; (c) external 
 - 3 -
communicating devices; and (d) surface coatings.13-16 The biomaterial field continues 
to grow, and new applications are continually being developed.  
In spite of this, there is much still to understand, in particular the biological response 
biomaterials elicit and their role in driving the regeneration of tissue. These relatively 
unresolved areas continue to motivate researchers to develop new products.16, 17 
 
1.1.1 Biomaterial classification 
In accordance with their medical applications, materials can be classified in the 
following way:18 
1. Class І: not used in direct contact with body tissues. 
2. Class ІІ: come into contact with tissues only at the initial stage, or intermittently. 
3. Class ІІІ: constantly in contact with the host tissue. 
It is materials of Class ІІІ which are today defined as biomaterials or biomedical 
materials, and these can be subdivided into three categories according to their 
biological interaction with surrounding tissue:19 
1. Inert materials: these do not produce an immune response in the host and their 
structure remains unaltered in the body after implantation.  
2. Active materials: these have biological function by which they mimic the tissue in 
which they are implanted.  
3. Degradable or resorbable materials: these are slowly biodegraded by the host and 
replaced with the natural, regenerated tissue. 
Another more traditional classification is that which subdivides biomaterials 
according to their chemical-structural characteristics. Following this classification it 
is possible to group different materials into three main categories: metals, ceramics 
and polymers.19 
 
Metals have been used to make simple prosthetic devices to repair the teeth and 
bones.3 However, many metals are vulnerable to corrosion and exhibit brittleness, 
while the release of metal ions may cause adverse tissue reaction. More recently, the 
development of new metal alloys and coatings has led to materials with improved 
corrosion resistance and strength, allowing a wider range of applications such as 
orthopaedic prostheses.20 
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Ceramics (for example, types of glass which may be inert, active or resorbable) are 
widely used inside the body (for instance, the application of bioglass in titanium 
bone replacement)21 and outside the body (for example, lenses, or porcelain crowns 
in dentistry).22 Hydroxyapatite (a naturally occurring ceramic material) is commonly 
used as a filler to replace amputated bone or as a coating to promote bone growth in 
prosthetic implants.23 Although used in medical applications throughout history, the 
disadvantages of ceramics include brittleness and difficulty of manufacture. However, 
over the last two decades some of these issues have been resolved, allowing the 
development of many different classes of bioceramics, which are now used 
successfully as orthopaedic materials.22, 24 
 
Polymers represent the most significant class of biomaterials in medical application, 
as they can be inert, active and resorbable. Polymers can encompass a wide range of 
physical and chemical properties; they can be used either directly or coated onto 
other materials, they are readily functionalised and they can be degraded by the body 
after a desired period. Additionally, they are easily processed and come in many 
different forms including solids, fibres, films and gels.25 As a result, biopolymers are 




Cellulose and derivatives Membranes for dialysis 
Poly(alkyl cyanoacrylates) Wound closure adhesives 
Poly(amides) Sutures 
Poly(carbonates) Device housings 
Poly(ethylene terephthalate) Surgical mesh, vascular prostheses 
Poly(lactic acid) Tendon repair, sutures, drug delivery 
Poly(lactic/glycolic acid) Drug delivery, sutures 
Poly(urethanes) Catheters, vascular prostheses, coatings, heart valves 
Poly(vinyl chlorides) Tubing, blood bags 
Poly(acrylates) Contact lenses, artificial teeth and bone cements 
Ultra high molecular weight poly(ethylene) Hip & knee bearing surfaces 
 
Table 1.1 Some of the most widely used “biocompatible” polymers and their biomedical application. 
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Initially utilised for their mechanical properties and high chemical resistance, 
biocompatible polymers are used as components of prosthetic devices including hip 
implants, artificial lenses, vascular graft and catheters.10, 19 More recently, new drugs 
(protein or peptide-based) have been developed that require novel formulations for 
efficient delivery. This discovery has led to the widespread use of biodegradable 
polymers for the controlled release of drugs and gene therapy. Additionally, in tissue 
engineering, polymers provide structures onto which three-dimensional tissues and 
organs can theoretically be generated.10, 19, 25, 26  
 
1.1.2 Introduction to polyurethanes and polyacrylates 
This thesis focuses principally on two categories of synthetic polymers: 
polyurethanes27 and polyacrylates,28 which are often used because of their 
transparency, resistance to breakage and elasticity.  
 
1.1.2.1 A brief history of polyurethanes and their applications 
Polyurethanes are copolymers composed by diol segments (for example, 
polyethylene glycol (PEG), polybutylene glycol (PTMG)) and hard segments of 
diisocyanates (for example, toluene diisocyanate (TDI), diphenylmethane 
diisocyanate (MDI), hexamethylene 1,6-diisocyanate (HDI)), and contain a 
carbamate or urethane linkage (-NH-CO-O-). They have been widely used in 
medical applications such as tubing, storage bags, dressings, pacemaker coatings and 
precisely controllable drug release from a biodegradable stent coating.29, 30 
Polyurethanes were first made in 1937 by Bayer.31 However, it was not until 1961 
that a polyurethane was first used as a biomaterial as a component in an artificial 
heart valve. This, however, gave disappointing results and was abandoned because, 
after implant, thrombus appeared first on the suture line and then grew and covered 
the entire surface of the artificial heart valve.32 
In recent years, advances have been made in the synthesis of polyurethanes, 
improving their mechanical resistance to abrasion, their tissue-compatibility, and the 
ways in which they are processed. Researchers have sought to alleviate the 
difficulties caused by biodegradability by optimising the ratio between hard 
components and soft in the polymeric chain.29, 33, 34 




1.1.2.2 A brief history of polyacrylates and their applications 
An acrylate polymer belongs to a group of polymers which could be referred to 
generally as plastics. They are noted for their transparency, elasticity and resistance 
to breakage. There are a number of common acrylates whose basic chemical formula 
is showed in Figure 1.1 A. These polymers can be prepared using a wide range of 
acrylic monomers as shown in Figure 1.1 B. These monomers can be polymerized 
by a free radical chain reaction process in which the reaction is started by an initiator 
such as benzoyl peroxide (BPO).35 Polymethyl methacrylate (PMMA) has high 
tensile strength and softening temperature, excellent light transparency, and high 
refractive index.36, 37 
 
 







Figure 1.1 A) Basic chemical structure of acrylates. B) Some acrylate monomers.
 
 
Acrylic acid was first synthesised in 1843 and polymerisation of its esters is well 
known. The polymerisation of acrylics was extensively studied by Rohm in 1901, 
who took out a patent for polyacrylic esters as a paint binder in 1915.38  
Commercial production of acrylate polymers began around 1927 as Acryloid and 
Plexigum and as an intermediate layer in “safety glass” Luglas. Chalmers’ discovery 
of the much harder methacrylate polymers led to the development of PMMA by 
Crawford in the mid 1930s. Around 1934, Rohm and Haas developed the first stable 
acrylic emulsion. A paint laboratory was established in 1938 but aqueous all-acrylic 
emulsions were not commercially produced until the 1950s. In around 1970, weather 
resistant acrylic emulsion paints were developed for use on timber, and have now 
largely replaced oil based paints.38, 39  
 
R1 R2 Name 
H H Acrylic acid 
CH3 H Methacrylic acid 
H CH3 Methyl acrylate 
CH3 CH3 Methyl methacrylate 
CH3 C2H5 Methyl ethylacrylate 
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Polyacrylates have multiple applications in the modern field of biomedicine: PMMA, 
for example, has been used to prepare hard contact lenses, artificial teeth, dental 
fillings and bone cements;37, 40, 41 while polyhydroxyethyl methacrylate (PHEMA) is 
used in soft contact lenses, drug delivery systems and dressings.42, 43  
 
1.1.3 Global biomaterial market and legislation 
The biomaterial market is continually expanding, and the 50 years of successful 
development in materials is reflected in an improved quality of life for countless 
numbers of patients and the economic growth of the industry, now valued in excess 
of $100 billion.12 Due to this constant growth, the EU has felt the need to make 
medical devices conform to high standards of safety.44 Newly developed biomaterials, 
before receiving approval for clinical application development, must, therefore fulfil 
rigorous criteria laid out by governmental authorities and international agencies, for 
example, the US Food and Drug Administration and the International Organization 
for Standardization.15 Testing begins with standard cell-based toxicity assays in vitro, 
which are performed in order to remove high-risk materials, with subsequent testing 
at both a pre-clinical and clinical level to ascertain where, and for how long, the 
material will be present in the body.15, 45 It is standard practice for new biomaterial 
implants to undergo testing for a number of years.46 
 
1.2 Biocompatibility 
Biocompatible materials must, by definition, minimise any adverse reactions 
occurring at the materials interface, and must not provoke problems such as 
embolism, tissue necrosis, or even cancer. The most widely accepted definition of 
biocompatibility has been formulated by Williams as “the ability of a material to 
perform with an appropriate host response in a specific application”.47 Normally 
biomaterials come into contact either with the cardiovascular blood system (the 
intravascular system) or soft and hard tissues (the extravascular system), or with both. 
Thus, in order to design materials for biomedical use, it is necessary to comprehend 
fully the events initiated when a biomaterial is implanted into the body.48 
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1.2.1 Blood response 
An essential aspect of biocompatibility is the complex interaction between blood and 
foreign materials. The greatest danger in any blood-material interaction is 
coagulation with the formation of thrombosis, which may cause embolisms (Figure 
1.2).19 It has been shown that when foreign materials come into contact with blood, 
the surface may, first, adsorb small molecules such as water and ions. This is 
followed by adsorption of blood plasma proteins such as albumin, fibrinogen, 
immunoglobulin G and fibronectin. These proteins may subsequently be desorbed 
and/or displaced by other proteins. This first adsorption on a biomaterial’s surface 
determines the initiation of a complex sequence of reactions. This can lead to the 
coagulation of platelets as well as their fragments (microparticles). 
This set of reactions initiates the coagulation cascade, which culminates in the 
production of thrombin (Factor II), which acts on fibrinogen, converting it into the 
insoluble protein fibrin, which forms fibres. Blood cells and platelets get caught up in 
the fibres, forming a clot. The generation of thrombin occurs via two pathways, 





Figure 1.2 General scheme of blood coagulation with formation of thrombosis. 
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The intrinsic pathway begins with the interaction of Factor XII, caused by contact 
with abnormal surfaces produced by injury. The extrinsic pathway is triggered by 
trauma, which releases Tissue Factor (TF) VII. Both pathways converge to a 
common pathway leading to the formation of thrombin, which in turn induces the 
formation of fibrin monomers from fibrinogen, and consequently the adhesion, 




Figure 1.3 Scheme of alternative intrinsic and extrinsic pathways that provide routes for the 
generation of factor X, by activation of Factor XII. Inactive forms of clotting factors are shown in red; 
their activated counterparts are in yellow; stimulatory proteins that are not themselves enzymes are 
shown in blue boxes. A striking feature of this process is that the activated form of one clotting factor 
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1.2.2 Tissue response  
Materials implanted in tissues always generate a response. The major tissue response 
in the extravascular system is inflammation, which starts as a local reaction to injury, 
insult or infection (Figure 1.4).49 The classic foreign body response involves initially 
a non-specific adsorption of plasma proteins onto the surface of the implanted 
material. These proteins then promote the adhesion of blood cells, which may 
subsequently instigate a proinflammatory process through the up-regulation of 
certain cytokines with the migration of neutrophils/macrophages to the implant site. 
As a consequence of this process, monocytes often differentiate into macrophages as 
the cell attempts through phagocytosis to clear the wound site of foreign bodies, dead 
cells and bacteria. The macrophages in turn fuse in order to form multinucleate giant 
cells. These giant cells then coordinate the secretion of derivative agents such as 
superoxides and free radicals that can damage the implant. The last stage of the 
reaction to a foreign body occurs when a poorly vascular collagen shell forms around 
the foreign body in order to separate it from the host tissue. This isolation of the 
foreign material can provoke several unwanted reactions such as chronic pain, device 




Figure 1.4 Illustration of the classic foreign body response. 
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1.2.3 Strategies to enhance biocompatibility 
There are several strategies for enhancing the biocompatibility of foreign surfaces, 
such as controlling protein adsorption by regulating the hydrophilicity or 
hydrophobicity of the material surface, and increasing cellular recognition by 
controlling the interaction of extracellular matrix (ECM) proteins with cell-surface 
receptors such as integrins and selectins.51 In the case of foreign materials only 
interacting with blood, haemocompatibility is enhanced by interfering directly with 
the coagulation cascade and inflammatory response. A widely used methodology for 
this purpose consists of immobilising the anticoagulant heparin onto the surface of 
implanted materials, resulting in the neutralisation of thrombin.52 
 
1.2.3.1 Controlling protein adsorption 
Adsorption of proteins onto hydrophilic surfaces is usually limited and reversible, 
whereas proteins irreversibly bind onto hydrophobic surfaces. Therefore, a typical 
method for reducing protein adsorption consists of increasing the hydrophilicity of 
the surface by functionalisation of the surface with hydrophilic polymers such as 
PHEMA, PEG and their derivatives in both a covalent and non-covalent manner 
using methodologies such as grafting,53 coating, and self-assembly.48 
 
Instead of functionalising the surface of materials, another approach aims to improve 
biocompatibility by producing bulk polymers which are able to control protein 
adsorption.  
 
Hydrogels are water-swollen polymeric networks prepared from hydrophilic 
monomers, which are insoluble due to the presence of chemical or physical cross-
links.42 They have been widely used as biomaterials as they present tissue-like 
properties and good biocompatibility.50, 54These hydrogels can be synthesised from 
cross-linked acrylate and methacrylate monomers Figure 1.1 B (Chapter 1.1.2.2), or 
from the crosslinking of polymers such as PEG with polyhydroxy acids (PHA)55 or 
polylactic acid (PLA).56 Modification of synthetic procedures, such as 
polymerisation conditions and amount of cross-linker, can afford easy control of a 
wide range of properties. 
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Microdomain containing polymers are co-polymers composed of both hydrophilic 
and hydrophobic moieties. The presence of “microdomains” allows these materials to 
control protein adsorption more easily. These materials have been shown to provide 
reversible platelet attachment while preventing platelet activation.54 The most 
popular of these polymers are polyurethanes, which contain both hard (hydrophobic) 
and soft (hydrophilic) segments (Chapter 1.1.2.1). Other examples are co-polymers 
of hydroxyethylmethacrylate (HEMA) and styrene.40 An advantage of these co-
polymers over hydrogels is that they demonstrate good elasticity, tensile strength and 
durability and for this reason, these materials are frequently used in blood-contacting 
applications where long-term non-thrombogenicity is required.57 
 
1.3 Polymer microarrays 
1.3.1 A brief history of microarrays 
In science a microarray is a tool for analysing a group of molecules or materials 
arranged as microscopic spots in a regular pattern on either a membrane or, more 
typically, a glass slide. The molecules or materials in an array are attached to their 
support, in order to be able to co-register each spot on the array with a specific 
material entity.  
The first microarrays as defined above were developed in 1991 by Fodor and co-
workers, who fabricated a miniaturised array of oligopeptides, which was employed 
to screen for potential binding sequences with a monoclonal antibody.58 The same 
research group later developed a strategy for the rapid synthesis and analysis of DNA 
sequences.59 Prior to Fodor’s discovery, in 1987 a related technology had already 
been described as a refinement of Southern blotting by Kulesh. This research group 
made an array by spotting cDNAs onto filter paper with a pin-spotting device in 
order to identify interferon-modulated proliferation-related cDNA sequences.60 In 
1995, Schena described a miniaturised microarray for gene expression measurements 
of 45 Arabidopsis genes by simultaneous two-colour fluorescent hybridisation.61 
Two years later, a high-density DNA microarray of the complete eukaryotic genome 
(Saccharomyces cerevisiae) was published.62 Since this time, DNA microarrays have 
dramatically accelerated many types of investigation, creating a powerful tool for 
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gene expression profiling, comparative genomic hybridization,63 SNP detection,64 
and in discovering useful biomarkers of human diseases.65, 66 
Over the last two decades, researchers have formulated alternative uses for the 
multiple properties of arrays, and new areas have been developed, such as protein,67 
small-molecule68 and carbohydrate microarrays.69 Arrays have also been exploited in 
an increasing number of fields, such as the characterisation of tissue analysis,70 and 
cell-based screening.71 
 
1.3.2 A brief history of polymer microarrays 
Polymers, as already stated, are essential in the area of biomaterials and have been 
used in a myriad of applications.19, 25 However, the nature of the interactions between 
a polymer and its biological environment is highly complex. For example, due to the 
multiplicity of the cell surface components (lipid bilayer, membrane proteins, 
glycoproteins and small molecules), the principles of immobilisation of cells on a 
surface are more difficult to predict than the immobilisation of single biomolecules. 
In fact, cell-biomaterial interactions should be considered as the result of a wide 
range of co-operative and dynamic non-covalent interactions (ionic bonds, 
hydrophobic interactions, hydrogen bonds, Van der Waals forces and dipole-dipole 
bonds) between these components and a given substrate. Surface characteristics, such 
as hydrophobicity, roughness and charge, and chemical composition, are all known 
to play key roles in regulating the response of cells that interact with biomaterials.72 
Due to the immense diversity of cells present in our bodies, there is no universal 
material suitable for studying cellular adhesion. It would appear, however, that the 
most efficient strategy for binding cells on polymers is to try to predict which 
properties each type of cell requires for binding and manufacture the polymer 
accordingly.73 
There has been a long-term reliance in the biomaterial industry on the use and study 
of conventional materials. Traditional methods of screening, identification and 
testing of new polymers are slow, yet over recent years the field of automated and 
parallel screening of polymers has grown enormously.  
The use of a high throughput approach, such as microarraying, to allow the rapid 
screening of chemically diverse polymers offers an important tool for finding 
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correlations between the design and performance of such materials.74, 75 
The use of polymer microarrays for cell-biomaterial screening has recently been 
developed by two independent research groups, Langer (2004)76 and Bradley 
(2004).40  
 
The Langer approach:76  
Langer and co-workers reported polymer microarrays for applications with human 
embryonic stem cells (hESCs). First, they mixed monomers using a liquid handling 
system and then contact printed in triplicate 576 different combinations of 25 
different acrylates, diacrylates, dimethacrylate and triacrylate monomers with a 
radical initiator onto a layer of PHEMA, on top of an epoxide-coated slide. These 
spots were then exposed to UV irradiation in order to polymerise them. Using this 
method 1,728 (576 x 3) polymer spots were manufactured in order to study the 
interaction between the newly formed polymers and the growth of hESCs.  
In general, cell attachment and spreading to display typical cellular morphology was 
supported by the majority of these materials. However, certain monomers inhibited 
hESC cell attachment and spreading, in particular monomers m-phenylene diacrylate, 
3-methacryloyloxy-2-hydroxypropyl methacrylate and 6-acryloxy-perfluorohexyl 
acrylate. To examine the polymer effect on other cell types, Langer and co-workers 
tested the arrays with C2C12, an embryonic muscle cell line. Unlike the hESCs, 
C2C12 cells attached to and grew on almost all the materials, including those 
containing 70% monomers m-phenylene diacrylate and 6-acryloxy-perfluorohexyl 
acrylate. 
An important aspect of Langer’s approach was related to the equipment used for 
polymer synthesis and the fabrication of microarrays. Langer discussed in detail the 
problems and solutions of liquid handling in a highly miniaturised manner, 
necessitating significant modification of existing robotic technology, including: 
1. The effect of viscous acrylate monomers on liquid handling equipment (during the 
pre-formulation of monomers) and printing and pin washing (during monomer 
contact printing). 
2. The radical polymerisation of monomers, which can be subject to oxygen-
mediated inhibition. This is particularly significant at small volumes, and as a 
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consequence printing must be performed in an atmosphere of humid argon. 
3. Due to the difficulty of controlling the speed of monomer spreading, in some cases 
irregular polymer spots form. 
4. The PHEMA would mix with the polymers being synthesised would generate a 
blent of all the polymers being synthesied. 
 
In 2005, in order to study human mesenchymal stem cells (hMSCs)-biomaterials 
interaction, Langer and co-workers generated polymer microarrays by blending 24 
different polymers in various proportions, producing 1152 polymer blends.77 
 
The Bradley approach:  
1. Contact printing of pre-formed polymers:40, 78-80 
The Bradley research group developed an alternative approach via the contact 
printing of pre-formed polymers (from a polymer library) onto cytophobic (agarose-
coated) slides to generate well-defined polymer microarrays. All the polymer 
libraries used were prepared on gram-scale by parallel synthesis, and all individual 
members were fully characterised by gel permeation chromatography (GPC), 
differential scanning calorimetry (DSC) and contact angle measurements. Before 
printing in a microarray-type format each library member was dissolved in a 
common, non-volatile solvent 1-methyl-2-pyrrolidinone (NMP) in order to minimise 
the formation of so-called “rings” during evaporation. Furthermore, a number of 
printing parameters, such as inking and printing time, were optimised in this process 
to ensure uniformity of polymer spot within the array. Since each library member 
was synthesised on a scale that allowed characterisation prior to array fabrication 
there was full confidence in any structure-activity relationship generated while 
allowing immediate scale-up following polymer identification. Several cell lines 
were studied, such as stem cells, primary cells, suspension cells, adherent cells, and 
prokaryotic cells. 
 
2. Inkjet fabrication of polymer microarrays:81 
More recently an inkjet printing approach was developed by the Bradley group in 
order to prepare, in a highly miniaturised manner, polymer microarrays on glass 
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slides, through the use of in situ pico-nano litre-scale polymerisation (Figure 1.5). 
This method used a redox initiator system and inkjet printing to print rapidly both an 
initiator and monomers that contained the reductant onto pre-treated glass slides.  
This system allowed 2280 hydrogels to be prepared, while the non-contact nature of 
the printing approach gave excellent morphology and size control (spot diameters of 
polymer printed 220 µm). This allowed rapid identification of “smart hydrogels” for 




Figure 1.5 The two approaches used for inkjetting mediated hydrogel (synthetic) on a microarray via 
in situ polymerization.81 
 
 
The main disadvantage of this method, however, was that it was limited to the use of 
water-compatible polymerisations.  
These difficulties were solved through the development of a second method of inkjet 
printing, which overcame the problem of evaporation.82 It consisted of inkjet printing 
(independently) both a photo-initiator (2,2-dimethoxy-2-phenylacetophenone) and 
monomers (or a mixture of initiators and monomers) onto agarose-coated glass slides, 
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Once printed the monomer drops (all dissolved in NMP) sank and settled onto the 
agarose layer where they were polymerised. Using this approach a polymer 
microarray of 1100 polymers was fabricated in situ on a single microscope glass 
slide with feature sizes of ~0.62 mm and a density of 100 spots/cm2. The advantage 
of this method is that it allows for the use of a much wider range of monomers, 
which do not have to be water-compatible. These arrays of polymers were used to 




Figure 1.6 Approach used to prepare polyacrylate microarrays. An oil film was used to prevent 
evaporation of the nanolitre volumes of the printed monomer solutions while maintaining the pattern 
on the glass surface. Following UV photo-polymerisation and removal of the oil film the polyacrylate 
library was left attached on the slide.82 
 
 
1.3.3 Contact printing polymer microarrays78, 80 
The work reported in this thesis used contact printing methods rather than inkjet 
printing in order to prepare more rapidly the arrays of polymers. In contrast to the 
inkjet method, contact printing has been shown to be the fastest method for mass 















 - 18 -
1.3.3.1 Polymer microarray fabrication 
There are three parameters essential in order to generate polymer microarrays with 
uniform and reproducible features: 
1. The surface onto which the polymers are printed. 
2. The solvent used to prepare the polymer solutions.  
3. The printing conditions used. 
It is important to note that three parameters are not independent of each other and 
will influence the quality and reproducibility of the final polymer microarray. 
 
1.3.3.1.1 Surfaces 
In order to develop a cell-based microarray, the substrate has to comply with several 
requirements:  
1. The substrate must be unaltered by the contact printing of the polymer solution. 
2. The substrate must be stable to UV-irradiation to allow sterilisation prior to the 
plating of the cells. 
3. Substrates with low levels of background binding must be developed to facilitate 
data analysis. 
As a result of previous work80 several functionalised and gold-coated glass slides 
were investigated for this application, most of which provide a suitable surface for 
polymer printing, and could be readily sterilised under UV-irradiation, but 
unfortunately did not prevent cellular adhesion. The following substrates were 
prepared and tested: C18-functionalised slides, aluminium slides, and 
perfluoroalkylthiol-modified slides. The best results were obtained by dip-coating 
aminoalkylsilane slides with a thin film of agarose. Importantly agarose is readily 
sterilised by UV irradiation and does not dissolve in most organic solvents. 
 
1.3.3.1.2 Solvents  
As a result of previous work80 a variety of solvents and solvent mixtures were 
investigated. As a result of this study, n-methyl-pyrrolidinone (NMP) was selected 
due to the solubility of over 90% of the polymers from both the polyurethane and 
polyacrylate libraries. Its boiling point (202 ºC/1 atm) also radiuses solvent 
evaporation, which allows large numbers of polymers and microarrays to be printed 
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in a single run. In order to fully remove the solvent following microarray fabrication, 
the arrays were dried under vacuum at 45 ºC overnight. 
 
1.3.3.1.3 Printing and washing of the polymer microarray 
Polymer printing was carried out using a Q-Array Mini contact microarrayer with 
150 μm solid pins (Figure 1.7).  
Using solid pins, the main factors effecting the shape and uniformity of the printed 
spot were the nature of the solvent and the substrate used. This array allows the 
control of a variety of parameters including inking time, stamping time, number of 
stamps per spot and washing conditions. Importantly, washing of the printing station 
can only be carried out with ethanol and water. However, this does not remove the 
trace amounts of NMP and dissolved polymers. Hence, this results in cross-
contamination between samples during printing. To remedy this, pins must be 




Figure 1.7 Q-Array Mini contact microarrayer.
 
 
Through the work of Mizomoto,40 Jose79 and Tourniaire,80 polymer microarrays were 
also studied in order to evaluate the properties of the printed polymers. Specifically, 
the morphology of the printed polymer spots was studied using scanning electron 
microscopy (SEM), chemical functionality and composition analysis were 
undertaken using Fourier Transform Infra Red (FT-IR) microscopy and Time-of-
384-well plate containing  
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Flight Secondary Ion Mass Spectrometry (TOF-SIMS).83 These techniques 
successfully characterised the functional groups present on the surface of the printed 
polymer spot, and in this way not only have polymer microarrays shown their 
versatility in biological uses, but also have allowed high throughput chemical 
analysis.83  
 
1.3.4 Detection methods 
Most of the detection and imaging systems used in the field of polymer microarrays 
rely on fluorescence. With the drive towards increasing throughput, such systems 
have required automation for both detection and image analysis.  
The detection methods used by Bradley, in order to allow the screening of polymer 
microarrays, can be divided into two main categories, depending on the level of 
resolution necessary. Low resolution systems (2-10 µm), where individual cells do 
not need to be observed, are based on standard DNA microarray scanners. These 
systems are compatible with a range of fluorophores and generate single images of a 
whole microarray. Subsequent analysis is generally carried out with commercial 
software (for example, LaVision BioTech GmbH) allowing quantification of 




Figure 1.8 A) Bioanalyser 4F/4S scanner (LaVision BioTech GmbH) with CCD camera allowing the 
rapid determination of fluorescence intensities. B) Scanning of a polymer microarray, containing 15 
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High resolution high-content screening (HCS) systems (down to 0.2 µm) was based 
on a conventional microscope fitted with a motorised stage allowing the automated 
capture of high-resolution images for each spot (Figure 1.9 A and B). 
The use of these systems, initially developed for microplate assays, is essential when 
individual cells need to be visualised or sub-cellular localisation is necessary.  
The main inconvenience of these systems comes from the handling and analysis of 
the data sets generated. However, with the development of high-content screening, 
several software packages (for example, Pathfinder™) have been developed to carry 
out automated image analysis (Figure 1.9 C).  
Such packages allow rapid analysis of multiple parameters (cell number, shape and 
size, fluorescent intensities etc.) from hundreds of images in order to provide 





Figure 1.9 A) Nikon 50i fluorescence microscope with a motorised X–Y–Z stage; B) general scheme 
of an IMSTAR HCS device equipped with the Pathfinder™ software package; C) pathfinder™ 
software automated cell quantification. Fluorescent images of K562 cells grown on a representative 
PA374 spot. From top to bottom: DAPI channel, pathfinder™ software automatic cell quantification. 
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1.4 Summary 
The development of biomaterials for the biomedical field, especially in the case of 
polymers, represents a major opportunity to improve quality of life. For this reason 
great quantities of resource have been spent with the intention of synthesising and 
improving biocompatible materials. However, due to the complexity and diversity of 
biocompatibility testing, it has been difficult to find a universal method which 
permits high throughput determination of in vitro properties. It is impossible to 
theoretically predict cellular response, and thus every time a new material is 
generated it is vital to test its biocompatibility using cells with which it will come 
into contact. Researchers need to create new systems and techniques which allow the 
acceleration of this type of screening, and which minimise expenditure of time and 
money.  
This issue has been addressed by the Bradley group with the development of a new 
system of screening, based on microarray technology. The technique of polymer 
microarrays has had, and will continue to have, a significant impact on the study and 
development of new biomaterials with diverse applications. Thousands of new 
polymers have been tested for their interaction with different cell lines, as will be 
discussed in future Chapters. The polymer microarray approach also appears to offer 
a significant advance when allied with cellular biology and the area of tissue 
engineering. 
 
1.5 Aim for the thesis 
The aim of this thesis was to apply polymer microarrays to the screening of polymer 
libraries with three main purposes: firstly, identifying substrates upon which specific 
cell lines would adhere and grow; secondly, gaining an understanding of the 
interactions between the cells and the biomaterials; and thirdly, to provide materials 
with potential applications. DNA-microarray analysis was undertaken in order to 
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Specific avenues of research included: 
 
(i) The control of fibroblast adhesion and morphology; 
(ii) The binding of suspension cells (erythroleukaemic K562 cells) with analysis to 
access the global gene expression profiles;  
(iii) The attachment, promotion and stabilisation of hepatocyte-like cells applicable 
to cell culture and bioartificial liver models; 
(iv) The promotion of adhesion, growth and function of endothelial progenitor cells 
to create living blood vessels and to mediate the endothelialisation of artificial vessel 
prostheses; 
(v) Selective bacterial enrichment or the prevention of surface contamination. 
 
It was hoped that the results of these investigations would offer practical applications 
for biomaterials, such as: developing new implant surfaces and tissue-engineered 
scaffolds while enhancing the study of cell-biomaterial interactions, and creating 
surface treatments for the prevention of bacterial contamination. 
 
 









One of the fundamental requirements for a biomaterial in tissue engineering, cell 
therapy and regenerative medicine is the capacity to control efficiently the adhesion 
of cells.85-88 Such adhesion requires an initial phase in which the cell recognises the 
substrate and it is essential to understand the mechanisms which determine this initial 
phase of adhesion, as well as how to control it.86, 89-91 Both the mechanical properties 
and the chemistry of the biomaterial determine the efficiency and success with which 
cells recognise and respond to it.92 Only by quantifying the relative success or failure 
of a given biomaterial to bind a specific cell type can biomaterials, implant surfaces 
and tissue-engineering scaffolds be designed.93 Cells exist in a complex and dynamic 
microenvironment which includes the surrounding ECM, growth factors and 
cytokines, as well as adjacent cells.94 Cell adhesion to the biomaterial involves firstly 
the physical interaction of ECM proteins in the given media with the biomaterial 
surface, and then the covalent connection of ECM proteins to cell surface receptors.95 
Integrins are the principal transmembrane receptors, which initiate the connection of 
the intracellular cytoskeleton to the ECM.94-96 This allows cells to react in an 
appropriate manner to extracellular events (outside-in signalling), while cell adhesion 
molecules are capable of transmitting signals from inside the cells to the extracellular 
environment (inside-out signalling).97 Binding of integrins to ligands on the ECM 
causes integrins to group into localised adhesions.98 These adhesive processes initiate 
a cascade of intracellular signalling events that can provoke changes in cellular 
behaviour, such as morphology, growth, migration, and differentiation.94, 97, 98 
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2.2 Scope of this study 
In this Chapter, cell adhesion studies were realised using a library of polyurethanes99 
to try and find optimal polymer support for mouse connective tissue cells (fibroblast 
cells (L929)). These cells are of interest in biomedical research since fibroblasts 
provide a structural framework (stroma) for many tissues and play a critical role in 
wound healing.100 For example, the healing of full-thickness skin defects requires 
extensive synthesis and remodelling of dermal and epidermal components. 
Fibroblasts play an important role in this process and are being incorporated in the 
latest generation of artificial dermal substitutes.101 Numerous physical parameters 
such as elasticity, surface topography102 and biochemical properties (in particular 
the ability to absorb ECM)103 are expected to play a relevant role in cellular 
adhesion and biocompatibility. In addition, the surface of a polymer often 
changes the conformation of the adsorbed ECM proteins which may partially or 
completely lose their bioactivity.104 All these factors are dependent on the 
chemical structure of the polymer and are, therefore, not easy to predict. The 
versatile, and time-saving, method of polymer microarray allows the simultaneous 
study of both cellular morphology and cell viability in relation to the polymers to 
which the cells adhere.105  
 
2.2.1 High content screening of L929 cells  
Cell-adhesion experiments used the mouse fibrosarcoma cell line, L929, and 
included incubation on a 214-member polymer microarray for 48 h and 72 h. In order 
to study the biocompatibility of the polymer support, cells were incubated with 
CellTracker Green-(CTG) one hour before fixing (CellTracker Green is an indicator 
of cell viability (see Chapter 2.2.2)).106 Subsequently, the cells were fixed, and cell 
nuclei and the cytoskeleton stained with Hoechst-33342 and AlexaFluor 568 
phalloidin respectively. Cell permeable Hoechst-33342 is an adenine-thymine-
specific dye that binds to the minor groove of DNA, and is used to enable the 
counting of cells.107 AlexaFluor 568 phalloidin is a fluorescent bicyclic peptide with 
high-affinity for F-actin, which is an important component of the cytoskeleton, and is 
used to study cell morphology.108 This fluorescent probe does not cross the 
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membrane of living cells and requires permeation of the cells. Once the cells are 
fixed, the staining of the cells with Hoechst-33342 is also accelerated, due to 
enhanced cellular permeability. Cell number, biocompatibility and morphology of 
each polyurethane member was determined using fluorescent (DAPI, fluorescein, 
and rhodamine-like band-pass filters) and brightfield channels by automated 





Figure 2.1 L929 cells grown on polymer microarrays after 72 h incubation. A) The top polymers for 
L929 cells. All polymers supported a minimum of 200 cells/mm2. Fluorescein channel images are 
shown in the cell viability column. Rhodamine/DAPI merged images and brightfield/DAPI composites 
are shown in the Cell Quantification/Morphology column. B–F) Fluorescent images of L929 cells 
grown on PU107: B) FITC channel; C) DAPI channel; D) rhodamine channel; E) 
FITC/DAPI/rhodamine channel, merged image; F) DAPI/brightfield channel merged, image (scale 
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2.2.2 Analysis of cell viability 
The viability of cells (i.e. the number that survived)109 was measured by CTG 
fluorescent emission of the content of each spot through the FITC-like channel. 
CellTracker Green 5-chloromethylfluorescein diacetate (CTG-CMFDA) is non-
fluorescent and able to diffuse freely through the membrane of live cells. Once inside 
the cell, intracellular esterases convert nonfluorescent CTG-CMFDA to fluorescent 
5-chloromethylfluorescein (CTG-CMF) to produce cells that are fluorescent. Cells 
are also covalently modified, due to the chloromethyl group which react with thiols 
on proteins and peptides to form aldehyde-fixable conjugates (Figure 2.2).106 
CellTracker Green is a useful indicator for showing whether or not cells are living. If 
cells have died, esterases will be denatured (just like any other protein in the cell) 
and unable to initiate the process of fluorescent marking. This, therefore, acts to 
determe the success of a biomaterial substrate. In general all polymers with the 









Figure 2.2 Intracellular reactions of CTG-CMFDA.
 
 
2.2.3 Analysis of cell adhesion and competitive affinity 
In order to quantify cellular adhesion on each polymer the average number of cells 
across the four spots was calculated, with values for L929 cells recorded at two time 
points, 48 h and 72 h. This was done by fluorescence analysis of images from the 
DAPI channel (Figure 2.1 C). 
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PathfinderTM was used to automatically count cell nuclei. In general, significant 
cellular adhesion was supported by a number of the polyurethane library members 
(Figure 2.3). PU87, PU147 and PU162, with difference in their polymer construction 
(Table 2.1), were the best substrates, providing an average of cell binding (over the 4 
identical polymer spots) higher than 1000 cells/mm2 mouse fibroblast cells. Thirteen 















































48 hours 72 hours
 
Figure 2.3 Polyurethanes cell binding after 48 and 72 h (average from 4 spots of same polymer). The 
number of cells/mm2 was calculated assuming a spot diameter of 300 µm. The error bars represent 
the standard error of the average. Complete L929 cell-polyurethane binding analysis is reported on 
CD (Supplementary Information, excel folder named “Chapter 2”). 
 
 
The diol, PTMG, although with different molecular weights (650, 1000, 2000), was a 
common component of ten of the “hit” polymers (Table 2.1), thus indicating 
correlation between polymer structure and cell binding. Although two different 
polymers could have similar capacity for binding a specific cell line, the cell 
adherence process could be faster on one polymer than on the other. Consequently, in 
order to quantify the cell proliferation, the average number of cells and the standard 
deviation across the replicates were determined at two different incubation times (48 
h and 72 h) on two separate polymer microarrays.  
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48 PPG 2000 BICH ED
69 PTMG 2000 MDI BD
87 PPG 2000 HMDI BD
89 PTMG 2000 HMDI BD
107 PTMG 650 HDI DEAPD
130 PTMG 650 TDI DMAPD
133 PHNGAD 1800 HDI BD
136 PTMG 250 BICH DEAPD
147 PTMG 250 HDI DEAPD
161 PTMG 650 MDI EG
162 PTMG 1000 MDI EG
163 PTMG 2000 MDI EG
172 PTMG 650 HDI none
269 PPG 2000 MDI DEAPD
PU
Polymer Structure
Diol Mn Diisocyanate Chain Extender
 
 
Table 2.1 L929 cell binding polymers with polymer composition: Diol/Diisocyanate/Chain Extender 




PHNGAD: poly[1,6-hexanediol/neopentyl glycol/diethylene glycol-alt-(adiptic 
acid)]diol 
PPG: poly(propylene glycol) 
PTMG: poly(butylene glycol) 
Diisocyanate: 









ED: ethylene diamine 
EG: ethylene glycol 
 
 
A comparative analysis of cell number per polymer over time would thus be a 
measure of the proliferation ability of L929 on the polymers. Data analysis revealed 
different behaviors for the polymers (Figure 2.3). For example, some polymers 
showed low cell binding after the first 48 h and then showed a “burst of growth” over 
the following 24 h. 
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 The 160 series (PU161,162 and 163), which has the same monomer structure (Table 
2.1), only differing in the molecular weight of the diol used (PTMG 650, 1000 and 
2000 respectively), showed similar cell attachment trends (Figure 2.3). Low cell 
binding was observed within the first 48 h followed by vigorous growth for the next 
24 h. On the other hand, polymers PU48, 69 and 147 (Table 2.1) showed steady cell 
numbers over time, associated with rapid cell immobilization achieved by these 
polymers (Figure 2.3). The number of cells on PU269 for both observation times 
was identical, with high affinity of these polymers for L929 after 48 h but, over the 
following 24 h, cellular proliferation was absent (Figure 2.3). 
 
2.2.4 Correlation between polymer wettability and cell 
adhesion abilities  
Bradley previously reported a high throughput method for evaluating the wettability 
of polymer libraries by measuring the spreading area of water droplets deposited 
onto spin-coated films of the polymer. The entire polyurethane library, was, therefore 
characterized with spreading areas determined after a contact time of 20 s. Analysis 
showed that 90% of the PU library members were relatively hydrophobic, with a 
spreading area ranging from 8 to 12 mm2 (equivalent to a contact angle from 90º to 
70º, respectively).99 These values were shown to be strongly correlated with the cell 
binding (Figure 2.4) with all hydrophilic polymers (having a spreading area > 15 
mm2, equivalent to contact angle < 50º) found to impede cell adhesion. This analysis 
emphasizes the significant role of the polymer’s physical properties on cell adhesion 
and indicates that L929 cells require a relatively hydrophobic substrate for adherence. 
 
2.2.5 Analysis of cell morphology  
Cells in contact with a binding surface will first attach and then spread according to 
the interactions created between the surface, the proteins from the growth serum and 
the ECM proteins. The nature of this adhesion will influence their morphology and 
their capacity for proliferation and differentiation. Fibroblasts are slow-moving cells 
in which the cytoskeleton plays a very important role in cell motility and shape.  
 
 


































Figure 2.4 Analysis of polymer wettability in relation to the average number of cells/mm2 per polymer. 
Polymer wettability is expressed as the area over which a droplet of water of defined volume spreads 
over a cover slip spin-coated with the polymer (and was determined in this case after a contact time of 
20 s). The numbers of the hit polymers described in Figure 2.3 are shown (blue diamonds). 
 
 
To observe the effects of polyurethanes on the typical morphology of this cell-type, 
confocal microscopy studies were carried out on cultured L929 fibroblasts. Cells 
cultured on the majority of the spots maintain their characteristic morphology 
(Figure 2.5 A). Closer analysis revealed alternative cell morphologies (Figure 2.5 
B-D). In spots showing low density cell binding a rounded morphology was typically 
observed (Figure 2.5 C), due presumably to the lack of suitable attachment points 




Figure 2.5 Confocal images of L929 cells on polymer microarrays. Cells were imaged under ex/em 
578/603 nm and ex/em 360/40 nm using a DeltaVision RT microscope (×63 objective) and then 
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2.3 Conclusion 
A fluorescence-based high-throughput microarray approach facilitated the rapid 
screening of libraries of potential biomaterials and was used for the study of L929 
cellular adhesion. This screening allowed the identification of a group of fourteen 
biocompatible polyurethanes which enabled a good adhesion of L929cells.  
Thirteen out of the fourteen best polyurethanes contained the diol, PTMG, 
underlining the important role of this monomer in the adhesion of L929 fibroblasts 
cells. Further analysis emphasizes the significant role of the polymer’s physical 
properties on cell adhesion and indicates that L929 cells require a relatively 
hydrophobic substrate for adherence. The method also allowed the study of 
polyurethane on the typical L929’s morphology. In spots showing low density cell 


















The Molecular Basis of Cell-Biomaterial 
Interactions: Transcriptomic Studies 
 
 
3.1 Introduction  
Various studies have been reported on gene expression analysis of cell-biomaterial 
investigations via reverse transcriptase polymerase chain reaction (RT-PCR)110, 111 
and Northern blotting.112 However, these methods look at only limited numbers of 
genes and are insufficient for conducting large-scale transcriptomic analysis. Over 
the last few years, there have been tremendous advances in high-throughput gene 
expression analysis via the application of DNA microarray technology, which has 
emerged as a valuable tool in providing important insights into the molecular basis of 
cellular responses to various physiological stimuli and toxic insults.113 Various 
studies have used microarray technology to understand the complex nature of cell–
biomaterial interactions.  
 
Xynos analysed the gene expression profile of human osteoblasts on Bioglass 
45S5.114 This biomaterial is an osteoproductive material which is resorbed by 
releasing its constitutive ions into solution. Using DNA microarray technology, they 
found that the expression of a potent osteoblast mitogenic growth factor, insulin-like 
growth factor II (IGF-II), was increased. There was also a large increase in the 
concentration of IGF-II protein in the conditioned media of treated osteoblasts. 
Expression levels of IGFBP-3, an IGF-II carrier protein, metalloproteinase-2 and 
cathepsin-D were also strikingly up-regulated. Metalloproteinase-2 and cathepsin-D 
are proteases that cleave IGF-II from its carrier proteins, resulting in the release of 
biologically active IGF-II. The authors concluded, therefore, that the stimulatory 
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effect of the ionic products of Bioglass 45S5 dissolution on osteoblast proliferation 
may be mediated by IGF-II. 
Ku tested a new thermal surface treatment which allowed an increase in the oxide 
layer thickness of a Titanium  alloy (Ti–6Al–4V) used in orthopaedic implants.115 In 
this study the reaction of osteoblasts to this new surface treatment was tested and 
compared to other surface treatments currently used in implant surgery. Twenty-eight 
genes were selected in order to compare the effects of these surfaces on osteoblasts. 
Based on the genes studied, a general pathway for the cells’ reaction according to the 
surface treatments was proposed. Metal ion release affected the time course of gene 
expression in the FAK pathway; over a certain threshold value metal ions release 
from the newly developed surface treatment diminished cell growth and apoptosis 
could occur. The release of metal ions stimulate PTK up-regulation; and the over-
expression of the Bcl-2 family and Bax suggest that metal ions provoke apoptosis. 
The new surface treatment tested in this study seemed to increase the Ti–6Al–4V 
biocompatibility compared to that of the other treatments currently available, as 
indicated by the reduced inflammatory reaction and reduced chance of apoptosis.  
Carinci used expression profiling to study the osteoblast-like cell line (MG-63) on 
zirconium oxide discs.116 The expression of several of the genes was significantly up 
or down-regulated and covered a broad range of functional activities, including 
immunity, vesicular transport and cell cycle regulation. The data reported allowed a 
better understanding of the molecular mechanism of biocompatibility and could be 
used as a model for comparing other materials. 
Allen used transcriptomic DNA microarray-based analysis to study the interaction of 
cells with a homologous series of copolymer films that had slightly different levels of 
surface hydrophobicity.117 They used various combinations of N-
isopropylacrylamide, which is currently used as an adaptive cell culture substrate, 
and the more hydrophobic, yet structurally similar, monomer N-tert-butylacrylamide. 
They examined the connection between phenotypic responses to cell–biomaterial 
interaction and global gene expression profile alterations. Their research showed that 
high-throughput analysis of gene expression enhances understanding of cell–
biomaterial interaction, and offers refinement of biocompatibility assessment. 
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3.2 Erythroleukaemia cells (K562) 
K562 cells are a suspension cell line derived from a chronic myelogenous leukaemia 
patient.118 These non-adherent, suspension cells do not need to be attached to ECM 
proteins in order to survive and grow.118, 119 This cell line does not normally undergo 
the same adhesion process as anchorage-dependent cells (see Chapter 2.1),120 and, 
therefore, is especially appropriate for the study of cell adhesion over long periods of 
time. Understanding why cells like K562 convert from suspension to adherent cells 
could be of enormous benefit in refining our understanding of metastasis.121 Using 
suspension cells, which have significantly fewer surface receptor proteins (integrins) 
than adherent cells,122 it is possible to separate out the effect of protein adsorption 
from adhesion phenomena, including the role of non-specific surface charge in cell 
binding.123 K562 cells are important as they lack the major histocompatibility 
complex (MHC) required to inhibit natural killer (NK) activity.124 If they can be 
successfully immobilised, as has been attempted in this study, it could be possible to 
develop a NK cell-cell killing assay, in an attempt to understand better how NK cells 
attach in order to destroy leukaemia cells, and, consequently, to develop new 
strategies for combating leukaemia.125, 126  
 
3.3 A polymer DNA-microarray approach to  
biomaterials 
The aim of the study undertaken in this Chapter was, first, to apply polymer 
microarrays to identify polymers which allow the immobilisation of K562, and 
secondly, use DNA-microarray analysis for the rapid transcriptomic examination of 
specific cell-biomaterial interaction arising as a result of the immobilisation (Figure 
3.1), which would allow better understanding of the links between phenotypic 
responses and global gene expression. Adhered cells, which usually grow in 
suspension, demonstrate a change in their gene expression profile. The importance of 
this research, therefore, lies not only in the identification of polymers which bind 
K562 (with all the possible applications already described) (Figure 3.1 A), but also 
potentially improved understanding of the changes in gene expression caused by 
forcing suspension cells to grow when bound to a surface (Figure 3.1 B). 
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Figure 3.1 Dual polymer–microarray-co-DNA-microarray strategies for the assessment of cell-
biomaterial interactions. A) Polymer libraries screening; B) transcriptomic analysis. 
 
 
3.3.1 Analysis of cell attachment and proliferation 
In the first instance, cellular binding of suspension cells onto polymer microarrays of 
271 polymers were explored. The identification of polymers that immobilised K562 
cells was achieved via the analysis of polymer microarrays that not only measured 
polymer-binding capacities but also cellular proliferation.127 In order to quantify both 
cellular adhesion and proliferation, the average number of cells and the standard 
deviation across the replicates were determined at three different incubation times 
(24 h, 48 h and 72 h) on six separate polymer microarrays. Each polymer microarray 
was washed at each time-point in order to remove the cells which had not adhered to 
the polymer. Consequently, via analysis of the arrays it was possible to profile the 
polymer libraries in terms both of binding and proliferation, through the analysis of 
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Figure 3.2 Parallel analyses of polymer cellular binding and proliferation on a representative spot 
(PA374): A) brightfield images; B) DAPI channel; C) cell nuclei automatically recognised and 




Analysis revealed a set of polyurethanes with high cell binding (Figure 3.3). 
Fourteen polyurethanes showed more than 1000 cells/mm2 after 72 h. The diols 
PTMG and PPG, were a common component of all the hit polymers, whereas more 
than half of the chain extender components were either DEAPD or DMAPD, both of 
which contained a tertiary amino group, which may be a factor in cellular adhesion 
activity, underlining that the positive surface charge of biomaterials plays a major 
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Figure 3.3 Polyurethanes cell binding after 24, 48 and 72 h (average from 4 spots of same polymer). 
The number of cells/mm2 was calculated assuming a spot diameter of 300 µm. The error bars 
represent the standard error of the average. Complete K562 cell-polyurethane binding analysis is 
reported on CD (Supplementary Information, excel folder named “Chapter 3”). 
 
 
87 PPG 200 HMDI BD
115 PPG 100 H DI BD
120 PPG 425 BICH DEAPD
121 PPG 100 BICH DEAPD
126 PPG 425 TDI DMAPD
135 PT MG 250 BICH DMAPD
136 PT MG 250 BICH DEAPD
147 PT MG 250 H DI DEAPD
150 PT MG 650 H DI EG
151 PT MG 100 H DI EG
197 PT MG 650 BICH DHM
227 PPG 190 H DI none
230 PPG 190 H DI BD
264 PT MG 100 H DI DMAPD
Polymer structure
PU
Diol Mn D iisocyanate Chain Extender
 
 
Table 3.1 K562 cell binding polymers with polymer composition: Diol/Diisocyanate/Chain Extender 
(1:2:1), except PU115 and PU227 which are: Diol/Diisocyanate (1:1), and PU264 which is: 









PPG: poly(propylene glycol) 











ED: ethylene diamine 
EG: ethylene glycol 
 
 
The three hit polyurethanes (PU135, 136 and 147) had a similar structure, 
demonstrating correlation between polymer structure and cell binding. Moreover, 
data analysis revealed the unique proliferation behaviour for different sets of 
polymers (Figure 3.3).  
Some polymers showed consistent proliferation through each period of 24 h. Others, 
meanwhile, showed poor cell binding for the first 24 h and 48 h, but then underwent 
a burst of growth over the following 24 h. 
For example, PU150 and 151, which have the same type of monomers (Table 3.1) 
(differing only in the molecular weight of the diol used – PTMG 650 and 1000 
respectively), showed similar cell-attachment trends. Low cell binding was observed 
during the first 48 h followed by a vigorous growth in the remaining 24 h. Other 
polyurethanes lacking the tertiary amino group (PA197, 227 and 230) (Table 3.1) 
showed a modest cell binding during the first 48 h followed by a vigorous growth 
only in the remaining 24 h. This suggested the importance of the positive surface 
charge in initiating an early process (first 24 h) during immobilisation of suspension 
cells. In fact, only polymers containing a tertiary amino group, showed both a rapid 
immobilisation at the beginning and than a further constant cell-binding trend for the 
following 48 h (Figure 3.3).  
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The polymers without a positive charge, probably allow the cell adhesion only 
involving: firstly the abortion of ECM proteins in the given media with the 
polyurethane surfaces, and then the covalent connection of ECM proteins to cell 
surface receptors.  
PU87 has already been shown (Chapter 2) to be one of the best polymer for binding 
L929 cells, and it confirms its status as a polymer with high cellular affinity by 
promoting strong adhesion and growth with K562 cells (Figure 3.3). 
 
3.3.1.2 Polyacrylates40 
A library of polyacrylates was also evaluated (Figure 3.4). Fifteen polyacrylates (co-
polymers with amino groups within monomer 2) showed significant cellular 
attachment (Figure 3.4, darker grey squares), possibly due to the overall positive 
surface charge. The four best polymers, which provided a binding higher than 3500 
cells/mm2 after 72 h, were PA365, 368, 371 and 374 (Figure 3.4, in red and Figure 
5). Those polymers are composed of HBMA (Table 3.2). The proliferation 





Figure 3.4 Polyacrylates cell binding after 72 h. A) Array design with 58 polyacrylates and 6 
“empty” areas, each square represents 9 replications of the same polymer spot. In darker grey 
squares: the 15 polyacrylates which showed more than 2000 cells/mm2. In red: the 4 polyacrylates 
which showed more than 3500 cells/mm2; B) brightfield mosaic image; C) DAPI mosaic image. 
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Figure 3.5 Polyacrylates cell binding after 24, 48 and 72 h (average from 9 spots of same polymer). 
The number of cells/mm2 was calculated assuming a spot diameter of 300 µm. The error bars 
represent the standard error of the average. Complete K562 cell-polyacrylate binding analysis is 











359 HPMA D EAEA
365 HBMA DEAEMA
368 HBMA DMAEMA
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MMA: methyl methacrylate 
Monomer 2 
DEAEA: 2-(diethylamino)ethyl acrylate  
DEAEMA: 2-(diethylamino)ethyl methacrylate 
DMAEA: 2-(diethylamino)ethyl acrylate  
DMAEMA: 2-(diethylamino)ethyl methacrylate 
 
 
3.3.2 SEM analysis 
SEM studies were undertaken so that the effect of the different polymers on the cells 
could be assessed in relation to the nature of the cells on the polymer surface. 
Analysis suggested that cell morphology had changed. Control cells (Figure 3.6 A-
B), appeared well rounded with numerous microvilli on their surfaces. Meanwhile, 
the surfaces of cells grown on the 4 polyacrylates (PA365, 368, 371 and 374) for 24 
h (Figure 3.6 C-F) appeared different with numerous contact points with the 
substratum. This forced them to take a slightly flatter morphology, presumably as a 
consequence of the positive charge on the surface. This was particularly evident after 
72 h with cells grown on PA368 (Figure 3.6 G) and PA365 (Figure 3.6 H).  
 
3.3.3 Gene expression profiling 
Following the adhesion of K562 cells onto coverslips coated with the selected 
polymers, total RNA was isolated and used for transcriptomic analysis. Gene 
expression analysis was carried out to study the result of interactions between 
polyacrylates PA368 and PA365 and K562 cells after 72 h using an Agilent 4 x 44 K 
Whole Human Genome microarray. Analysis gave 709 genes with a p-value < 0.01, 
which were then subjected to a fold change analysis to determine which genes were 
up- and down-regulated using a 2-fold increase or decrease as a cut-off value.  
 
3.3.3.1 Analysis 
The general effect of polyacrylates on transcriptomic response was studied 
irrespective of whether PA368 or PA365 was used. The entire dataset across the four 
arrays was grouped and analysed as a single entity. 34 genes appeared to be up-
regulated, while 135 were down-regulated.  
 
 - 43 -
 
 
Figure 3.6 Scanning electron micrographs. A-B) Control K562 cells after 24 h. C-F) Cells grown on 
PA365, 368, 371, 374 after 24 h, respectively. G and H) Cells grown on PA368 and PA365 after 72 h, 
respectively. 
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Figure 3.7 Structures of polymer PA368 (top left) and polymer PA365 (top right) and profile plot of 
up- and down-regulated genes across the 4 polymer samples (normalized values in log2 scale). [1]–
[4] represent analysis on the four different subarrays. [1] and [2] represent subarrays hybridised 
with total RNA obtained from cells grown on PA368 and [3] and [4] from cells grown on PA365 
compared to the “suspension cell control”. Up-regulated genes have a negative value as the control 
genes were labelled with Cy5. (GeneSpring GX 9.0.2 software assumed that control genes are 
labelled with Cy3). 
 
 
The expression of the up- and down-regulated genes on each array is shown in 
Figure 3.7 with the profile plots of these genes. Further refinement was carried out 
by increasing the cut-off value to identify genes which showed the largest changes in 
expression. Using a 3-fold change as a cut-off value128 just three genes were 
identified as being up-regulated and 74 as down-regulated (Table 7.1 in Chapter 7).  
This showed that when K562 cells become immobilised on polyacrylates, a chain of 
cellular changes is triggered, most notably resulting in gene down-regulation.  
The 3 up-regulated genes were mediator complex subunit 18 (MED18), xenotropic 
and polytropic retrovirus receptor 1 (XPR1) and 3-hydroxy-3-methylglutaryl-
coenzyme A synthase 1 (HMGCS1), and they were individually analysed in order to 
ascertain their function.  
MED18 is a component of the Mediator complex, which is a co-activator for DNA-
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functions act as a bridge to convey information from gene-specific regulatory 
proteins to the basal RNA polymerase II transcription machinery. Mediator is 
recruited to promoters by direct interactions with regulatory proteins and serves as a 
scaffold for the assembly of a functional pre-initiation complex with RNA 
polymerase II and the general transcription factors.130 
XPR1 may function in G-protein coupled signal transduction, and may act as a 
receptor for xenotropic and polytropic murine leukaemia retroviruses. Polytropic 
leukaemia viruses use this receptor to enter into cells, and, interestingly, adhesion on 
surfaces PA-368 and PA-365 induces over-expression of this receptor.131 As a result, 
G proteins maybe were altered to deal with this new forced adhesion arena in which 
K562 cells were constricted and consequently act to ensure that only the appropriate 
response is triggered. 
HMGCS1 is known to stimulate lipid synthesis and uptake and is part of the sterol-
regulatory element binding proteins (SREBPs),132 which are essential in cholesterol 
metabolism regulation and show the need for the cells to increase membrane lipid 
content when binding onto the polyacrylates. 
 
3.3.3.1.1 Pathway analysis 
The 74 down-regulated genes were analysed using KEGG (Kyoto Encyclopedia of 
Genes and Genomes) database,133 allowing the identification of gene products which 
form part of six known biological pathways. As shown in Table 3.3, some identified 
pathways were found to be involved in intracellular pathways including: mitogen-
activated protein kinase (MAPK) signalling; cytokine-cytokine receptor interaction; 
adipocytokine signalling; calcium signalling pathway; neuroactive ligand-receptor 
interaction pathway; and the focal adhesion pathway.  
Many of the pathways were found to be involved in the process of cell adhesion and 
proliferation control, as well as in cell membrane modification. The MAPK pathway 
is involved in various cellular functions, including cell proliferation, differentiation 
and migration. Mammals express at least four distinctly regulated groups of 
MAPKs.134 The cytokine-cytokine receptor interaction pathway is involved in the 
control of cytokines, which are crucial intercellular regulators and mobilises of cells 
engaged in innate as well as adaptive inflammatory host defences, cell growth, 
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differentiation, cell death, angiogenesis, and development and repair processes aimed 
at the restoration of homeostasis.135 The calcium signalling pathway is involved in 
the control of calcium concentration. Ca2+ that enters the cell from the outside is 
driven by the presence of a large electrochemical gradient across the plasma 
membrane. Cells use this external source of Ca2+ signal by activating various entry 
channels with widely different properties. The influx of Ca2+ from the environment 
or release from internal stores causes a very rapid and dramatic increase in 
cytoplasmic calcium concentration, which has been widely exploited for signal 
transduction.136 The focal adhesion pathway plays an essential role in biological 
processes such as cell motility, cell proliferation, cell differentiation and cell 
survival.137 These results suggest that the process, by which K562 cells adhere alters 
the cellular membrane, produces a significant down-regulation of membrane 
receptors and ligands. Furthermore, this down-regulation interferes with cell-cell 
communication through the control of cytokines. It seems also that the 
electrochemical gradient across the plasma membrane is highly modified by an 
alteration of calcium exchange between cells and environment. 
 
 
Kegg ID Name Class Total genes 
Genes 
found 




hsa04060 Cytokine-cytokine receptor interaction 
Environmental Information 






hsa04920 Adipocytokine signaling  
Cellular Processes; Endocrine 
System 72 
CAMKK2    
TNFRSF1A   
IRS2 
hsa04020  Calcium signaling  Environmental Information Processing; Signal Transduction 174 
CACNA1B   
CACNA1E 
hsa04080 Neuroactive ligand-receptor interaction  
Environmental Information 
Processing; Signaling Molecules 
and Interaction 
254 GPR156  NPBWR1 




Table 3.3 Down-regulated pathways of genes identified in the microarray screening. 
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Gene abbreviations: 
TNFRSF1A: tumor necrosis factor receptor superfamily, member 1A 
CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit  
CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit  
CXCR3: chemokine (C-X-C motif) receptor 3 
CXCL3: chemokine (C-X-C motif) ligand 3  
IRS2: insulin receptor substrate 2 
CAMKK2: calcium/calmodulin-dependent protein kinase kinase 2, beta  
GPR156: G protein-coupled receptor 156  
NPBWR1: neuropeptides B/W receptor 1 
COL6A1: collagen, type VI, alpha 1 
PIP5K1C: phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 
 
 
3.3.3.1.2 Gene ontology analysis 
The 3 up-regulated and 74 down-regulated genes identified in the first investigation 
were subjected to a gene ontology (GO) enrichment study performed using the 
GeneSpring GX 9.0.2 GO browser138 to analyse their roles in biological processes. 
This analysis showed an over-representation of one molecular function category, 
“cadmium ion binding” (GO:0046870, p=0.0000838, 10 genes were found on the 4 x 
44 K Whole Human microarray belonging to this GO term), with five of them 
(MT1X, MT1B, MT1H, MT2A, MT1E),139 which belong to the metallothionein 
family, down-regulated when K562 cells adhered onto the “hit” PA368 and 365.  
 
3.3.4 Data validation 
One of the disadvantages of high throughput methods, such as DNA microarrays, is 
the sheer quantity of data, and the consequent risk of data error. Therefore, in order 
to validate the DNA microarray approach, the expression profiles of three down-
regulated genes (MT1E, MT2A and MT1X) were analysed by real-time PCR. These 
three genes were selected because they were involved in a particularly striking result 
the over-representation of one molecular function category “cadmium ion binding” 
(Chapter 3.3.3.1.2). In order to validate the results for these three genes, quantitative 
real-time PCR was performed on K562 cells grown for 72 h on PA368, PA365 and 
in suspension as a control. The gene expression was normalised with respect to the 
expression of a human ring finger protein 7 (hRNF7) housekeeping gene.  
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The relative mRNA level for each gene (as the fold change) is shown in Figure 3.8. 
The mRNA levels obtained clearly confirmed the data obtained via DNA microarray 




























MT1E -8.240 -7.594 -6.630
MT2A -4.780 -5.277 -5.612
MT1X -3.644 -3.704 -4.745
PA-365 PA-368 Microarray
 
Figure 3.8 Real-time PCR for three members of the metallothionein family (MT1E, MT2A, and 
MT1X) on the two polyacrylates (368 and 365). Fold change (in log2) of the genes expression levels is 





Polymer microarrays were successfully used for the identification of a family or 
group of polyurethanes that enabled adhesion and proliferation of a suspension cell 
line. Half of these PUs contained a tertiary amino group on their chain-extender, 
underlining the important role that positive surface charge plays in immobilising 
suspension cells on polyurethanes. To further emphasise the importance of positive 
surface charge, a group of polyacrylates containing the tertiary amino group was 
analysed by means of live cell scanning. Four polyacrylates PA365, 368, 371 and 
374 showed particularly strong cell immobilisation, and these were composed of 
HBMA. Further analysis of the interaction between the four hit polyacrylates and 
K562 cells, by means of SEM, showed cells with numerous contact points with the 
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substratum, as a consequence of adhesive growth onto the positively charged surface. 
This demonstrates that K562 cells not only interact with the polymer electrostatically 
but also by means of the involvement of membrane receptors. 
DNA microarrays were successfully used for gene expression profiling analysis, 
demonstrating that interactions between cells and some polyacrylates induce a 
number of changes in the transcriptom. When K562 cells become immobilised on 
polyacrylates, a chain of cellular changes is triggered, most notably resulting in 
down-regulation of the altered genes. The results of pathway analysis suggest that the 
process by which K562 cells adhere alters the cellular membrane, producing a 
significant down-regulation of membrane receptors and ligands. Furthermore, this 
down-regulation interferes with cell-cell communication through the control of 
cytokines. It seems also that the electrochemical gradient across the plasma 
membrane is modified by an alteration of calcium exchange between cells and 
environment. Validation by quantitative real-time PCR confirmed the gene 
expression analysis. 
 




Promotion and Stabilisation of hESC-
Derived Cells by New Polymer Matrix 
 
 
4.1 Human embryonic stem cells 
hESCs are pluripotent cells which are isolated from the inner cells of blastocysts 
approximately four to five days post fertilization.140, 141  
hESCs can differentiate into any of the three germ layers (ectoderm, endoderm and 
mesoderm) or they can, through self-renewal, maintain their undifferentiated state.142 
Theoretically, they can develop into each of the more than 200 primary cell types of 
the body when given the necessary stimulation (Figure 4.1).143 
The therapeutic use of stem cells began in the 1970s with bone marrow transplants 
(containing human stem cells) into patients with diseased blood or bone marrow.144 
Following many advances in the field, stem cells have become the subject of 
extensive research and are now being investigated in many areas of cell-based 
therapy, such as: (a) the development of new treatments for nervous system diseases 
by surgical implantation of fetal cells;145 (b) in tissue engineering for producing 
'spare parts' of the body for replacement of damaged or lost organs;146 and (c) in the 
field of drug and toxicity studies by monitoring the behaviour of embryonic stem 
cells exposed to a drug-candidate compounds.147, 148 However, it is necessary to 
reduce or obviate the current dependence that all stem cell types and their derivatives 
have on vertebrate animal cell and tissue derived biological reagents (ie. ECM 
preparations, blood serum/serum fractions) for their growth, differentiation and 
storage.149 These reagents can contribute to variations in stem cell behaviour through 
their own variability in purity and bioactivity. They also pose serious risks to 
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transplant recipients and through them, the general population, for transmission of 








4.2 Introduction to the Chapter 
Hepatocytes are the primary cells of the liver, and have been the particular focus of 
many studies, because the liver plays a central role in many functions of the human 
body.151 The ability to derive hepatocyte-like cells (HLCs) from hESCs constitutes 
an attractive scalable resource which holds great potential to develop a detailed 
understanding of human liver disease and metabolism. In particular, any strategies 
which might streamline and standardize the process of drug and toxicology testing  
would represent a significant development.152 Presently, primary human hepatocytes 
(PHHs) are the “gold standard” cell type used in predictive drug toxicology. 
Unfortunately PHHs are scarce, heterogeneous and expensive resources which 
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function only short term in vitro. The generation of HLCs from hESCs has the 
potential to address the major challenge to acquire a reliable and clonal source of 
functional human hepatocyte cells for this purpose.153 
Over the last few years, several studies have reported the differentiation of HLCs 
from hESCs.154-156 Although there have been improvements in efficiencies, current 
strategies still yield relatively heterogeneous populations. Recently Hay developed 
an efficient model of deriving HLCs from hESCs.157, 158 The generation of hepatic 
endoderm from hESCs for the first time provides a reliable and stable source of 
primary HLCs. As with hepatocytes freshly isolated from the liver,159 however, a 
technique has not yet been found for maintaining the phenotype and function of these 
HLCs in vitro. Long-term HLC culture would permit the in-depth study of human 
liver development and create novel opportunities to model hepatic disease in vitro.  
 
The investigation reported in this chapter relates to the search for polymers to which 
HLCs derived from hESCs are able to attach and maintain long term hepatocyte 
function. This may provide not only alternatives to current dependence on crude 
biological reagent (Matrigel (MG)), but a new generation of better extra-cellular 
support which significantly improves both HLCs function and lifespan. Once a 
suitable polymer was found, able to maintain and cultivate HLCs to such an extent 
that it might potentially allow the generation of a bio-artificial liver, tests to assess 
drug inducibility were also carried out. 
 
4.3 Polymer microarray screening 
Polymer libraries were screened in order to identify new supports for attachment, 
stabilisation and promotion of hepatocyte function. Hay cultivated hESC-derived 
HLCs using the in vitro model given in Figure 4.2.158, 160 At day 9 in the 
differentiation process the cells were removed from their substrate. Following this, 
HLCs were re-plated onto the polymer microarray and cultured in maturation 
medium (Chapter 7.4.3). The medium was changed every second day during 
maturation up to day 16 (Figure 4.2). The polymer microarray onto which the HLCs 
were re-plated at day 9 consisted of 337 polymers printed in quadruplicate onto an 
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agarose-coated glass microscope slide. At day 16, cells were fixed and stained with a 
nuclear stain (Hoechst 33342), and a monoclonal antibody against albumin followed 
by incubation with a fluorescein-conjugated secondary antibody. Cell attachment 
was recorded by using the HCS systems and PathfinderTM software. Hepatic 
phenotype and function was assessed by albumin production, which is an efficient 




Figure 4.2 The Hay model. hESCs were differentiated into HLCs using an efficient differentiation 
protocol (Chapter 7.4.2). Abbreviations – bFGF – basic fibroblast growth factor; MEF-CM – mouse 
embryonic fibroblast conditioned medium; KO DMEM – knock out Dulbecco's Modified Eagle 
Medium; DMSO - Dimethyl sulfoxide ; SR- serum replacement ; L-15 - Leibovitz's L-15 ; FCS – Fetal 





Primary screening identified eight polyurethanes and eleven polyacrylates that 
supported HLCs attachment, providing (over the 4 identical polymer spots) over 250 
cells/mm2 (Figure 4.3). It was observed that all the polyurethane surfaces formed 
from diol PHNGAD, MDI as the diisocyanate and an extender (see Table 4.1 for 
structure), as well as enabling high cell adhesion, displayed hepatic function for 8 
days after re-plating (Table 4.1).  
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and the extender all serve to modulate physical parameters, such as elasticity, 
wettability, surface topography, and that MDI helps to absorb ECM proteins. 
Polyurethanes which did not comprise an extender did not bind HLCs (Table 4.1). 
PU134 was found to be the most successful member of this family of polyurethanes 
in terms of binding and promoting the function of hepatocytes, although other related 
























































Figure 4.3 Polymers HLC binding after 8 days of cultivation on polymer microarray (day 16). The 
number of cells/mm2 (average from 4 spots) was calculated assuming a spot diameter of 300 µm. The 
error bars represent the standard error of the average. Complete HLC-polyacrylate binding analysis 
is reported on CD (Supplementary Information, excel folder named “Chapter 4”). 
 
 
Polymer structure Microarray screening 
PU 
Diol Diisocyanate Chain Extender Adhesion 
Hepatic 
Functions 
103 PHNGAD MDI DMAPD   
104 PHNGAD MDI DEAPD   
134 PHNGAD MDI BD   
247 PHNGAD MDI OFHD   
248 PHNGAD MDI none   
 
Table 4.1 The polyurethanes which promote HLC adhesion and hepatocyte phenotype. Only PU248 
which lacks a chain extender does not allow adhesion. 
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Monomers abbreviations: 
Diol: 












Figure 4.4 Fluorescent microscopy of HLCs re-plated for 8 days on the polyurethane spots which 
promote adhesion and hepatocyte function (DAPI channel shows the cell nucleus stained with 
(Hoechst 33342). FITC channel shows the hepatocyte phenotype via albumin staining using a 
monoclonal antibody followed by incubation with a fluorescein-conjugated secondary antibody. A) 
PU134; B) PU103; C) PU104; D) PU247. 
 
 
4.4 Coverslip experiments 
In order to study hepatic function in further detail and confirm the results of these 
experiments, six hit selected polymers (PU134, 212, 223 and PA119, 196, 395) 
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4.4.1 Serum protein production analysis 
After re-plating at day 9 as above, cells were cultured for a further 15 days onto the 
six polymer coverslips in conditions that support hepatic function and differentiation 
in vitro (Chapter 7.4.3),158, 160 with hepatocyte function defined by the expression of 
a panel of hepatocyte-specific export proteins (fibronectin,119 fibrinogen161 and 
transthyretin (TTR)162).Using an enzyme-linked immunoabsorbant assay (Chapter 
7.4.4.2),163, 164 PU134 was identified as the most effective bio-active support, 

























Figure 4.5 HLCs serum export protein production. HLCs were plated and maintained in 1 mL of 
hepatocyte culture medium on MG, PU134, 212, 223 and PA119, 196, 395. After 24 h, culture 
supernatants were harvested and serum protein production was measured by ELISA and quoted as 
nanograms per milligram of tissue culture medium. In all lines, the serum protein tested was detected: 
fibrinogen, fibronectin and TTR (n = 3). 
 
 
4.4.2 Morphology analysis 
MG was used as the control as it has previously been shown to improve hepatocyte 
performance in vitro and is currently considered the “gold standard”.165  
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A significant change in HLCs morphology was observed by day 24, with HLCs 
passaged and maintained on MG or PU196, 212 and PA119, 196, 395, having 
become granular. In contrast, HLCs passaged on PU134 maintained a clear hepatic 





Figure 4.6 Contrast microscopy (x10) of HLC morphology plated on: A) MG; B-D) PU134, 212, 223 
respectively and (E-G) PA119, 196, 395 respectively. Scale bar 50 µm. 
 
 
4.5 Polyfibre core experiments (bio-artificial liver) 
A subsidiary branch of this research concerns hepatocyte transplantations, whose aim 
is to increase the number of functional hepatocytes, and could be employed as an 
alternative therapeutic approach to whole organ transplantation for liver failure.166  
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Stem cell-derived hepatocytes could also be used to develop extra-corporeal support 
devices for acute liver failure.167 In order to explore the potential for generating a 
bio-artificial liver, a polyfibre core (PFC) was prepared by dip-coating it with PU134.  
 
4.5.1 SEM analysis 
In order to generate a bio-artificial liver, a PFC (Figure 4.7 A) was dip-coated in 
PU134 (Figure 4.7 B). The control was PFC in its native form. Upon adopting a 
hepatic fate (day 9), HLCs were detached from the biological ECM and re-plated 
onto native or PU134-coated PFC and cultured for a further 15 days under conditions 
that supported hepatic identity (Chapter 7.4.3).158, 160 At day 24 HLCs had attached to 
the uncoated and PU134-coated PFC matrix, and the cells were fixed for scanning by 
electron microscopic examination of cell structure. HLCs maintained on uncoated 
PFC demonstrated cell attachment and cell processes resembling stress fibres 
(Figure 4.7 C), suggesting that a particular arrangement of the microfilament system 
may be necessary for their adhesion. In contrast, HLCs maintained on PU134-coated 
PFC exhibited a smooth tissue-like appearance (Figure 4.7 D), which may limit the 
effects of fluid shear stress (the drag exerted by liquid flowing over cells in culture). 
The tissue-like substance, formed by HLCs and PU134, might limit this stress when 
compared to HLCs plated on the uncoated PFC but this hypothesis remains to be 
investigated. 
 
4.5.2 Bio-artificial liver drug inducibility analysis 
At day 9 in the differentiation process the cells were removed from their biological 
ECM. HLCs were cultured on the two PFCs (one native, one dip-coated in PU134) 
for 13 days, changing media every second day. At day 22 HLCs were induced with 
0.4mM phenobarbital and maintained in control media for 48 h, changing the media 
daily. At day 24 the HLCs maintained on both the PFC support matrices was 
assessed for CYP3A4 drug induction. CYP3A4 was chosen because it has been 
estimated to play a role in the metabolism of approximately 50% of therapeutic drugs 
and is, therefore, essential to predictive drug toxicity and extra-corporeal support.168 
The uncoated PFC supported hepatocyte attachment and function (Figure 4.8, - 
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PU134, violet bar), but however did not support phenobarbital drug induction of 
CYP3A4 (Figure 4.8, - PU134, purple bar). In contrast HLCs re-plated onto 
PU134-coated PFC supported both HLC attachment (Figure 4.8, + PU134, violet 
bar) and phenobarbital inducible CYP3A4 drug metabolism (Figure 4.8, + PU134, 
purple bar). These data exemplify the value of PU134 and HLCs in both a bio-





Figure 4.7 HLCs were either plated on an uncoated or PU134 coated polyfibre. At day 24 in culture 
the cells were fixed and examined by electron microscopy. A) PFC with SEM image of uncoated 
(native) PFC; B) SEM image of PU134 coated PFC; D) SEM image of uncoated PFC with cells 
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Figure 4.8 HLCs cytochrome P450 metabolism. HLCs were either plated in an uncoated or coated 
PFC of the bio-artificial liver. The cultures were incubated in the presence (purple bars) or absence 
(violet bars) of phenobarbital in order to measurement of CYP3A4 activity (Chapter 7.4.5.3). At 48 h 
after treatment, 50 µL of culture medium was removed and read on a luminometer (POLARstar 
optima). CYP3A4 activity is expressed as relative light units (R.L.U.) per milliliter of tissue culture 




By fusing cutting-edge hESC models and high throughput polymer screening 
technologies we have developed a novel system which identifies ECM supporting 
cell specific function and viability. Using this approach a generic polyurethane extra-
cellular support (PU134) has been pinpointed which significantly improves both 
hESC-HLC function and lifespan.  
Before the advent of scalable hESC-HLC models, a number of strategies were 
focused on improving primary human hepatocyte lifespan and function by means of 
immortilisation. Cells established using these methods exhibited, however, 
phenotypic changes, poor hepatic specific gene function and karyotypic 
abnormalities over prolonged culture. By contrast, the method reported in this 
chapter maintains long-term hESC-HLC function of high fidelity in a scalable model 
synthesizable to GMP standards, which contains no xenobiotic material.  
In conclusion, a system has been created in which we observe improved hESC-HLC 
performance. More importantly, proof-of-concept has been provided that high 
throughput polymer screening is a viable approach for identifying simple and 
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scalable culture matrices which may “hold” or regulate specific cell phenotypes. This 
























Biopolymer Matrices as Defined 




5.1 Adult stem cells 
The primary role of adult stem cells in a living organism is to maintain and repair the 
tissue in which they are found. 169-172 Adult stem cells are rare: they are found in so-
called niches, surrounded by millions of ordinary cells, which differ according to the 
tissue in which they are located. Although adult stem cells are rare they are more 
abundant in organs which have the constant requirement for cell regeneration such as 
blood and skin. Bone marrow (BM) and umbilical cord blood (UCB) are particularly 
rich tissues for adult stem cells.173 There are three type of adult stem cells contained 
in the bone marrow: hematopoietic stem cells (HSCs), which give rise to the three 
classes of blood cells that are found in the circulation – white blood cells 
(leukocytes), red blood cells (erythrocytes), and platelets (thrombocytes);174-176 
mesenchymal stem cells (MSCs), which are found arrayed around the central sinus in 
the bone marrow and have the capability to differentiate into osteoblasts, 
chondrocytes, myocytes, and many other types of cells, while also functioning as 
‘gatekeeper’ cells of the bonemarrow;171, 177 and endothelial progenitor cells 
(EPCs).178, 179 
Typically, once removed from the body, the capacity of adult stem cells to divide 
without differentiating is limited, making generation of large quantities of stem cells 
difficult.180, 181 There are many efforts to find better ways to grow large quantities of 
undifferentiated adult stem cells in cell culture and to manipulate them to generate 
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specific cell types so they can be used to treat injury or disease.180 An example of 
potential treatments includes repairing damaged heart muscle following a heart 
attack with cardiac muscle cells.182 Importantly, it must be demonstrated that a single 
adult stem cell can generate a line of genetically identical cells that then gives rise to 
all the appropriate differentiated cell types of the tissue.183 To confirm 
experimentally that a putative adult stem cell is indeed a stem cell, scientists tend to 
show either that the cell can give rise to these genetically identical cells in culture, 
and/or that a purified population of these candidate stem cells can repopulate or 
reform the tissue after transplant into an animal.184, 185 
 
5.1.1 Endothelial progenitor cells 
Traditionally, vascular repair in adults was thought only to occur through the 
proliferation and migration of pre-existing mature endothelial cells (ECs) from the 
adjacent vasculature.186 Evidence now confirms the existence of bone-marrow-
derived EPCs which play an important role in de novo vascularisation.187-190 In 
response to injury, EPCs are mobilised and recruited to the ischaemic sites where 
they contribute to new-vessel formation.179, 186, 187, 190, 191 EPCs not only directly 
incorporate into blood vessels, replacing the defective or injured mature endothelial 
cells, but also secrete a variety of cytoprotective or proangiogenic factors in a 
paracrine manner to promote the survival and proliferation of endothelial cells.192 
EPCs can be isolated from adult peripheral and umbilical cord blood (UCB). Robust 
proliferative activity is an important property of EPCs that distinguishes them from 
monocyte/macrophage-derived endothelial-like cells.193 EPCs are identified 
according to the expression of both hematopoietic stem cell markers and endothelial 
cell markers.191 However, their characterisation remains controversial,189 partly 
because researchers have used EPCs from a variety of sources and employed 
substantially different isolation procedures.189, 191, 192 Initially, two antigens shared by 
EPCs and haematopoietic stem cells, vascular endothelial growth factor (VEGF) 
receptor 2 (also referred to as Flk-1 or KDR) and CD34, were used to isolate EPCs 
from the leukocyte fraction of peripheral blood,189 and subsequent studies have 
identified EPCs on the basis of co-expression of CD133 with CD34 expression.179, 189, 
191 More recently the co-expression of CD34, CD133 and CD146 has been used to 
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identify a representative population of human EPCs, which can be isolated by flow 
cytometry sorting based on co-expression of these markers.194, 195 In spite of the 
existence of numerous clinical studies based on localised implantation of autologous 
cells to revascularise ischaemic tissue, particularly in myocardial and critical limb 
ischaemias, a precise definition of EPCs remains elusive. In vitro phenotypic studies 
have demonstrated that cells defined as EPCs by different groups consist of a 
heterogeneous population, containing cells with differential phenotype and 
outgrowth potential.196, 197 EPC definitions include cells which contribute to 
angiogenesis directly by incorporation into new vessels (true EPCs), also referred to 
as endothelial outgrowth cells (EOCs) and, indirectly, by positively regulating the 
angiogenic process (myeloid-derived EPCs or also referred to as CFU-Hill colony 
forming cells).198 
 
5.2 Introduction to the study 
Since the discovery of circulating endothelial cells in peripheral blood a decade 
ago,179 regenerative stem-cell-based therapeutic strategies aimed at developing novel 
therapies or improving current treatments to restore the ischaemic tissue have been 
under investigation.199 Traditional methods of direct cell infusion or injection (which 
represent the most commonly utilised cell delivery strategy in the clinic – for 
example, bone marrow transplants) often lead to: a) massive cell death of the 
transplanted cells due to mass transport limitations of oxygen and nutrients in case of 
local injection;200 b) extremely poor (typically less than 3%) homing/engraftment 
efficiency to the target tissue (in the case of systemically infused cells);201 and c) the 
loss of control over the fate of the transplanted cells.202 
The introduction of biomaterial scaffolds as a cell carrier provides a potential 
solution to these problems, because they can be a template for guiding the formation 
of new tissue and for promoting engraftment with the host.200 An emerging area of 
bioengineering research is the development of synthetic biopolymer matrices as 
defined environments for EPC growth, providing sites of adhesion together with 
signals that control EPC propagation and synchronise their differentiation.203 
Peripheral blood-derived EPCs have been explored for the generation of blood 
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vessels in vitro and for the endothelialisation of artificial vessel prostheses and 
endoluminal vessel prostheses.204, 205  
This study aims to develop, via high throughput screening of a polymer microarray, 
the identification of new polymer matrices which contain the necessary signals that 
not only promote adhesion and propagation of EPCs but also, synchronise their 
endothelial specialisation.206 If these could be manufactured to GMP standards they 
could potentially provide a resource for the construction of extra-corporeal devices 
(artificial vessel prostheses)207 and facilitate novel studies in modern vascular 
surgery. 
 
5.3 Polymer microarray screening  
Polymer libraries were screened in order to identify new supports for attachment, 
promotion, propagation, and to synchronise endothelial cells function.204 
Cord blood (CB) products (50 mL) were aspirated from the umbilical placental veins 
from normal caesarean deliveries and collected into heparin.208 Mononuclear cells 
(MNCs) were isolated by buoyant density centrifugation and cultured over 3 weeks 
in endothelial basal medium (EBM-2). By that time, spindle-shaped endothelial cells 
now called EOCs started to emerge.195 These cells express a number of endothelial 
markers (Chapter 5.4.1) comparable to a mature endothelial cell and human 
umbilical vein endothelial cells (HUVECs) are able to form new blood vessels in 
MG (Figure 5.1 A and B).209 Thereafter cells were passaged until incubation with 
the polymer microarrays. As a control HUVECs,210 which are specialised endothelial 
cells, were maintained in culture. At this point EOCs and HUVECs were removed 
from their substrate.211 Following this, cells were re-plated onto two identical 
polymer microarrays containing 345 polyurethanes and polyacrylates each printed in 
quadruplicate. After 3 days, cells were fixed and stained with a nuclear stain 
(Hoechst 33342), and directly conjugated monoclonal mouse anti-human CD31-PE 
antibody. CD31 (Anti-PECAM-1) recognizes the platelet/endothelial cell adhesion 
molecule-1 (PECAM-1), a 130 to 140-kdalton single-chain integral membrane 
glycoprotein that is a member of the immunoglobulin gene superfamily.212 The 
CD31 antigen is expressed on endothelial cells, functions as a vascular cell adhesion 
 
 - 66 -
molecule and is involved in the process of leukocyte migration through the 




Figure 5.1 Contrast microscopy using an inverted microscope (Nikon Eclipse TS100-F) equipped 
with an integrated digital camera (x40). Images were taken at 22 h. Both A) HUVECs and B) EOCs 
are able to form tubular structures in MG.196 
 
 
5.3.1 Polymers analysis 
At this point analysis was carried out as described previously (Chapter 2.2.1), using 











Figura 5.2 Fluorescent microscopy: A) EOCs; and B) HUVECs on PA383 which promote adhesion 
and endothelial phenotype. DAPI channel shows the cell nucleus stained with (Hoechst 33342); 
rhodamine channel shows the endothelial phenotype via CD31 antigen staining using a directly 
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Primary screening identified six polyurethanes and twelve polyacrylates that 
supported attachment of EOCs providing over 150 cells/mm2 (Figure 5.3). PU139 
and 140 have an almost identical chemical structure, composed of diol PTMG and 
diisocyanate 1,3-Bis(isocyanatomethyl) cyclohaxane (BICH) and chain extender 
ethylene glycol (EG) and differing only in the molecular weight of the diol (650 and 
1000 respectively). PU134, which was the most successful for binding HLCs 
(Chapter 4), was shown to have high affinity also for EOCs and HUVECs.  
A few polyacrylates have almost identical chemical structures, differing only in their 
molar ratios, for example polyacrylates 395 and 398 and polyacrylates 175 and 177 
(for polymer structures, see Appendix II). PA119, 383 and 395 (Figure 5.4) were 
found to be the most successful polymers for both cell lines (EOCs and HUVECs), 
providing over 200 cells/mm2 (Figure 5.3). This result is consistent with the 
hypothesis that PA119, 383 and 395, as well as enabling high cell adhesion, 
displayed endothelial specialisation of EOCs after re-plating (rendering them as 
























































Figura 5.3 Polyurethanes and polyacrylates which provide a high EOC binding, compared to the 
HUVEC, after 3 days of cultivation on polymer microarray. The number of cells/mm2 (average from 4 
spots) was calculated assuming a spot diameter of 300 µm. The error bars represent the standard 
error of the average. Complete EOC and HUVEC-polymer binding analysis is reported on CD 
(Supplementary Information, excel folder named “Chapter 5”). 
 





























Figure 5.4 Chemical compositions of PA119, 383 and 395. Abbreviations: MEMA – 2- 
methoxyethylmethacrylate; VP-4 – 4-vinylpyridine; EMA – ethyl methacrylate; DEAEA – 2- 
(diethylamino)ethyl acrylate; BMA – butyl methacrylate. 
 
 
5.4 Coverslip experiments 
In order to study the endothelial function in further detail and confirm the results of 
these experiments, the three selected polymers (PA119, 383 and 395), with excellent 
binding for EOCs and HUVECs (Figure 5.4), were scaled-up and spin-coated onto 
glass coverslips for flow cytometry analysis.  
 
5.4.1 Flow cytometry analysis 
EOCs and HUVECs were cultivated as previously described (Chapter 5.3) on the 
glass coverslips (Chapter 7.5.4.1), then directly stained and analysed for 
immunophenotyping expression of surface endothelial markers using anti-human 
monoclonal antibodies (MAbs) conjugated to phycoerythrin (PE), fluorescein 
isothiocynate (FITC), Peridin Chlorophylla protein (PerCP) or Allophycocyanin 
(APC) as described.196 Harvested cells were resuspended and analysed by flow 
cytometry (Figure 5.5 A and B). Phenotype analysis revealed that all 3 polymers 
promote endothelial cellular growth and endothelial specialisation comparable to 
cells grown in their gold-standard conditions (collagen and bare plastic for EOCs and 
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HUVECs, respectively). PA119, 383 and 395 confirmed the result from the high 
throughput analysis (Figure 5.3). EOCs and HUVECs expressed endothelial cells 
surface markers von Willebrand factor (vWF), vascular endothelial growth factor 
(VEGF) receptor 2 (also referred to as Flk-1 or KDR), endothelial nitric oxide 
synthase (eNOS), CD31, CD34, CD105 and CD146 but not the haematopoietic cell 






































Figure 5.5 Flow cytometry analysis: A) EOCs grown on PA119, 383, 395 and, as a control, collagen; 
B) HUVECs grown on PA119, 383, 395 and, as a control, bare plastic. Shown are representative data 
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5.5 Sponge experiments 
Further studies were undertaken by cultivating EOCs and HUVECs on pieces of 
polyether sponges dipped in a solution of PA383. The ultimate aim of studying 
sponge as a cell scaffold was to generate functional 3-D tissues outside of the 
organism, which might then be implanted into the organism. In an ideal scenario 
PA383 would have the ability to adhere EOCs from in vitro cultivation, and once 
implanted, either promote the growth and the specialisation of cells anchored to the 
sponge previously or recruit distant bone marrow-derived progenitor cells for 
restoring vascularisation at the implanted scaffold/host tissue interface. 
 
5.5.1 In vitro 
Two 1 cm3 polyether sponges were dip-coated in a 1% solution of PA383 and a 
further two 1 cm3 sponges were dip-coated in the gold standard matrix support 
(growth factor reduced (GFR)-MG). Polymer coated sponge showed a smoother 
uniformly coated layer allowing a friendlier environment for cells to grow (Figure 
5.6). The coated sponge was impregnated with either EOCs or HUVECs in complete 
EBM-2 medium that supports endothelial cultivation.193 After overnight incubation 
cells in both sponges were fixed and SEM analysed, Figure 5.7 A and C clearly 




Figure 5.6 Sponge pre-treated with either GFR-MG or PA385. A) 1 cm3 polyether sponge, scale bar 5 






 - 71 -
The other two sponges pre-treated with GFR-MG lacked tube formation (Figure 5.7 
B and D). It is evident that on increased number of EOCs adhered to the PA383 
sponge, allowed a major release of cytoprotective or proangiogenic factors in a 




Figure 5.7 EOCs and HUVECs were either loaded on an uncoated or PA383 coated sponge. After 12 
h incubation the cells were fixed and examined by electron microscopy. A) PA383 coated sponge with 
HUVECs; B) GFR-MG pre-treated sponge with HUVECs; C) PA385 coated sponge with EOCs; D) 
GFR-MG pre-treated sponge with EOCs. 
 
 
5.5.2 In vivo 
The functional 3-D tissue generated (in vitro) was tested for its ability to promote 
cell growth and recruit distant bone marrow-derived progenitor cells for promoting 
engraftment with the host, after implantation. Mice were anaesthetised and a 
sterilised polymer-coated sponge cylinder (0.5 cm/1 cm) was implanted 
subcutaneously on each flank. Sponges were impregnated with PA383 and loaded 
with EOCs. Each animal had a EOCs-loaded PA383 impregnated sponges on one 
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Twenty days after implantation, mice were sacrificed and sponges were excised and 
analysed for vessel formation. Sponges were divided into 3 pieces and analysed as 
follows: SEM imaging; Chalkley count215 and haemoglobin assay.216 
 
5.5.2.1 SEM analysis 
After implantation in mice, the sponges impregnated with PA383 promoted better 
engraftment within the host. Figure 5.8 B shows clearly the formation of a vascular 
network in contrast with the blank (uncoated) sponge (Figure 5.8 A, red arrows). 
Notably, uncoated sponge resulted in a poor and incomplete engraftment within the 
host, showing the native sponge without cells at several points (Figure 5.8 A, red 
arrows). It seems evident that the large number of EOCs adhered to the PA383 
sponge, allowed not only a large quantity of local cell growth but also made possible 
a major release of cytokines which recruited distant bone marrow-derived progenitor 






Figure 5.8 Electron microscopy analysis: A) sponge uncoated (native); B) sponge pre-coated with 
PA383. Both sponges were pre-incubated with EOCs overnight. 
 
 
5.5.2.2 Blood vessels formation analysis 
Histological analysis revealed that significantly increased numbers of vessels formed 
on the polymer coated sponge compared with the control (sponge uncoated). 
One part of the sponge was fixed in 10% formalin and embedded in paraffin wax. 
B A 
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Sections (5 µm) were stained with haematoxylin/eosin for identification of blood 
vessels, as described.217 Sponge vessel density was determined by using the mean of 
triplicate Chalkley counts on two sections per sponge (Figure 5.9 left).215, 218 
Histology showed vascularisation by a number of blood vessels but in polymer 
coated sponges had significantly more blood vessels compared to non polymer 
coated sponges (Figure 5.9 left). 
 
5.5.2.3 Haemoglobin assay  
A further study focused on measuring the concentration of haemoglobin in the 
sample. It is an excellent method of determining the frequency of blood vessels, 
which are proportional to the blood haemoglobin.216 One part of the sponge was 
weighed, homogenized in 1 ml sterile PBS, centrifuged and the amount of 
haemoglobin present in the sample measured (Figure 5.9 right). Polymer coated 
sponges had significantly more haemoglobin, displaying ~2-fold increase compared 





Figure 5.9 Left) Sponge vessel density determination by the Chalkley method on two sections per 
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5.6 Stent experiments 
5.6.1 Stenosis 
Stenosis is one of the most common pathological conditions connected to the 
cardiovascular system: it is a restriction of the blood vessels caused by an 
atherosclerotic plaque which is deposited on the arterial wall reducing or arresting 
the flow of blood to the heart.219, 220 Coronary angioplasty is an interventional 
strategy which consists of pressing the stenotic plaque against the arterial wall 
through the introduction and expansion, at the site of the obstruction, of a catheter 
with balloon.221 This treatment was introduced in 1979 and rapidly became the 
principal method of coronary revascularisation as well as the most common 
therapeutic procedure used in cardiology.222, 223 Nonetheless, in the long term 
angioplasty often ends in reblockage of the treated vessel, that is, restenosis.224 
Restenosis is the response of the blood vessel to the tissue damage caused by 
angioplasty and is linked mainly to huge proliferation of neointima and the elastic 
recoil of the vessel walls.225 Elastic recoil is the collapse of the vessel wall into the 
lumen, caused by loss of elasticity, at the position of plaque pressed on the vessel 
walls.226  
 
5.6.2 Stents and scope of the study 
A notable step forward in the treatment of such pathological ischemia occurred in the 
1990s with the introduction of metal scaffolds, stents, capable of giving the stenotic 
vessel the necessary mechanical support to avoid collapse.227 The introduction into 
medical practice of such devices revolutionised the field of interventional cardiology, 
bringing notable improvements in prevention of restenosis.228 In spite of the fact that 
stents are capable of eliminating elastic recoil of the stenotic vessel, however, their 
implantation and the consequent trauma to the vessel walls initiates an excessive 
proliferation of neointima and, therefore, an in-stent restenosis.229  
An initial negative reaction following implant of the stent is due to the raised 
thrombogenicity of the metal link of which it is made. Therefore, a first intuitive 
approach is aimed at improving the biocompatibility of the implant through the 
recoating of the stent with polymer film.230  
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Although such modification brings substantial improvements in clinical intervention, 
through the use of hybrid devices capable of combining the supportive properties of 
metal with the biocompatibility of polymers, in a certain percentage of cases in-stent 
restenosis still occurs. In light of this, researchers in engineering, biology, 
biomaterials and cardiology have, through an interdisciplinary approach, developed a 
new device combining the supportive properties and biocompatibility previously 
described with pharmacological therapy. Stents have been developed which release 
drugs – Drug-Eluting Stent (DES) – which use the metal structure of the stent as a 
platform for local release of drugs capable of preventing and avoiding restenosis.231, 
232. More recently, other techniques, including impregnating stents with either 
antibodies or integrin-binding cyclic Arg-Gly-Asp (cRGD) peptides, were analysed 
in vitro and in vivo. These functionalised stents display molecules that are directed 
toward proteins on the cell surface of endothelial progenitor cells, thereby attracting 
the EPCs to migrate to the surface of the stent and limit coronary neointimal 
formation.233 
The project reported in this chapter describes a possible alternative which involves 
the use of polymers which promote the adhesion of endothelial progenitor cells.  
 
5.6.3 Stent cell coating 
In order to study adhesion of endothelial outgrowth cell to the polymer-coated stent, 




Figure 5.10 A) Coronary stent, scale bar 1cm. B) SEM image of uncoated stent; C) SEM image of 
PA383 coated stent. 
B A C 
C 
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The control was a coronary stent in its native form. EOCs were removed from their 
substrate and re-incubated onto both, a PA383-coated stent or native stent and culture 
ed over-night in conditions that support endothelial cell survival.193 
In order to assess cellular adhesion and the utility of PA383, following incubation 
cells on both stents were fixed and SEM analysed (Figure 5.11). EOCs maintained 
on the uncoated stent showed poor cell attachment (Figure 5.11 A, B), whereas 
EOCs maintained on the PA383-coated stent exhibited a consistent adhesion with 
around 80% of confluence (Figure 5.11 C, D).These data exemplify the value of 




Figure 5.11 EOCs were either plated on uncoated or PA383-coated coronary stent. After overnight 
incubation in vitro the cells were fixed and examined by electron microscopy. A and B) Uncoated 
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5.7 Conclusions 
Thanks to polymer microarray a library of 345 polyacrylates and polyurethanes were 
screened to identify new synthetic biopolymer matrices as defined environments for 
endothelial progenitor cell adhesion, cell propagation and synchronise their 
endothelialisation. Six polyurethanes and thirteen polyacrylates supported attachment 
of EOCs. Three polymers (PA119, 383 and 395) showed strong binding both for 
EOCs and HUVECs. This suggests that those three polymers might allow 
specialisation of EOCs, a hypothesis supported by the expression of endothelial 
surface markers when EOCs were cultivated on the scaled up coverslips in contrast 
with the gold standard supports.  
PA383 was used to coat a sponge for the generation of blood vessels in vitro and for 
the endothelialisation of artificial vessel prostheses. The results showed a notable 
difference in the process of vascularisation between the sponge coated with PA383 
and that coated with the gold standard matrix support GFR-MG. 
This result suggested a possible application in vivo as a potential method for 
remedying ischaemic injury. The artificial vessel prostheses generated in vitro coated 
with PA383 was implanted in mice with a notable difference in the re-
endothelialisation in contrast to the native sponge. The reason for this is unclear but 
might have been due to the fact that there was already a large quantity of cells 
growing on the sponge. Alternatively, it might have been caused by the fact that 
those cells attracted bone marrow-derived progenitor cells through the release of 
cytokines. The capacity of PA383 to bind endothelial progenitor cell suggests the 
possibility of using this polymer for coating stents. These cells might be isolated 
from blood from the patient and used to adhere and cover the stent pre-coated with 
the selected polymer in vitro. At this point the stent could be reintroduced into the 
patient avoiding the problems mentioned above. It was demonstrated that a stent can 
easily be coated with PA383, and, as a consequence of cell adhesion, an EOCs layer 
was generated in vitro. This method might, therefore, offer a future means of 












Polymer microarrays were used to identify a number of polymers that would 
selectively capture Salmonella or E. coli (prokaryotic cells), or prevent microbial 
binding. The approach offers tools for the identification of new biomaterials for 
either selective bacterial enrichment or preventing surface contamination, with 
polymers identified that allowed discrimination between bacterial genera. 
 
 
6.1 Introduction to the study 
Salmonella is a serious pathogen of medical and veterinary importance in both 
developing and developed nations.234, 235 For humans, infection occurs mainly via 
contaminated food and water, with disease largely manifesting itself as 
gastroenteritis with fever and other associated symptoms, such as occasional reactive 
arthritis or meningitis,236 but in the case of serovars Typhi and Paratyphi, infection 
can result in typhoid fever. Worldwide, around 1.3 billion cases of salmonellosis are 
reported per year with 3 million fatalities,237 while there are approximately 20 
million cases of typhoid fever per annum, with 200,000 deaths.238 Where drug 
intervention is required, fluoroquinolones are the primary drugs of choice for treating 
systemic infections, however, many patient isolates now exhibit multi-drug 
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It is well known that bacterial surface charge, cell density, and the presence of 
microbially-produced compounds, such as exopolysaccharides, pili or flagella, are 
determinant factors in the adhesion process, but other physicochemical features such 
as pH, temperature, composition of growth media are also known to affect surface 
attachment.240, 241 
In order to control bacterial attachment, there is a need for materials which result in 
specific bacterial sequestration or repulsion. Such materials would offer a means for 
the rapid isolation of organisms from hospital, industrial or domestic environments, 
or for minimising surface contamination through the development of microbe 
repelling/killing surfaces, as well as innovative intervention approaches for reducing 
bacterial loads via human, animal or poultry feeds. 
In this chapter polymer microarrays were used to explore: (i) the identification of 
polymers that allowed rapid and specific/selective attachment (sequestration) of 
bacteria; (ii) materials that are capable of limiting or preventing bacterial adhesion. 
These studies focused on the adhesion of the food-borne pathogenic bacterium 
Salmonella enterica serovar typhimurium (S. typhimurium), strain SL1344,242 and the 
commensal bacterium Escherichia coli, strain W3110.243 
 
6.2 Analysis of bacteria attachment 
S. typhimurium was evaluated in comparison with a commensal strain of E. coli, both 
expressing Green Fluorescent Protein (GFP).244 Fluorescence was used to profile 
bacterial binding on a library of 372 polyurethanes and polyacrylates. S. 
typhimurium-GFP or E. coli-GFP were added to duplicate polymer microarrays, each 
containing 1480 spots (four per polymer), and incubated at room temperature (RT). 
Subsequently the polymer microarrays were washed and analysed using a FITC filter 
with a BioAnalyzer 4F/4S LaVition BioTech scanner, with bacterial adhesion 
evaluated via the integrated fluorescence intensity for each spot after background 
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Figure 6.1 La Vition BioTech software automatic quantification. A) Fluorescence associated with the 
expression of GFP on a library of 372 polyurethanes and polyacrylates (scale bare 3.5mm). Areas in 
the square are hit polymers, shown in B and C (scale bare 300 µm). B) Background of the polymer 
auto fluorescence (left) is shown prior to adding bacteria and fluorescence intensity detection in 
presence of bacteria (right) after background correction on representative strong binding PA141. C) 
Poor binding PA311. In A and B: 3D image of the spot in the selected area is shown in lower panel 
(scale bare 100µm). In B and C: the number in the square is the position of the polymer spot in the 
array, allocated automatically by the software. An intensity scale bar is shown (botton right).  
 
 
Analysis revealed six polyacrylates and thirteen polyurethanes which showed strong 
binding of Salmonella (polymer microarray slides were washed vigorously with 
shaken three times with PBS, and then rinsed in deionised water) (Figure 6.2). 
Binding of E. coli on these polymers was weaker in general but varied with the 
particular polymer. For example, PU222 showed good binding of Salmonella and E. 
coli, whereas there was a substantial difference between the binding of Salmonella 
and E. coli on PU178. Analysis of the polyurethanes revealed that the diols, PTMG 
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Four of the six hit polyacrylates (141, 158, 167 and 168) contained the monomer 




































































Figure 6.2 Polymers which mediate high Salmonella binding for two gram-negative bacteria linegies 
(Salmonella and E. coli). Bacteria binding expressed as background corrected mean fluorescent 
intensity (a.u = arbitrary units) with error bars representing the standard deviation. Complete 
Salmonella and E. coli-polymer binding analysis is reported on CD (Supplementary Information, 
excel folder named “Chapter 6”) 
 
 
39 PT MG 1000 HDI BD
92 PHN AD 900 BICH OFHD
104 PPG 425 BICH DEAPD
116 PT MG 2000 HDI BD
119 PHN AD 900 BICH DMAPD
120 PHNGAD 1800 MDI DEAPD
126 PPG 425 TDI DMAPD
138 PT MG 2000 MDI EG
159 PT MG 250 BICH EG
178 PPG 1000 MDI OFHD
208 PPG 425 BICH BD
219 PT MG 250 MDI BD
222 PPG 1000 MDI DMAPD
PU
Polymer Structure
Diol Mn Diisocyanate Chain Extender
` 
 
Table 6.1 Salmonella binding polyurethanes with polymer composition. Diol/Diisocyanate/Chain 
Extender (1:2:1), except PU39 and PU208 which are: Diol/Diisocyanate (1:1). 
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Monomers abbreviations: 
Diol: 
PPG: poly(propylene glycol) 











ED: ethylene diamine 
EG: ethylene glycol 
 
 
mon (1) mon (2) mon (3)
73 HBMA DEAAm - 90 10 -
141 HEMA DMAEMA - 50 50 -
158 HEMA BACOEA - 70 30 -
167 HEMA VI - 70 30 -
168 HEMA VI - 50 50 -
571 MEMA A-H DEAEA 50 15 35
PA
Polymer structure
Monomer 1 Monomer 2 Monomer 3 Ratio (mol)
 
 









DMAEMA: 2-(diethylamino)ethyl methacrylate 
BACOEA: 2-[[(butylamino)carbonyl]oxy]ethyl acrylate 
VI: 1-vinylimidazol 
A-H: acrylic acid 
Monomer 3 
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Sixteen polyacrylates showed substantial inhibition of Salmonella adhesion, with 
thirteen containing the monomer MMA. Eleven of these also contained the monomer 
glycidyl methacrylate GMA (Figure 6.3). PA221 and PA222 which were composed 
of both MMA and MA-H were highly successful in preventing adhesion of both 
Salmonella and E. coli. PA317, PA323 and PA324 selectively bound E. coli, but did 
not bind Salmonella, with PA323 and PA324 differing only in the molar ratios of the 
monomers. MMA and GMA, the related polymer PA322 showed a similar trend 
(Figure 6.3), but with slightly less selectivity (see Appendix II for monomer 























































Repellent for both strains Selective binding/poor binding 
MA-H
 
Figure 6.3 Polyacrylates showing Salmonella binding and both poor and strong E .coli binding (a.u 
= arbitrary units). X-axis: polymer references. Complete Salmonella and E. coli-polymer binding 
analysis is reported on CD (Supplementary Information, excel folder named “Chapter 6”). 
 
 
6.2.1 Reprinting  
Following the analysis of the entire library, several polymers which resulted in the 
strongest or weakest binding of Salmonella were printed onto another microarray 
slide and examined. Each polymer was printed in a 5 x 5 pattern and incubated 
overnight with bacteria.  
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PU104, 120, 126 and 141 showed consistent cellular attachment, whilst the four poor 
binding polymers PA221, 311, 408 and 412 confirmed their anti-bacterial binding 





Figure 6.4 A) Slide template with 8 fields of 25 spots pattern (PU104, PU120, PU126, PA141, 
PA221, PA311, PA408 and PA412 respectively); B) fluorescent microscopy imaging of Salmonella-
GFP (Fluorescein channel). Scale bar 3.5 mm. 
 
 
6.2.2 Impact of time on attachment 
It would clearly be advantageous for a polymer to be able to bind bacteria in a rapid 
time frame. Therefore, to test the rapidity of Salmonella binding, an array with the 
letters ‘UK’ was fabricated using high and low binding polymers (PU104 and PA311, 
respectively) and Salmonella were incubated on the array for four hours (instead of 
24 h, as previously). As can be seen (Figure 6.5), a uniform binding pattern was 

















Figure 6.5 Salmonella attachment/repulsion: A) Array design with the good-binding polymer PU104 
(in black) and the non-binding polymer PA325 (in white); B) BioAnalyzer scanning of the array using 
a Fluorescein filter; C) Fluorescent microscopy imaging (x20 objective); D-G) fluorescent and 
brightfield microscopy images of Salmonella attached to representative polymer spots; D) fluorescein 
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6.3 SEM Analysis 
6.3.1 Polymer analysis 
A SEM study was undertaken of Salmonella binding on some of the selected high 
binding PU104, 120, 126 and PA141 (Figure 6.6 A-D), as well as low binding 
PA221, 311, 408 and 412 (Figure 6.6 E-H). Particular attention was paid to the 





Figure 6.6 SEM images of Salmonella binding on selected polymers. Single spots: A-D) PU104, 120, 
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Bacteria appeared firmly attached and closely packed on PA141, aligning along their 
longitudinal axis. Small micro-colonies were observed on the strong-binding 
polymer surface (Figure 6.7 A). In contrast, non-binding polymers (PA331) showed 
little attachment and no evidence for early biofilm formation, implicating these 




Figure 6.7 SEM images of Salmonella binding on selected polymers. High magnification: A) PA141 
and B) PA311. 
 
 
6.3.2 Coverslip analysis 
In order to see if the selected polymers could be scaled-up and, to find whether those 
polymers could be used in practical applications, PA141 and 311 were spin-coated 
onto glass coverslips, which were formed of a central square (1 x 1 mm) subdivided 
in one hundred squares (100 x 100 µm). These coated coverslips, and uncoated 
coverslips (as a control), were incubated with Salmonella-GFP as previously reported 
(Chapter 6.2) and imaged via SEM (Figure 6.8). The number of bacteria on 
randomly selected subsquares on the coverslips were counted in give the number of 
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The analysis of binding on both coated and uncoated coverslips confirmed the 
expected results. Salmonella maintained on PA141 displayed ~7-fold increase in 
binding function over an uncoated coverslip, whereas the number of Salmonella on 




Figure 6.8 SEM of Salmonella binding on coverslips. A, D) Control (no-polymer coating); B, E) 































Figure 6.9 The average number of bacteria per millimeter square on PA141 (binding), PA311 (non-




Polymer microarrays were successfully used for the high throughput screening of 
Salmonella typhimurium and E. coli for binding or repultion. A fluorescence imaging 
detection analysis allowed rapid, parallel, and comprehensive evaluation of bacteria 
adhesion on 372 polymers. Immobilisation of bacteria was shown to be highly 
dependent on both the chemical structures and properties of the polymers and their 
ability to discriminate between different bacterial genera was observed. Bacteria 
generally exhibited similar binding characteristics for the same polymers over long 
(24 h) and short (4 h) periods. For strong binding polymers, SEM revealed the 
formation of early biofilm-like microcolonies, where cells were longtitudinally 
aligned and closely packed. A number of polymers were also identified which clearly 
prevented bacterial attachment, even at these high cell densities and over a long time 
period (24 h).  
 







7.1 General information 
7.1.1 Equipment 
Q-Array Mini microarrayer (Genetix). 
BioAnalyzer 4F/4S white light scanner and FIPS software (LaVision BioTech). 
HCS platform and Pathfinder™ software (IMSTAR). 
Biosafety cabinet: HERAsafe KS 18 class II (Heraeus). 
Incubator: HERAsafe KS 18 class II (Heraeus). 
Vacuum oven: Vacutherm VT6025 (Heraeus). 
P6708 spin coater (Speedlines Technologies). 
2100 Electrophoresis Bioanalyzer (Agilent). 
DNA Microarray hybridization oven (Agilent). 
DNA Microarray hybridization Chamber – SureHyb (Agilent). 
G2565AA DNA microarray scanner (Agilent). 
NanoDrop® ND-3300 fluorospectrometer (Agilent). 
Eppendorf biophotometer plus (Eppendorf). 
 
7.1.2 Polymers 
The polymer libraries (poly(urethane) and poly(acrylate) libraries, respectively, 
Appendices I and II) were synthesised by Jean-Francois Thaburet, Hitoshi Mizomoto 
and Ann Jasmine Jose as part of a previous project. 40, 79, 245  
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Each polymer had been previously characterised in terms of molecular weight by 
GPC, wettability245 and glass transition temperature (DSC).83 
 
7.1.3 Chemicals and solvents 
Chemicals and solvents used in all the experiments were obtained from Sigma-
Aldrich. Phosphate Buffer Saline (10 mM phosphate, 27 mM KCl, 137 mM NaCl, 
pH 7.4) is referred to as PBS. 
 
7.1.4 Microscope slides and coverslips 
Aminoalkylsilane microscope slides were obtained from Sigma-Aldrich and the 
coverslips from VWR International Ltd.  
 
7.1.5 Cell culture media and supplements 
All cell culture media were from Sigma-Aldrich and all supplements added to the 
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7.2 Experimental for Chapter 2 
7.2.1 Polymer microarray fabrication 
214 polyurethanes were “spotted” on aminoalkylsilane-treated glass slides, 
previously coated with agarose to impede unspecific cell adhesion. Coating with 
agarose was achieved by manually dip-coating the slide in agarose Type I-B (1 % 
w/v in deionised water at 65 ºC), followed by removal of the coating on the 
bottom of the side by wiping with a clean piece of tissue. Subsequently, the slides 
were dried overnight at room temerature in a dust free environment. 
Polyurethanes were prepared by dissolving 10 mg of polymer in 1mL (10 mg.mL-
1) of NMP. Polymer microarrays were then fabricated by contact printing (Q-
Array Mini microarrayer) with 32 aQu solid pins (K2785, Genetix) using the 
polymer solutions placed in polypropylene 384-well microplates (X7020, 
Genetix). The 214 members of the PU library were printed following a four-
replicate pattern with 1 single field of 32 x 32 spots containing 42 control 
(emptied) areas. Printing conditions were as follows: 5 stampings per spot, 200 
ms inking time and 10 ms stamping time. The typical spot size was 300-320 µm 
in diameter with a pitch distance of 1120 µm (y-axis) and 560 µm (x-axis), 
allowing up to 1024 features to be printed on a standard 25 x 75 mm slide. Once 
printed, the slides were dried under vacuum (12 h at 42 ºC/200 mbar) and 
sterilised in a bio-safety cabinet by exposure to UV irradiation for 20 min prior to 
use. 
 
7.2.2 Polymer microarray screening  
Mouse fibroblast cells (L929) (kindly provided by Prof. Timothy Elliott, School of 
Medicine, University of Southampton) were grown in Dubelcco’s Modified Eagle’s 
Medium (DMEM) supplemented with heat inactivated fetal bovine serum (FBS) 
(10% v/v), penicillin (100 units.mL-1), streptomycin (100 mg.mL-1) and L-glutamine 
(4 mM) at 37 °C with 5% CO2. 
Prior to seeding onto the polymer microarray, L929 cells were washed with PBS, 
detached with trypsin (0.050% w/v), EDTA (0.20% w/v) in PBS and, counted and 
diluted with media to a final concentration of (1 x 105 cells/slide in 5 mL). This 
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dilution was gently added onto the polymer microarray contained in a sterile four 
well-plate (Nunc) and incubated for different periods of time (48 h and 72 h). Cell 
performed was done as follows: (i) incubation with CTG-CMFDA (5 μM in PBS, 
Molecular Probes Inc, Invitrogen) at 37 °C and 5% CO2 for 15 min; (ii) slides were 
then gently washed in PBS and fixed with 4% w/v p-formaldehyde in PBS at RT for 
15 min; (iii) incubation with Hoechst-33342 (1 μg/mL in PBS) (Sigma-Aldrich) for 
15 min at RT; and subsequently, (iv) incubation with AlexaFluor 568 phalloidin (0.2 
μM in 1% in PBS containing 1% v/v FBS, Molecular Probes Inc, Invitrogen) for 15 
min at RT. The polymer microarray slides were then rinsed in deionized water and 
air-dried before scanning.  
 
7.2.2.1 Image capture and analyses 
Image capture and analyses were carried out using a high content screening 
(HCS) platform (Nikon 50i fluorescence microscope (x20 objective) with an X-
Y-Z stage), equipped with PathfinderTM software package. Cell number (Hoechst-
33342: ex/em 355/465 nm), biocompatibility (CellTracker Green: ex/em 492/516 
nm), and morphology (AlexaFluor 568: ex/em 578/603 nm, Invitrogen) for each 
polyurethane member was determined using fluorescent (DAPI, FITC, and 
rhodamine-like band-pass filters) and bright field channels by automated 
scanning of polymer spots. Complete L929 cell-polyurethane binding analysis is 
reported on CD (Supplementary Information, excel folder named “Chapter 2”). 
 
7.2.3 Analysis of cell morphology 
Cell morphology was analysed by confocal microscopy after 72 h of culture. 
Image capture was performed by a DeltaVision Real-Time Microscope (x63 
objective) using DAPI and rhodamine channels. 
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7.3 Experimental for Chapter 3 
7.3.1 Polymer microarray printing 
Polymer microarrays were prepared using the same conditions as described in 
Chapter 7.2.1. However, the 213 members of the polyurethane library were 
printed following a four-replicate pattern with 1 single field of 32 x 32 spots 
containing 45 control (empty) areas. The 58 members of the polyacrylate library 
were printed following a nine-replicate pattern within 1 single field of 24 x 24 
spots containing 6 control (empty) areas. 
 
7.3.2 Cell cultures 
Human erythroleukemic cells (K562) (kindly provided by Salim Khakoo, 
Department of Hepatology, Division of Medicine, Imperial College, London, UK) 
were grown in RPMI 1640 growth medium supplemented with heat inactivated 
FBS (10% v/v), penicillin (100 unit.mL-1), streptomycin (100 µg mL-1) and L-
glutamine (4 mM) at 37 °C with 5% CO2. 
 
7.3.3 Scanning for cell binding 
K562 were centrifugated at 250 x g for 5 min. The resulting cell pellet was 
resuspended in PBS and centrifugated again at 250 x g 5 min. The pellet was 
resuspended in 2 mL of RPMI 1640. K562 were counted and diluted with media 
to a final concentration of 1 x 105 per mL. An aliquot of 6 mL of this dilution was 
gently added to each of the six polymer microarrays contained in two four well-
plate (Nunc) and incubated for 24, 48 and 72 h. Thirty minutes before screening, 
slides were washed with PBS and then incubated for 30 min with fresh RPMI 
1640 media and Hoechst 33342 (1 μg/mL) for nuclei staining. The polymer 
microarray slides were then rinsed in an isotonic solution (8.1 g/L NaCl, 0.2 g/L 
KCl) and immersed in this solution to facilitate K562 live cell analysis. Cell 
binding with the different polymers was carried out, using DAPI and brightfield 
channels, as described in Chapter 7.2.2.1. Complete K562 cell-polyurethane and 
polyacrylate binding analysis is reported on CD (Supplementary Information, 
excel folder named “Chapter 3”). 
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7.3.4 Polymer coating of coverslips 
50 mm diameter glass coverslips (CB00500RA1, Menzel-Gläser) were cleaned 
with tetrahydrofuran (THF). 500 μL of each of the polyacrylate (PA365, 368, 371 
and 374) solution (2.0% w/v in THF) was placed onto the coverslips and spin 
coated for 10s at 2000 rpm. Coverslips were dried under vacuum (12 h at 45 
°C/200 mbar) and irradiated with UV light for 20 min before using. 
 
7.3.5 SEM 
As controls, K562 cells were collected, centrifuged for 5 min at 250 x g. The 
resulting cell pellet was resuspended in 10 mL of (0.1 M cacodylate buffer, and 
centrifugated again at 250 x g for 5 min. The pellet was fixed in 2 mL of 2.5% v/v 
glutaraldehyde in 0.1 M cacodylate buffer at RT for 2 h. After washing twice (0.1 
M cacodylate buffer), the cells were seeded on coverslips coated with PA365. For 
polymer treated samples, cells were then grown for 24 h and 72 h directly on 
glass coverslips coated with the selected polyacrylates (365, 368, 371 and 374) 
and were fixed with 2 mL of 2.5% v/v glutaraldehyde for 2 h at RT and washed as 
above. All samples were fixed with 1% w/v osmium tetroxide for 1 h at RT, 
dehydrated through graded ethanol (50, 70, 90 and 100%), critical point dried in 
CO2 (EMS 850 Critical Point Drier) and gold coated by sputtering (Edwards 
S150B Sputter Coater). The samples were examined with a Philips XL30CP 
Scanning Electron Microscope. 
 
7.3.6 Gene expression analysis 
7.3.6.1 RNA isolation 
Total RNA was isolated from both K562 cells grown adhesively on coated 
coverslips (Chapter 7.3.4) and in suspension. RNA extraction was performed 
using a SV total isolation kit according to the manufacturer’s protocol (Promega). 
The integrity and concentration of total RNA was determined using a RNA 6000 
Nano Assay Kit and a Bioanalyzer 2100 supported with RNA integrity number 
(RIN) software according to the manufacturer’s protocols (Agilent). The RIN 
software algorithm allowed the determination of critical features (peak markers, 
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18 S and 28 S) extracted from three electrophoretic traces (Figures 7.1) using 
appropriate integrators.246 This allowed the categorization of total RNA, with a 
numbering system from 1 to 10 (with 1 being the most degraded profile and 10 
being the most intact). The RIN software also calculated total RNA concentration 
(right Figures 7.1). 
 
 
Total RNA concentration: 310 ng/μl 








Total RNA concentration: 272 ng/μl 








Total RNA concentration: 298 ng/μl 











Figure 7.1 Agilent 2100 Bioanalyzer data electropherogram used to measure the quality and 
quantity of total RNA. A) Total RNA isolated from K562 cells grown in suspension (control); B) 
total RNA isolated from K562 cells grown adhesively on coated coverslips (PA368); C) total RNA 
isolated from K562 cells grown adhesively on coated coverslips (PA365). X-axis: time [s]; Y-
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7.3.6.2 cRNA labelling 
cRNA synthesis and labelling reactions (fluorophores Cy3 and Cy5 both from 
PerkinElmer/NEN Life Sciences) were performed using a Low RNA Input Linear 
Amplification Kit according to the manufacturer’s protocol (Agilent). Labelled 




































Figure 7.2 NanoDrop 3300 data viewer software displays a full UV-Vis absorbance spectrum as well 
as the calculated concentrations of both the nucleic acid (red rectangle) and the fluorescent labelled 
cRNA (green rectangle). Peaks for cRNA, and incorporated Cy3 and Cy5 are found at 260, 550 and 
650 nm, respectively. 1 uL absorbance measurement of: A) Cy5-labelled cRNA from K562 cells grown 
in suspension (control); B) Cy3-labelled cRNA from K562 cells grown adhesively on coated 
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7.3.6.3 Hybridisation and scanning 
Array hybridisation was carried out using 4 x 44 K Whole Human Genome 
microarray (design 014850 Agilent).  
Array hybridisation was performed using a Gene Expression Hybridization Kit 
(Agilent). Briefly, 850 ng of each CyDye™-labeled cRNA (Chapter 7.3.6.2) were 
added with a 2X Hi-RPM Hybridization Buffer (Agilent) up to a final volume of 
500 µL. The hybridization was carried out using a DNA microarray hybridization 
oven with a constant temperature of 65 ºC for 17 h at 10 rpm. The hybridized array 
was washed following the post-hybridization washing step according to the 
manufacturer’s Gene Expression Wash Buffer Kit protocol (Agilent). The dried 




Figure 7.3 Agilent DNA microarray scanning (2 micron resolution). A) 4 x 44 K Whole Human 
Genome microarray; B) subarray 2; C) magnification of subarray 2. 
 
 
Subarray 1 PA368 
Subarray 2 PA368 
Subarray 3 PA365 
BA 
C
Subarray 4 PA365 
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7.3.6.4 Data analysis 
Datasets pre-processed by Agilent's Feature Extraction 9.1, were analysed by 
Genespring GX 9.0.2. Datasets were filtered by flags given by the FE software 
(present, marginal and absent), only samples detected as present were used for the 
statistical analysis. The four datasets were grouped together and assigned as a 
unique condition to analyse the more general interaction between polymers and 
K562 cells, irrespective of the polyacrylates (PA365 or 368), against the control 
(suspension cells). T Test statistical analyses were carried out (T Test against 
zero) and p-values were computed asymptotically, where p-values < 0.01 were 
considered significant, meaning a probability of real changes in expression of 
99.9%. Gene expression data has been deposited in ArrayExpress EBI 
(www.ebi.ac.uk/arrayexpress) under accession number E-MEXP-1570. Results 
are presented in Table 7.1. 
 
 
MED18 Hs.479911 mediator of RNA polymerase II transcription up 3.60
XPR1 Hs.227656 xenotropic and polytropic retrovirus receptor (XPR1) up 3.43
HMGCS1 Hs.397729
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(soluble) (HMGCS1) up 3.10
A_24_P110101 down 6.86
MT1E Hs.534330 metallothionein 1E (MT1E) down 6.63
GDNF Hs.248114
Glial cell line-derived neurotrophic factor precursor 
(Astrocyte- derived trophic factor 1) (ATF-1). down 5.93
MT2A Hs.647371 metallothionein 2A (MT2A) down 5.61
PIP5K1C Hs.282177 phosphatidylinositol-4-phosphate 5-kinase down 5.48
OTUD7A Hs.355236 OTU domain containing 7A (OTUD7A) down 5.40
MT1L Hs.647358 mRNA for metallothionein isoform 1R. [X97261] down 5.35
NPBWR1 Hs.248117 neuropeptides B/W receptor 1 (NPBWR1) down 5.28
BX089650 Hs.520524 BX089650 Soares_senescent_fibroblasts_NbHSF down 5.23
PPP1R11 Hs.82887 protein phosphatase 1 down 5.13
SCRT2 Hs.355284 scratch homolog 2 down 5.12
MT1G Hs.433391 metallothionein 1G (MT1G) down 5.10
ENAH Hs.497893 enabled homolog (Drosophila) (ENAH) down 4.95
FOXC1 FOXD4a mRNA down 4.90
KRT80 Hs.140978 keratin 80 (KRT80) down 4.81
SLC26A1 Hs.658244 solute carrier family 26 (sulfate transporter) down 4.80
Fold 
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SLC26A1 Hs.658244 solute carrier family 26 (sulfate transporter) down 4.80
AVP Hs.89648 arginine vasopressin (neurophysin II down 4.77
MT1X Hs.374950 metallothionein 1X (MT1X) down 4.74
MT1H Hs.438462 metallothionein 1H (MT1H) down 4.63
BG182941 Hs.635280 RST1823 Athersys RAGE Library   cDNA down 4.60
AF100640 metastasis related protein (MB2) mRNA down 4.57
IFITM5 Hs.443469 interferon induced transmembrane protein 5 (IFITM5) down 4.48
LOC146325 Hs.632220 similar to hypothetical protein FLJ13841 (LOC146325) down 4.47
GPX1 Hs.76686 glutathione peroxidase 1 (GPX1) down 4.45
MT1X Hs.374950 metallothionein 1X (MT1X) down 4.43
THC2724451 down 4.43
DEAF1 Hs.243994
deformed epidermal autoregulatory factor 1 (Drosophila) 
(DEAF1) down 4.34
CACNA1E Hs.437444 calcium channel down 4.21
GPR78 Hs.350588 G protein-coupled receptor 78 (GPR78) down 4.21
BX427435 Hs.625249 BX427435   FETAL LIVER   cDNA clone CS0DM010YK16 3-PRIME down 4.16
LBH Hs.567598 limb bud and heart development homolog (mouse) (LBH) down 4.13
PRR15 Hs.91109 proline rich 15 (PRR15) down 4.12
BM913108 Hs.675862
AGENCOURT_6614092 NIH_MGC_41   cDNA clone 
IMAGE:5475119 5' down 4.09
FOXE1 HFKH4 mRNA for fork head like protein. down 4.08
LOC728864
PREDICTED:   similar to Mucin-2 precursor (Intestinal 
mucin 2) (LOC728864) down 4.06
A_32_P105865 down 4.02
LCE2D Hs.490225 late cornified envelope 2D (LCE2D) down 4.00
AY227436 drug-sensitive protein 1 mRNA down 3.96
NP511100 GB|AB065467.1|BAC05726.1 seven transmembrane helix 
t
down 3.92
AF264621 uncharacterized gastric protein YA42P mRNA down 3.82
C6orf85 Hs.132340 chromosome 6 open reading frame 85 (C6orf85) down 3.80
NKX2-8 Hs.234763 NK2 transcription factor related down 3.76
MPHOSPH9 Hs.577404 M-phase phosphoprotein 9 (MPHOSPH9) down 3.75
BU191598 Hs.657999
AGENCOURT_8099541 NIH_MGC_102   cDNA clone 
IMAGE:6254414 5' down 3.74
AA420998 Hs.178095 AA420998 zu08f10.s1 Soares_testis_NHT down 3.69
ZNF771 Hs.148584 zinc finger protein 771 (ZNF771) down 3.69
A_32_P101195 down 3.68
ALDH7A1 Hs.483239 aldehyde dehydrogenase 7 family down 3.65
NKD2 Hs.240951 naked cuticle homolog 2 (Drosophila) (NKD2) down 3.62
AT_ssH_RR_5 down 3.61
Fold 
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MT1B Hs.656629 metallothionein 1B (MT1B) down 3.61
GLIS2 Hs.592087 GLIS family zinc finger 2 (GLIS2) down 3.56
CDH24 Hs.155912 cadherin-like 24 (CDH24) down 3.55
GPSM3 Hs.520046 G-protein signalling modulator 3 (AGS3-like down 3.51
LOC441204 Hs.587432 cDNA FLJ31922 fis down 3.48
A_24_P932958 down 3.47
BC080624 Hs.661522 cDNA clone MGC:99790 IMAGE:6304510 down 3.46
RHBDL1 Hs.137572 rhomboid down 3.41
THC2545510
ALU1_HUMAN (P39188) Alu subfamily J sequence 
contamination warning entry down 3.33
THC2625851 down 3.32
C19orf31 Hs.620488 chromosome 19 open reading frame 31 (C19orf31) down 3.30
ARTN Hs.632404 artemin (ARTN) down 3.25
MT1H Hs.438462 metallothionein 1H (MT1H) down 3.15
LOC651746 Hs.680828 PREDICTED:   similar to ankyrin repeat domain 33 (LOC651746) down 3.14
CXorf57 Hs.274267 chromosome X open reading frame 57 (CXorf57) down 3.12
AK095945 Hs.134857 cDNA FLJ38626 fis down 3.12
PYY2 Hs.157195 peptide YY down 3.11
LIPE Hs.656980 lipase down 3.07
BC009749 Hs.611748 cDNA clone IMAGE:3689276 down 3.07
CTSL2 Hs.660866 cathepsin L2 (CTSL2) down 3.05
SYNGR4 Hs.408333 synaptogyrin 4 (SYNGR4) down 3.04
MAFA Hs.670866
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
A (avian) (MAFA) down 3.01
A_24_P928250 down 3.01
Fold 
changeGene Symbol UniGene Gene Description Regulation
 
 
Table. 7.1 A list of genes either up- or down-regulated when K562 cells were adhered onto 
PA368 and 365. The data was processed with a cut-off value of 3 fold increase or decrease in 
expression when compared to the “suspension cell control”. aGenes Symbol starting by A_ are 
still unknown. bNormalised absolute values. 
 
 
7.3.6.5 Quantitative real-time PCR analysis 
Quantitative real-time PCR was used to validate the effect of the cell-polymer 
interactions on the gene expression profile. 
 
7.3.6.5.1 RNA isolation 
Total RNA was isolated from both K562 cells grown adhesively on coated 
coverslips (PA368 and 365) and K562 grown in suspension (Chapter 7.3.6.1).  
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RNA extraction was performed using a RNeasy Mini Kit according to the 
manufacturer’s protocol (QIAGEN). The integrity and concentration of total RNA 
were determined as described in Chapter 7.3.6.1 (Figure 7.4). 
 
 
Total RNA concentration: 461 ng/μl 









Total RNA concentration: 368 ng/μl 










Total RNA concentration: 367 ng/μl  










Figure 7.4 Agilent 2100 Bioanalyzer data electropherogram used to measure the quality of total 
RNA for dat validation. A) Total RNA isolated from K562 cells grown adhesively on coated 
coverslips (PA365); B) total RNA isolated from K562 cells grown adhesively on coated 
coverslips (PA368); C) total RNA isolated from K562 cells grown in suspension (control). X-
axis: time [s]; Y-axis: arbitray fluorescence units [FU]. 
 
 
7.3.6.5.2 Real-time PCR 
RNA (500 ng) was used for cDNA synthesis using Superscript III (Invitrogen), 
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using a LightCycler 480 (Roche) and a LightCycler 480 SYBR Green 1 Master 
(Roche). PCR primers and annealing temperature (Ta) for RNF7, MT1E, MT2A, 
MT1X genes were those available the in literature.247, 248 0.04 µmol HPLC 
purified primers were purchased from Microsynth AG (Switzerland). The 
following cycling conditions were used: denaturation: 95 oC 5 min, amplification: 
95 oC 5 s, 58 oC 10 s, 72 oC 20 s (45 cycles), acquisition: 81 oC 1 s, melting 
curve: 95 oC 1 s, 65 oC 10 s, 95 oC – ramp 5 oC/s continuous, cool: -40 oC 10 s. 
Standard curves were generated from cDNA dilutions. Data were normalised 
relative to hRNF7 expression levels. PCR primers are shown in Table 7.2. 
 
 







Table 7.2 Sequences of PCR primers. *Primers are writer 5'        3' 
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7.4 Experimental for Chapter 4 
The preparation of HLCs, incubation with the polymer microarray, fixing and 
staining were carried out by Dr David Hay in the Centre for Regenerative Medicine 
(University of Edinburgh). 
 
7.4.1 Polymer microarray preparation 
Polymer microarrays were prepared using the same conditions as described in 
Chapter 7.2.1. However, the 337 members of the polyurethane (161) and 
polyacrylate (176) libraries were printed following a four-replicate pattern with 1 
single field of 32 x 48 spots containing 47 control (empty) areas with a pitch 
distance of 560 µm (y-axis) and 750 µm (x-axis). 
 
7.4.2 Cell culture and differentiation – David Hay Method – 
Human embryonic stem cells (H9) were cultured and propagated in MG coated 
plates with mouse embryonic fibroblast conditioned medium (MEF-CM) 
supplemented with basic fibroblast growth factor in feeder-free, serum-free 
conditions as previously described.158, 160 Differentiation was initiated at 60-70% 
confluence, by replacing the MEF-CM with differentiation medium (RPMI1640 with 
1 x B27 (Invitrogen), 100 ng/mL activin A (Peprotech) and 50 ng/ml Wnt3a (R&D 
Systems)). After 72 h (changing medium every day) differentiating cells were 
cultured in differentiation medium (SR/DMSO medium: knockout-DMEM 
containing 20% v/v serum replacement (SR), 1 mM glutamine, 1% v/v non-essential 
amino acids, 0.1 mM β-mercaptoethanol and 1% v/v dimethyl sulfoxide (DMSO)) 
for 6 days. At day 9 in the differentiation process the HLCs were removed from their 
substrate using 5 min 37 oC incubation with trypsin (0.050 % w/v), EDTA (0.20 % 
w/v) in PBS.  
 
7.4.3 Scanning for cell binding 
HLCs were counted and diluted with L15 medium supplemented with 8.3% v/v 
FCS, 8.3% v/v tryptose phosphate broth, 10 μM Hydrocortisone 21-
hemisuccinate, 1 μM insulin and 2 mM glutamine containing 10 ng/mL 
 
 - 105 -
hepatocyte growth factor (Peprotech) and 20 ng/mL oncostatin M (R&D 
Systems). An aliquot of 10 mL (0.5 x 106 per mL) of this dilution was gently 
added to the polymer microarrays contained in a 100 x 25 petri dish (Nunc) and 
incubated for a further 8 days changing the medium every 2 days.158, 160 At this 
point cells were fixed in ice-cold methanol for 10 min at RT. After blocking with 
PBS containing 10% v/v FBS, cells were incubated with primary antibody 
(human serum albumin 1:500, SIGMA or human IgG2a, DAKO) at 4 °C 
overnight, followed by 30 min incubation with appropriate secondary antibody at 
RT.160 Cell compatibilitity with the different polymers was carried out, using 
DAPI and FITC channels as described in Chapter 7.2.2.1. Complete HLC-
polymer binding analysis is reported on CD (Supplementary Information, excel 
folder named “Chapter 4”). 
 
7.4.4 Coverslip experiments 
The preparation of HLCs (see Chapter 7.4.2), incubation with the coverslips, and 
measurement of hepatocyte export proteins were carried out by Dr David Hay in the 
Centre for Regenerative Medicine (University of Edinburgh). 
 
7.4.4.1 Polymer coating of coverslips 
19 mm diameter glass coverslips (CB00190RA1, Menzel-Gläser) were prepared 
using the conditions described in Chapter 7.3.4 with the following samples: 200 µL 
of three polyurethanes (PU134, 212 and 223) and three polyacrylates (PA119, 196 
and 395). 
 
7.4.4.2 Measurement of hepatocyte export proteins on coverslips 
Human embryonic stem cells (H9) were differentiated to HLCs and cultured using an 
established method (David Hay’s method, Chapter 7.4.2). At day 23, 1 mL of HLCs 
culture medium (0.5 x 106 per mL) was incubated with either each of six polymer 
spin-coated coverslips (PU134, 212 and 223) and (PA119, 196 and 395) or pre-
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After 12 h culture supernatants were harvested and serum protein production 
(fibrinogen, transthyretin and fibronectin) measured by ELISA as previously 
described,163, 164 and quoted as nonogram of cellular protein per milligram of tissue 
culture medium. 
 
7.4.4.3 Morphology analysis  
HLCs were detached from their biological ECM (Chapter 7.4.2) and replated onto 
the six polymers coated coverslips and MG as described above (Chapter 7.4.4.2). 
HLCs morphology plated on MG or both PA119, 196 and 395 and PU134, 212 and 
223 were evaluated visually with Zeiss Axiovert 200 fluorescence microscope 
(magnification x10). 
 
7.4.5 Bio-artificial liver experiments 
The preparation of HLCs, incubation with the coated and uncoted PFCs, fixing and 
induction experiments were carried out by Dr David Hay in the Centre for 
Regenerative Medicine (University of Edinburgh). 
 
7.4.5.1 Dip-coating of PFC 
PFCs were placed onto 2 mL of polyurethane 134 solution (2.0% w/v in THF) for 
2 min. PFCs were dried under vacuum (12 h at 45 °C/200 mbar) and irradiated 
with UV light for 20 min before use. 
 
7.4.5.2 SEM 
HLCs were plated and maintained on uncoated and PU134 coated PFCs for 15 days. 
At day 16, HLCs maintained on both matrices were fixed and visualised as described 
in Chapter 7.3.5. 
 
7.4.5.3 Drug inducibility 
HLCs were incubated with PFC in its native form or coated with PU134. HLCs were 
cultured on these different substrates for 13 days as described in Chapter 7.4.3, 
changing media every second day, before assessing HLCs drug inducibility. At day 
14 the cultures were incubated in the presence or absence of a known CYP3A4 
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inducer, phenobarbital (0.4 mM), for 48 h prior to measurement of CYP3A4 activity. 
On day 16, HLCs were incubated with hepatocyte culture media supplemented with 
50 µM of CYP3A4 pGlo ™ substrate as per the manufactureris instructions. 4 h post-
treatment a 50 µL sample of the supernatant was removed and read on a luminometer 
(POLARstar optima). CYP3A4 activity was expressed as relative light units 
(R.L.U.)/mg protein. * p < 0.05 by the Student’s t-test. (n = 3). 
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7.5 Experimental for Chapter 5 
HUVECs were purchases from Lonza, UK. The isolation and cultivation of EOCs, 
incubation with the polymer microarray, fixing and staining were carried out by Dr 
Olga Tura in the Centre for Regenerative Medicine (University of Edinburgh).  
 
7.5.1 Polymer microarray manufacture 
Polymer microarrays were prepared using the same conditions as described in 
Chapter 7.4.1.  
 
7.5.2 Cell isolation and culture 
7.5.2.1 Cell source and sampling 
Cord blood (CB) products (20-50 mL) were aspirated from the umbilical placental 
veins from normal caesarean deliveries and collected into heparin. Appropriate ethics 
committee approval was obtained and written informed consent from each patient.  
 
7.5.2.2 Mononuclear cell isolation 
MNCs were separated by buoyant density centrifugation of blood samples over 
Histopaque (1.077 g/ml; Sigma Diagnostics, UK). Once isolated, EOCs culture was 
performed as described.193 Briefly, a minimum of 10-30 x 106 MNCs were 
resuspended in endothelial growth medium (EGM)-2 medium (Cambrex) and plated 
onto type 1 collagen six-well tissue culture wells (BD Bioscience). The cells were 
incubated at 37 °C with 5% CO2 for 3-4 weeks. Medium was changed every 2 days 
for 7 days and then twice a week until first passage. Thereafter cells were passaged 
until the incubation with the polymer microarrays.  
 
7.5.3 Scanning for cell binding 
EOCs and HUVECs were harvested using 1 mL trypsin (0.050 % w/v)-EDTA 
(0.20 % w/v) in PBS. After 10 min at 37 oC, 5 mL of IMDM with 10% v/v FBS 
was added and cells were recovered by vigorous aspiration. Cells were counted 
and re-plated at 0.5 x 106 for 3 days on two identical polymer microarrays 
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(Chapter 7.5.1). The cells were fixed in 100% methanol for 10 min and blocked in 
10% goat serum for 1 h after washing with PBS. 20 µL of directly conjugated 
monoclonal mouse anti-human CD31-PE antibody (BD, UK) was applied 
overnight at 4 °C. The cells were washed with PBS and finally mounted with 
DAPI-containing Vectashield hardest mounting medium (Vector Lab Ltd, UK). 
Image capture and cell binding quantification with the different polymers were 
carried out using DAPI and rhodamine channels as described in section 7.2.2.1. 
Complete EOC and HUVEC–polymer binding analysis is reported on CD 
(Supplementary Information, excel folder named “Chapter 5”). 
 
7.5.4 Polymer coating of coverslips 
Flow cytometry analysis reported below was undertaken by Dr Olga Tura at the 
Centre for Regenerative Medicine, University of Edinburgh. 
 
7.5.4.1 Coverslips preparation 
Polymer-coated coverslips (19 mm diameter, CB00190RA1, Menzel-Gläser) were 
prepared using the conditions described previously in Chapter 7.4.4.1. Polymer 
coating of coverslips used 200 µL of the following three polyacrylates (119, 383 and 
395) samples. 
 
7.5.4.2 Flow cytometry analysis 
EOCs and HUVECs were cultivated as previously described (Chapter 7.5.2.2) on the 
glass coverslips (Chapter 7.5.4.1), then directly stained and analysed for phenotypic 
expression of surface markers using anti-human monoclonal antibodies (MAbs) 
conjugated to phycoerythrin (PE), fluorescein isothiocynate (FITC), Peridin 
Chlorophylla protein (PerCP) or Allophycocyanin (APC) as described.196 Harvested 
cells were resuspended in FACS-PBS (PBS supplemented with 0.1% v/v FBS and 
0.1% w/v sodium azide), at 1 x 107 cells/mL for use. Aliquots of up to 1 x 106 cells 
were incubated for 30 min in RT at the dark with 5 µL of untouched antibody 
(determined by titration), of directly conjugated antibody (below listed, Chapter 
7.5.4.2.1). Cells were washed twice to remove unbound antibody and resuspended in 
300 µL FACS-PBS solution. Unstained cells were included as controls. Dead and 
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apoptotic cells and debris were excluded from analysis using an electronic ‘live’ gate 
on forward scatter and side scatter parameters. Data for 5, 000 - 100,000 ‘live’ events 
were acquired for each sample using a FACSCaliber cytometer equipped with a 488 
nm and 633 nm lasers and analysed using CellQuest software (Becton Dickinson).249 
 
7.5.4.2.1 Antibodies  
The anti-human monoclonal antibodies (MAbs) used for flow cytometry included 
anti-CD34-FITC, anti-CD45-PerCP, anti-CD49d-FITC, anti-CD49e-APC (Becton 
Dickinson, UK); anti-CD133-APC (Myltenyi Biotec, UK); anti-CD29-FITC, anti-
CD54 (ICAM-1) and anti-CD50 (ICAM-3) (Caltag, UK). 
 
7.5.5 Sponge experiments 
The isolation and culture of EOCs (see Chapter 7.5.2) and incubation with the 
sponges were carried out by Dr Olga Tura in the Centre for Regenerative Medicine 
(University of Edinburgh). The animal experiments, Chalkley count and 
haemoglobin assays reported below were undertaken by Dr Olga Tura and Mrs Kay 
Samuel in the Centre for Regenerative Medicine (University of Edinburgh). All 
animal experiments were undertaken with an approved licence from the Animal 
Scientific Procedure Division of the Home Office, London, UK. 
 
7.5.5.1 In vitro 
Two 1 cm3 sponges were dip coated in 2 mL of PA383 solution (2.0% w/v in 
THF) and GFR-MG respectively. Sponges were dried under vacuum (12 h at 45 
°C/200 mbar) and irradiated with UV light for 20 min. One of each type of coated 
sponge was impregnated with 1 x 107/mL of EOCs and the other one using the 
same concentration of HUVECs in complete EBM-2 medium (Lonza, UK).196 
After overnight incubation, cells in both sponges were fixed and SEM analysed as 
described in Chapter 7.3.5. 
 
7.5.5.2 In vivo (subcutaneous sponge implantation) 
Male C57B6J mice aged 10-12 weeks were purchased from Charles River 
Laboratories (UK). Experimental procedures were approved by the University of 
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Edinburgh ethics committee and were authorized by the Home Office under the 
Animals (Scientific Procedures) Act 1986. 
Mice were anesthetized with halothane two sterilized sponges (0.5 cm/1cm) were 
implanted subcutaneously on each flank. EOCs were incubated for overnight with 
native sponges or sponges impregnated with PA383 (Chapter 7.5.5.1). Each animal 
had an intervention-no-impregnated sponge (EOCs + native sponge) on one side and 
a placebo-impregnated sponge (EOCs + PA383) on the other. Twenty days after 
implantation, mice were killed by asphyxiation in CO2 and sponges excised were 
trisected and analysed as follows:  
 
SEM analysis 
The first section was fixed and analysed via SEM microscopy as previously 
described (Chapter 7.3.5). 
 
Chalkley count 
A second frozen section was fixed in 10% v/v neutral buffered formalin, embedded 
in paraffin. Sections (5 μm) were mounted on poly-L-lysine-coated slides and stained 
with hematoxylin/eosin for identification of blood vessels density within Chalkley 
counts by using the mean of the triplicate values as described.215 
 
Haemoglobin assay 
The third frozen section was weighed, homogenized in 1 mL of sterile PBS, and 
centrifuged (2,000 g for 10 min) to measure the amount of haemoglobin present in 
the sample. Following the manufacturer's instructions (Bioassay systems, 
QuantiChrom) haemoglobin was converted into a uniform colored end product which 
its intensity was measured at 400 nm. The colour intensity is directly proportional to 
the amount of haemoglobin concentration in the sample.217, 218 
 
7.5.6 Stent experiment 
Two coronary stents (Abbott Laboratorieas) were cleaned with THF. One stent was 
placed into 2 mL of PA383 solution (2.0% w/v in THF) for 5 min. This stent was 
dried under vacuum (12 h at 45 ºC/200 mbar) and together with the uncoated stent 
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was irradiated with UV light for 20 min before using. Both coated and uncoated 
stents impregnated with 1 x 107/mL of EOCs in complete EBM-2 medium (Lonza, 
UK). After overnight incubation, cells in both stents were fixed and SEM analysed as 
described in Chapter 7.3.5. 
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7.6 Experimental for Chapter 6 
The work reported in this Chapter was undertaken at the Bradley Group, School of 
Chemistry, University of Edinburgh by Mei Wu and myself.  
7.6.1 Polymer microarray fabrication and growth of bacteria 
Polymer microarrays were prepared using 372 members of the polyurethane and 
polyacrylate libraries previously described (Chapter 7.4.1). 
Salmonella SL1344 and E. coli W3110 transformed with pHC60 (to be  referred to as 
Salmonella-GFP and E. coli-GFP) constitutively express GFP and were grown 
overnight with aeration at 37 °C or 30 °C respectively in Luria-Bertani (LB) broth 
containing tetracycline (10 µg.mL-1). Cultures were collected by centrifugation at 
15,000 rpm for 5 min, washed with fresh LB broth and diluted tenfold to a final 
concentration of approximately (2 x 108 CFU mL-1) for microarray binding studies. 
 
7.6.2 Bacteria binding analysis 
6 mL (12 x 108 CFU mL-1) of either Salmonella-GFP or E. coli-GFP were added 
to duplicate polymer microarrays in a four-well plate (Nunc) and incubated 12 h 
(except where stated) at RT. Subsequently, the polymer microarray slides were 
washed vigorously three times with PBS, rinsed in deionised water, and dried 
with a stream of air. A GeneFrame and coverslip (1.9 x 6.0 cm, AB-0630, Thermo 
Scientific) was then applied to each slide. Polymer microarrays were analysed 
using a BioAnalyzer 4F/4S scanner with a FITC filter. Bacterial adhesion was 
evaluated via integration of the fluorescence intensity of a spot (300 μm in 
diameter) after background correction. The average and the standard deviation for 
sets of four identical polymer features were determined, with the reproducibility 
between two identical microarrays evaluated by a student t-test. Polymers with p-
values < 0.001 and 6 degrees of freedom were considered statistically significant. 
Results for E. coli-GFP and Salmonella-GFP-polymer binding analysis are 
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7.6.2.1 SEM 
Bacteria on the polymer samples were washed twice with 0.1 M cacodylate buffer 
and then fixed and visualised as described in Chapter 7.3.5. 
 
7.6.2.2 Polymer microarray for reproducibility binding studies 
Polymer microarrays were prepared using the same conditions as described in 
Chapter 7.2.1. However, the 8 members of the polyurethane and polyacrylate 
libraries were printed using 8 aQu solid pins (K2785, Genetix), following a four-
replicate pattern with 8 single fields of 5 x 5 spots with a pitch distance of 900 µm 
(y-axis) and 900 µm (x-axis). Salmonella imaging was carried out using a HCS 
platform with PathfinderTM software package (IMSTAR) as described in Chapter 
7.2.2.1. 
 
7.6.2.3 Polymer microarrays for time-dependent binding 
Polymer microarrays with letters U and K were fabricated with PU104 and PA311 
using 1 aQu solid pins (K2785, Genetix) in accordance with the same conditions as 
described in Chapter 7.6.2.2. Salmonella-GFP, prepared as in Chapter 7.6.2, were 
incubated for 4 h at RT on this array and scanned and imaged as described in 
Chapters 7.2.2.1and 7.6.2 respectively.  
 
7.6.3 Coverslip scale-up 
PA141 and PA331 were spin-coated onto grided glass coverslips (CELL-VU DRM 
800) and incubated overnight with Salmonella-GFP at RT and imaged via SEM as 
described in Chapter 7.3.5. The number of bacteria in randomly selected sub-squares 
(100 µm x 100 µm), four for each coverslip, was counted with Image-Pro Plus 4.5 
(Media Cybernetics, Silver Spring, MD)250 on the coated and non-polymer coated as 
a control (Figure 7.5). The software was instructed to count the number of “objects” 
in the image, in this case the number of bacteria. The data were then exported to 
excel and reproducibility was determined by calculating the average and the standard 








Figure 7.5 Automated counting of Salmonella binding. The picture files were transferred to Image-
Pro Plus for processing. In this example, the number of bacteria on one single square of the uncoated 
coverslip (control) was counted. Salmonella identified by Image-Pro Plus are in red with an 
associated number in green. 
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Appendix I: polyurethane library245 
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PEG:   poly(ethylene glycol) 
PPG:   poly(propylene glycol) 
PTMG:  poly(butylene glycol) 
PHNAD:  poly[1,6-hexanediol/neopentyl glycol-alt-(adiptic acid)]diol 
PHNGAD:  poly[1,6-hexanediol/neopentyl glycol/diethylene glycol-alt-(adiptic 
acid)]diol 
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Diisocyanate: 
PDI:   1,4-diisocyanobenzene 
TDI:   4-methyl-1,3-phenylene diisocyanate 
MDI:   4,4’-methylenebis(phenylisocyanate) 
HDI:   1,6-diisocyanohexane 
BICH:   1,3-bis(isocyananatomethyl)cyclohexane 
HMDI:  4,4’-methylenebis(cyclohexylisocyanate) 
 
Chain Extender: 
ED:   ethylene diamine 
EG:   ethylene glycol 
BD:  1,4-butanediol  
PG:   propylene glycol 
NMPD:  2-nitro-2-methyl-1,3-propanediol 
DMAPD:  3-dimethylamino-1,2-propanediol 
DEAPD:  3-diethylamino-1,2-propanediol 
DHM:   diethyl bis(hydroxymethyl)malonate 
OFHD:  2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol 
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List of polyurethanes used in the thesis with their corresponding monomers and 
monomer molecular ratio used in the synthesis 





1 PEG 2000 HDI none 48.5 51.5 0
2 PEG 900 HDI none 48.5 51.5 0
3 PEG 400 HDI none 48.5 51.5 0
4 PPG 2000 HDI none 48.5 51.5 0
5 PTMG 2000 HDI none 48.5 51.5 0
6 PEG 2000 BICH none 48.5 51.5 0
7 PEG 900 BICH none 48.5 51.5 0
8 PEG 400 BICH none 48.5 51.5 0
9 PPG 2000 BICH none 48.5 51.5 0
10 PTMG 2000 BICH none 48.5 51.5 0
11 PEG 2000 TDI none 48.5 51.5 0
12 PEG 900 TDI none 48.5 51.5 0
13 PEG 400 TDI none 48.5 51.5 0
14 PPG 2000 TDI none 48.5 51.5 0
15 PTMG 2000 TDI none 48.5 51.5 0
16 PEG 2000 MDI none 48.5 51.5 0
17 PEG 900 MDI none 48.5 51.5 0
18 PEG 400 MDI none 48.5 51.5 0
19 PPG 2000 MDI none 48.5 51.5 0
20 PTMG 2000 MDI none 48.5 51.5 0
21 PEG 2000 PDI none 48.5 51.5 0
22 PEG 900 PDI none 48.5 51.5 0
23 PEG 400 PDI none 48.5 51.5 0
24 PPG 2000 PDI none 48.5 51.5 0
25 PTMG 2000 PDI none 48.5 51.5 0
26 PEG 2000 HMDI none 48.5 51.5 0
27 PEG 900 HMDI none 48.5 51.5 0
28 PEG 400 HMDI none 48.5 51.5 0
29 PPG 2000 HMDI none 48.5 51.5 0
33 PEG 900 HDI BD 0.25 0.52 0.23
35 PEG 400 HDI BD 0.25 0.52 0.23
37 PPG 2000 HDI BD 0.25 0.52 0.23
39 PTMG 2000 HDI BD 0.25 0.52 0.23
41 PEG 2000 BICH BD 0.25 0.52 0.23
48 PPG 2000 BICH ED 0.25 0.52 0.23
53 PEG 900 TDI BD 0.25 0.52 0.23
61 PEG 2000 MDI BD 0.25 0.52 0.23
65 PEG 400 MDI BD 0.25 0.52 0.23
67 PPG 2000 MDI BD 0.25 0.52 0.23
69 PTMG 2000 MDI BD 0.25 0.52 0.23
71 PEG 2000 PDI BD 0.25 0.52 0.23
73 PEG 900 PDI BD 0.25 0.52 0.23
77 PPG 2000 PDI BD 0.25 0.52 0.23
79 PTMG 2000 PDI BD 0.25 0.52 0.23
81 PEG 2000 HMDI BD 0.25 0.52 0.23
83 PEG 900 HMDI BD 0.25 0.52 0.23
85 PEG 400 HMDI BD 0.25 0.52 0.23
87 PPG 2000 HMDI BD 0.25 0.52 0.23
39DE PTMG 2000 HDI DEAPD 0.25 0.52 0.23
49DE PTMG 2000 BICH DEAPD 0.25 0.52 0.23
91 PTMG 650 HDI BD 0.485 0.515 0
92 PTMG 1000 HDI BD 0.485 0.515 0
93 PTMG 650 BICH BD 0.485 0.515 0
94 PTMG 1000 BICH BD 0.485 0.515 0
95 PTMG 650 MDI BD 0.485 0.515 0
96 PTMG 1000 MDI BD 0.485 0.515 0
97 PHNGAD 1800 BICH DMAPD 0.25 0.52 0.23
98 PHNGAD 1800 BICH DEAPD 0.25 0.52 0.23
99 PTMG 650 HDI DMAPD 0.25 0.52 0.23
100 PTMG 1000 HDI DMAPD 0.25 0.52 0.23
101 PTMG 650 BICH DMAPD 0.25 0.52 0.23
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103 PHNGAD 1800 MDI DMAPD 0.25 0.52 0.23
104 PHNGAD 1800 MDI DEAPD 0.25 0.52 0.23
105 PHNGAD 1800 HDI DMAPD 0.25 0.52 0.23
106 PHNGAD 1800 HDI DEAPD 0.25 0.52 0.23
107 PTMG 650 HDI DEAPD 0.25 0.52 0.23
108 PTMG 1000 HDI DEAPD 0.25 0.52 0.23
110 PTMG 1000 BICH DEAPD 0.25 0.52 0.23
111 PTMG 650 MDI DEAPD 0.25 0.52 0.23
112 PTMG 1000 MDI DEAPD 0.25 0.52 0.23
114 PPG 425 HDI BD 0.485 0.515 0
115 PPG 1000 HDI BD 0.485 0.515 0
116 PPG 425 BICH BD 0.485 0.515 0
117 PPG 1000 BICH BD 0.485 0.515 0
118 PPG 425 MDI DMAPD 0.25 0.52 0.23
119 PPG 1000 MDI DMAPD 0.25 0.52 0.23
120 PPG 425 BICH DEAPD 0.25 0.52 0.23
121 PPG 1000 BICH DEAPD 0.25 0.52 0.23
122 PPG 2000 BICH DEAPD 0.25 0.52 0.23
123 PPG 2000 MDI DMAPD 0.25 0.52 0.23
124 PPG 2000 TDI DMAPD 0.25 0.52 0.23
125 PPG 1000 TDI DMAPD 0.25 0.52 0.23
126 PPG 425 TDI DMAPD 0.25 0.52 0.23
127 PPG 1000 BICH DMAPD 0.25 0.52 0.23
128 PPG 2000 BICH DMAPD 0.25 0.52 0.23
129 PPG 425 BICH DMAPD 0.25 0.52 0.23
130 PTMG 650 TDI DMAPD 0.25 0.52 0.23
131 PTMG 1000 TDI DMAPD 0.25 0.52 0.23
132 PHNGAD 1800 BICH BD 0.25 0.52 0.23
133 PHNGAD 1800 HDI BD 0.25 0.52 0.23
134 PHNGAD 1800 MDI BD 0.25 0.52 0.23
135 PTMG 250 BICH DMAPD 0.25 0.52 0.23
136 PTMG 250 BICH DEAPD 0.25 0.52 0.23
137 PTMG 250 BICH BD 0.25 0.52 0.23
138 PTMG 250 BICH EG 0.25 0.52 0.23
139 PTMG 650 BICH EG 0.25 0.52 0.23
140 PTMG 1000 BICH EG 0.25 0.52 0.23
141 PTMG 2000 BICH EG 0.25 0.52 0.23
142 PTMG 250 BICH PG 0.25 0.52 0.23
143 PTMG 650 BICH PG 0.25 0.52 0.23
144 PTMG 1000 BICH PG 0.25 0.52 0.23
145 PTMG 2000 BICH PG 0.25 0.52 0.23
146 PTMG 250 HDI DMAPD 0.25 0.52 0.23
147 PTMG 250 HDI DEAPD 0.25 0.52 0.23
148 PTMG 250 HDI BD 0.25 0.52 0.23
149 PTMG 250 HDI EG 0.25 0.52 0.23
150 PTMG 650 HDI EG 0.25 0.52 0.23
151 PTMG 1000 HDI EG 0.25 0.52 0.23
152 PTMG 2000 HDI EG 0.25 0.52 0.23
153 PTMG 250 HDI PG 0.25 0.52 0.23
154 PTMG 650 HDI PG 0.25 0.52 0.23
156 PTMG 2000 HDI PG 0.25 0.52 0.23
157 PTMG 250 MDI DMAPD 0.25 0.52 0.23
158 PTMG 250 MDI OFHD 0.25 0.52 0.23
159 PTMG 250 MDI BD 0.25 0.52 0.23
161 PTMG 650 MDI EG 0.25 0.52 0.23
162 PTMG 1000 MDI EG 0.25 0.52 0.23
163 PTMG 2000 MDI EG 0.25 0.52 0.23
164 PTMG 250 MDI PG 0.25 0.52 0.23
165 PTMG 650 MDI PG 0.25 0.52 0.23
166 PTMG 1000 MDI PG 0.25 0.52 0.23
167 PTMG 2000 MDI PG 0.25 0.52 0.23
168 PTMG 250 BICH none 48.5 51.5 0
169 PTMG 650 BICH none 48.5 51.5 0
171 PTMG 250 HDI none 48.5 51.5 0
172 PTMG 650 HDI none 48.5 51.5 0
173 PTMG 1000 HDI none 48.5 51.5 0
174 PTMG 250 MDI none 48.5 51.5 0
175 PTMG 650 MDI none 48.5 51.5 0
176 PTMG 1000 MDI none 48.5 51.5 0
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Nature MW (Da) Monomer    (Diol)
Momomer  
(Diisocyanate)
Monomer    
(Extender)
179 PTMG 2000 HDI NMPD 0.25 0.52 0.23
181 PTMG 2000 BICH NMPD 0.25 0.52 0.23
183 PTMG 1000 MDI NMPD 0.25 0.52 0.23
184 PTMG 2000 MDI NMPD 0.25 0.52 0.23
185 PHNAD 900 MDI OFHD 0.17 0.52 0.33
185 PHNAD 900 MDI OFHD 0.17 0.52 0.33
186 PTMG 650 BICH OFHD 0.25 0.52 0.23
187 PTMG 1000 BICH OFHD 0.25 0.52 0.23
188 PTMG 2000 BICH OFHD 0.25 0.52 0.23
189 PPG 1000 BICH OFHD 0.17 0.52 0.33
190 PTMG 650 HDI OFHD 0.25 0.52 0.23
191 PTMG 1000 HDI OFHD 0.25 0.52 0.23
192 PTMG 2000 HDI OFHD 0.25 0.52 0.23
196 PTMG 2000 MDI OFHD 0.25 0.52 0.23
197 PTMG 650 BICH DHM 0.25 0.52 0.23
199 PTMG 2000 BICH DHM 0.25 0.52 0.23
201 PTMG 1000 HDI DHM 0.25 0.52 0.23
202 PTMG 2000 HDI DHM 0.25 0.52 0.23
203 PTMG 650 MDI DHM 0.25 0.52 0.23
204 PTMG 1000 MDI DHM 0.25 0.52 0.23
205 PTMG 2000 MDI DHM 0.25 0.52 0.23
206 PPG 1000 HDI OFHD 0.25 0.52 0.23
207 PPG 1000 BICH OFHD 0.25 0.52 0.23
208 PPG 1000 MDI OFHD 0.25 0.52 0.23
210 PPG 1000 BICH PG 0.25 0.52 0.23
212 PHNAD 900 HDI PG 0.25 0.52 0.23
213 PHNAD 900 BICH PG 0.25 0.52 0.23
214 PHNAD 900 MDI PG 0.25 0.52 0.23
215 PHNAD 900 HDI BD 0.25 0.52 0.23
216 PHNAD 900 BICH BD 0.25 0.52 0.23
217 PHNAD 900 MDI BD 0.25 0.52 0.23
218 PHNAD 900 HDI DMAPD 0.25 0.52 0.23
219 PHNAD 900 BICH DMAPD 0.25 0.52 0.23
220 PHNAD 900 MDI DMAPD 0.25 0.52 0.23
221 PHNAD 900 HDI OFHD 0.25 0.52 0.23
222 PHNAD 900 BICH OFHD 0.25 0.52 0.23
223 PHNAD 900 MDI OFHD 0.25 0.52 0.23
224 PHNAD 900 HDI none 48.5 51.5 0
225 PHNAD 900 BICH none 48.5 51.5 0
226 PHNAD 900 MDI none 48.5 51.5 0
227 PPG-PEG 1900 HDI none 48.5 51.5 0
228 PPG-PEG 1900 BICH none 48.5 51.5 0
229 PPG-PEG 1900 MDI none 48.5 51.5 0
230 PPG-PEG 1900 HDI BD 0.25 0.52 0.23
233 PPG-PEG 1900 HDI OFHD 0.25 0.52 0.23
234 PPG-PEG 1900 BICH OFHD 0.25 0.52 0.23
235 PPG-PEG 1900 MDI OFHD 0.25 0.52 0.23
236 PPG-PEG 1900 HDI PG 0.25 0.52 0.23
238 PPG-PEG 1900 MDI PG 0.25 0.52 0.23
239 PPG-PEG 1900 HDI DMAPD 0.25 0.52 0.23
241 PPG-PEG 1900 MDI DMAPD 0.25 0.52 0.23
242 PPG-PEG 1900 HDI EG 0.25 0.52 0.23
244 PPG-PEG 1900 MDI EG 0.25 0.52 0.23
245 PHNGAD 1800 HDI OFHD 0.25 0.52 0.23
246 PHNGAD 1800 BICH OFHD 0.25 0.52 0.23
247 PHNGAD 1800 MDI OFHD 0.25 0.52 0.23
249 PHNGAD 1800 HDI none 48.5 51.5 0
250 PHNGAD 1800 BICH none 48.5 51.5 0
252 PHNGAD 1800 HDI DHM 0.25 0.52 0.33
253 PPG-PEG 1900 MDI DMAPD 0.17 0.52 0.33
254 PHNGAD 1800 BICH BD 0.17 0.52 0.33
255 PPG-PEG 1900 MDI BD 0.17 0.52 0.33
256 PPG 425 MDI none 48.5 51.5 0
257 PTMG 1000 BICH DMAPD 0.17 0.52 0.33
259 PTMG 2000 BICH DMAPD 0.17 0.52 0.33
260 PTMG 2000 BICH OFHD 0.17 0.52 0.33
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Nature MW (Da) Monomer    (Diol)
Momomer  
(Diisocyanate)
Monomer    
(Extender)
264 PTMG 1000 HDI DMAPD 17.0 52.0 33.0
266 PPG-PEG 1900 BICH DMAPD 17.0 52.0 33.0
267 PPG-PEG 1900 BICH BD 17.0 52.0 33.0
268 PTMG 1000 MDI DMAPD 25.0 52.0 23.0
269 PPG 2000 MDI DEAPD 25.0 52.0 23.0
270 PTMG 2000 MDI DMAPD 25.0 52.0 23.0
271 PEG 400 MDI DMAPD 25.0 52.0 23.0
272 PEG 400 MDI none 58.0 42.0 0.0
273 PPG 425 MDI DMAPD 25.0 52.0 23.0
274 PPG 425 MDI none 48.5 51.5 0.0
275 PEG 400 MDI none 48.5 51.5 0.0
276 PTMG 1000 MDI OFHD 17.0 52.0 33.0
277 PTMG 2000 MDI OFHD 17.0 52.0 33.0
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Appendix II: polyacrylate libraries40  
 





Random copolymerMonomer 1 Monomer 2






Random terpolymerMonomer 1 Monomer 2








List of monomers used in the synthesis of the polyurethanes 
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Functionalisation scheme for the copolymer of GMA 
 
p(MEMA-co-GMA) : R = -C2H4-O-CH3























TMEDA DEMEDA TMPDA MnHA
 
 





















St:  styrene 
MMA:  methyl methacrylate 
MEMA: 2-methoxyethylmethacrylate 
MEA:   2-methoxyethylacrylate 
HEMA:  2-hydroxyethylmethacrylate 
HPMA: hydroxypropylmethacrylate 
HBMA: hydroxybutylmethacrylate 
EMA:  ethyl methacrylate 
BMA:  butyl methacrylate 
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NIPAAm: N-isopropylacrylamide 
A-H:  acrylic acid 
MA-H: methacrylic acid 
VAA:  N-vinylacetamide 
VP-4   4-vinylpyridine 
VP-2:  2-vinylpyridine 
DMVBA: N,N-dimethylvinylbenzylamine 
VI:  1-vinylimidazol 
VPNO: 1-vinyl-2-prrolidinone 
DMAEMA: 2-(diethylamino)ethyl methacrylate 
DMAEA: 2-(diethylamino)ethyl acrylate 
DEAEMA: 2-(diethylamino)ethyl methacrylate 
DEAEA: 2-(diethylamino)ethyl acrylate 
DMAPMAAm: N-[3-(dimethylamino)propyl]acrylamide 
MTEMA: 2-(methylthio)ethyl methacrylate 
BACOEA: 2-[[(butylamino)carbonyl]oxy]ethyl acrylate 
MNPMA: 2-methyl-2-nitropropyl methacrylate 
BAEMA: 2-(tert-butylamino)ethyl methacrylate 
DAAAm: diacetone acrylamide( N-(1,1-dimethyl-3-oxobutyl)-acrylamide ) 
AES-H: mono-2-(acryloyoxy)ethyl succinate 
AAG-H: 2-acrylamidoglycolic acid 
EGMP-H: ethylene glycol methacrylate phosphate 
GMA  glycidyl methacrylate 
 
Monomers 3: 
DEAEMA: 2-(diethylamino)ethyl methacrylate 
DEAEA: 2-(diethylamino)ethyl acrylate 
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MnHA  N-methylhexylamine 
DnBA  di-n-Butylamine 
DnHA  di-n-hexylamine 
TEDETA N,N,N',N'-tetraethyldiethylenetriamine 
MAn  N-methylaniline 
Pyrrole pyrrole 
DBnA  dibenzylamine 
BnMA  N-benzylmethylaimne 
DcHA  dicyclohexylamine 
cHMA  cycloheanemethylamine 
Mpi  1-methylpiperazine 
MAEPy 2-(2-methylaminoethyl)pyridine 
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List of polyacrylates used in the thesis with their corresponding monomers and 
monomer molecular ratio used in the synthesis 
M (1) M (2) M (3)
1 1a9 St DEAA - 90 10 -
2 1a7 St DEAA - 70 30 -
3 1a5 St DEAA - 50 50 -
4 1b9 St DMAA - 90 10 -
5 1b7 St DMAA - 70 30 -
6 1b5 St DMAA - 50 50 -
7 1c9 St PAA - 90 10 -
8 1c7 St PAA - 70 30 -
9 1c5 St PAA - 50 50 -
10 2a9 MMA DEAA - 90 10 -
11 2a7 MMA DEAA - 70 30 -
12 2a5 MMA DEAA - 50 50 -
13 2b9 MMA DMAA - 90 10 -
14 2b7 MMA DMAA - 70 30 -
15 2b5 MMA DMAA - 50 50 -
16 2c9 MMA PAA - 90 10 -
17 2c7 MMA PAA - 70 30 -
18 2c5 MMA PAA - 50 50 -
19 3a9 MEMA DEAA - 90 10 -
20 3a7 MEMA DEAA - 70 30 -
21 3a5 MEMA DEAA - 50 50 -
22 3b9 MEMA DMAA - 90 10 -
23 3b7 MEMA DMAA - 70 30 -
24 3b5 MEMA DMAA - 50 50 -
25 3c9 MEMA PAA - 90 10 -
26 3c7 MEMA PAA - 70 30 -
27 3c5 MEMA PAA - 50 50 -
28 4a9 MEA DEAA - 90 10 -
29 4a7 MEA DEAA - 70 30 -
30 4a5 MEA DEAA - 50 50 -
31 4b9 MEA DMAA - 90 10 -
32 4b7 MEA DMAA - 70 30 -
33 4b5 MEA DMAA - 50 50 -
34 4c9 MEA PAA - 90 10 -
35 4c7 MEA PAA - 70 30 -
36 4c5 MEA PAA - 50 50 -
37 5a9 HEMA DEAA - 90 10 -
38 5a7 HEMA DEAA - 70 30 -
39 5a5 HEMA DEAA - 50 50 -
40 5b9 HEMA DMAA - 90 10 -
41 5b7 HEMA DMAA - 70 30 -
42 5b5 HEMA DMAA - 50 50 -
43 5c9 HEMA PAA - 90 10 -
44 5c7 HEMA PAA - 70 30 -
45 5c5 HEMA PAA - 50 50 -
46 6a9 HPMA DEAA - 90 10 -
47 6a7 HPMA DEAA - 70 30 -
48 6a5 HPMA DEAA - 50 50 -
49 6b9 HPMA DMAA - 90 10 -
50 6b7 HPMA DMAA - 70 30 -
51 6b5 HPMA DMAA - 50 50 -
52 6c9 HPMA PAA - 90 10 -
53 6c7 HPMA PAA - 70 30 -
54 6c5 HPMA PAA - 50 50 -
55 7a9 HBMA DEAA - 90 10 -
56 7a7 HBMA DEAA - 70 30 -
57 7a5 HBMA DEAA - 50 50 -
58 7b9 HBMA DMAA - 90 10 -
59 7b7 HBMA DMAA - 70 30 -
60 7b5 HBMA DMAA - 50 50 -
61 7c9 HBMA PAA - 90 10 -
62 7c7 HBMA PAA - 70 30 -
63 7c5 HBMA PAA - 50 50 -
Monomer (3)Bradley reference Monomer (1) Monomer (2)
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M (1) M (2) M (3)
64 6a9 HPMA DEAA - 90 10 -
65 6a7 HPMA DEAA - 70 30 -
66 6a5 HPMA DEAA - 50 50 -
67 6b9 HPMA DMAA - 90 10 -
68 6b7 HPMA DMAA - 70 30 -
69 6b5 HPMA DMAA - 50 50 -
70 6c9 HPMA PAA - 90 10 -
71 6c7 HPMA PAA - 70 30 -
72 6c5 HPMA PAA - 50 50 -
73 7a9 HBMA DEAA - 90 10 -
74 7a7 HBMA DEAA - 70 30 -
75 7a5 HBMA DEAA - 50 50 -
76 7b9 HBMA DMAA - 90 10 -
77 7b7 HBMA DMAA - 70 30 -
78 7b5 HBMA DMAA - 50 50 -
79 7c9 HBMA PAA - 90 10 -
80 7c7 HBMA PAA - 70 30 -
81 7c5 HBMA PAA - 50 50 -
82 3e9 MEMA DEAEMA - 90 10 -
83 3e7 MEMA DEAEMA - 70 30 -
84 3e5 MEMA DEAEMA - 50 50 -
85 3f9 MEMA DMAEMA - 90 10 -
86 3f7 MEMA DMAEMA - 70 30 -
87 3f5 MEMA DMAEMA - 50 50 -
88 3g9 MEMA DEAEA - 90 10 -
89 3g7 MEMA DEAEA - 70 30 -
90 3g5 MEMA DEAEA - 50 50 -
91 3h9 MEMA DMAEA - 90 10 -
92 3h7 MEMA DMAEA - 70 30 -
93 3h5 MEMA DMAEA - 50 50 -
94 3i9 MEMA MTEMA - 90 10 -
95 3i7 MEMA MTEMA - 70 30 -
96 3i5 MEMA MTEMA - 50 50 -
97 3j9 MEMA BAEMA - 90 10 -
98 3j7 MEMA BAEMA - 70 30 -
99 3j5 MEMA BAEMA - 50 50 -
100 3l9 MEMA DMAPMAA - 90 10 -
101 3l7 MEMA DMAPMAA - 70 30 -
102 3l5 MEMA DMAPMAA - 50 50 -
103 3m9 MEMA BACOEA - 90 10 -
104 3m7 MEMA BACOEA - 70 30 -
105 3m5 MEMA BACOEA - 50 50 -
106 3n9 MEMA DMVBA - 90 10 -
107 3n7 MEMA DMVBA - 70 30 -
108 3n5 MEMA DMVBA - 50 50 -
109 3v9 MEMA VAA - 90 10 -
110 3v7 MEMA VAA - 70 30 -
111 3v5 MEMA VAA - 50 50 -
112 3x9 MEMA VI - 90 10 -
113 3x7 MEMA VI - 70 30 -
114 3x5 MEMA VI - 50 50 -
115 3z9 MEMA VPNO - 90 10 -
116 3z7 MEMA VPNO - 70 30 -
117 3z5 MEMA VPNO - 50 50 -
118 3AA9 MEMA VP-4 - 90 10 -
119 3AA7 MEMA VP-4 - 70 30 -
120 3AA5 MEMA VP-4 - 50 50 -
121 3AB9 MEMA VP-2 - 90 10 -
122 3AB7 MEMA VP-2 - 70 30 -
123 3AB5 MEMA VP-2 - 50 50 -
124 3AC9 MEMA DAAA - 90 10 -
125 3AC7 MEMA DAAA - 70 30 -
126 3AC5 MEMA DAAA - 50 50 -
127 3AE9 MEMA MNPMA - 90 10 -
128 3AE7 MEMA MNPMA - 70 30 -
129 3AE5 MEMA MNPMA - 50 50 -
130 3i9 MEMA MTEMA - 90 10 -
131 3i7 MEMA MTEMA - 70 30 -
Monomer (3)Bradley reference Monomer (1) Monomer (2)
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132 3i5 MEMA MTEMA - 50 50 -
133 3m9 MEMA BACOEA - 90 10 -
134 3m7 MEMA BACOEA - 70 30 -
135 3m5 MEMA BACOEA - 50 50 -
136 5e9 HEMA DEAEMA - 90 10 -
137 5e7 HEMA DEAEMA - 70 30 -
138 5e5 HEMA DEAEMA - 50 50 -
139 5f9 HEMA DMAEMA - 90 10 -
140 5f7 HEMA DMAEMA - 70 30 -
141 5f5 HEMA DMAEMA - 50 50 -
142 5g9 HEMA DEAEA - 90 10 -
143 5g7 HEMA DEAEA - 70 30 -
144 5g5 HEMA DEAEA - 50 50 -
145 5h9 HEMA DMAEA - 90 10 -
146 5h7 HEMA DMAEA - 70 30 -
147 5h5 HEMA DMAEA - 50 50 -
148 5i9 HEMA MTEMA - 90 10 -
149 5i7 HEMA MTEMA - 70 30 -
150 5i5 HEMA MTEMA - 50 50 -
151 5j9 HEMA BAEMA - 90 10 -
152 5j7 HEMA BAEMA - 70 30 -
153 5j5 HEMA BAEMA - 50 50 -
154 5l9 HEMA DMAPMAA - 90 10 -
155 5l7 HEMA DMAPMAA - 70 30 -
156 5l5 HEMA DMAPMAA - 50 50 -
157 5m9 HEMA BACOEA - 90 10 -
158 5m7 HEMA BACOEA - 70 30 -
159 5m5 HEMA BACOEA - 50 50 -
160 5n9 HEMA DMVBA - 90 10 -
161 5n7 HEMA DMVBA - 70 30 -
162 5n5 HEMA DMVBA - 50 50 -
163 5v9 HEMA VAA - 90 10 -
164 5v7 HEMA VAA - 70 30 -
165 5v5 HEMA VAA - 50 50 -
166 5x9 HEMA VI - 90 10 -
167 5x7 HEMA VI - 70 30 -
168 5x5 HEMA VI - 50 50 -
169 5z9 HEMA VPNO - 90 10 -
170 5z7 HEMA VPNO - 70 30 -
171 5z5 HEMA VPNO - 50 50 -
172 5AA9 HEMA VP-4 - 90 10 -
173 5AA7 HEMA VP-4 - 70 30 -
174 5AA5 HEMA VP-4 - 50 50 -
175 5AB9 HEMA VP-2 - 90 10 -
176 5AB7 HEMA VP-2 - 70 30 -
177 5AB5 HEMA VP-2 - 50 50 -
178 5AC9 HEMA DAAA - 90 10 -
179 5AC7 HEMA DAAA - 70 30 -
180 5AC5 HEMA DAAA - 50 50 -
181 5AE9 HEMA MNPMA - 90 10 -
182 5AE7 HEMA MNPMA - 70 30 -
183 5AE5 HEMA MNPMA - 50 50 -
184 2BA9 MMA A-H - 90 10 -
185 2BA7 MMA A-H - 70 30 -
186 2BA5 MMA A-H - 50 50 -
187 2BB9 MMA AES-H - 90 10 -
188 2BB7 MMA AES-H - 70 30 -
189 2BB5 MMA AES-H - 50 50 -
190 2BC9 MMA MA-H - 90 10 -
191 2BC7 MMA MA-H - 70 30 -
192 2BC5 MMA MA-H - 50 50 -
193 2BE9 MMA AAG-H - 90 10 -
194 2BE7 MMA AAG-H - 70 30 -
195 2BE5 MMA AAG-H - 50 50 -
196 2BG9 MMA EGMP-H - 90 10 -
197 2BG7 MMA EGMP-H - 70 30 -
198 2BG5 MMA EGMP-H - 50 50 -
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200 3BA7 MEMA A-H - 70 30 -
201 3BA5 MEMA A-H - 50 50 -
202 3BB9 MEMA AES-H - 90 10 -
203 3BB7 MEMA AES-H - 70 30 -
204 3BB5 MEMA AES-H - 50 50 -
205 3BC9 MEMA MA-H - 90 10 -
206 3BC7 MEMA MA-H - 70 30 -
207 3BC5 MEMA MA-H - 50 50 -
208 3BE9 MEMA AAG-H - 90 10 -
209 3BE7 MEMA AAG-H - 70 30 -
210 3BE5 MEMA AAG-H - 50 50 -
211 3BG9 MEMA EGMP-H - 90 10 -
212 3BG7 MEMA EGMP-H - 70 30 -
213 3BG5 MEMA EGMP-H - 50 50 -
214 2BAe7-2.0 MMA A-H DEAEMA 70 20 10
215 2BAe7-1.5 MMA A-H DEAEMA 70 15 15
216 2BAe7-1.0 MMA A-H DEAEMA 70 10 20
217 2BAg7-2.0 MMA A-H DEAEA 70 20 10
218 2BAg7-1.5 MMA A-H DEAEA 70 15 15
219 2BAg7-1.0 MMA A-H DEAEA 70 10 20
220 2BCe7-2.0 MMA MA-H DEAEMA 70 20 10
221 2BCe7-1.5 MMA MA-H DEAEMA 70 15 15
222 2BCe7-1.0 MMA MA-H DEAEMA 70 10 20
223 2BCg7-2.0 MMA MA-H DEAEA 70 20 10
224 2BCg7-1.5 MMA MA-H DEAEA 70 15 15
225 2BCg7-1.0 MMA MA-H DEAEA 70 10 20
226 3BAe7-2.0 MEMA A-H DEAEMA 70 20 10
227 3BAe7-1.5 MEMA A-H DEAEMA 70 15 15
228 3BAe7-1.0 MEMA A-H DEAEMA 70 10 20
229 3BAg7-2.0 MEMA A-H DEAEA 70 20 10
230 3BAg7-1.5 MEMA A-H DEAEA 70 15 15
231 3BAg7-1.0 MEMA A-H DEAEA 70 10 20
232 3BCe7-2.0 MEMA MA-H DEAEMA 70 20 10
233 3BCe7-1.5 MEMA MA-H DEAEMA 70 15 15
234 3BCe7-1.0 MEMA MA-H DEAEMA 70 10 20
235 3BCg7-2.0 MEMA MA-H DEAEA 70 20 10
236 3BCg7-1.5 MEMA MA-H DEAEA 70 15 15
237 3BCg7-1.0 MEMA MA-H DEAEA 70 10 20
238 3GM9 MEMA GMA - 90 10 -
239 3GM7 MEMA GMA - 70 30 -
240 3GM5 MEMA GMA - 50 50 -
241 3GA1-9 MEMA GMA DnBA 90 10 -
242 3GA1-7 MEMA GMA DnBA 70 30 -
243 3GA1-5 MEMA GMA DnBA 50 50 -
244 3GA2-9 MEMA GMA DnHA 90 10 -
245 3GA2-7 MEMA GMA DnHA 70 30 -
246 3GA2-5 MEMA GMA DnHA 50 50 -
247 3GA3-9 MEMA GMA DcHA 90 10 -
248 3GA3-7 MEMA GMA DcHA 70 30 -
249 3GA3-5 MEMA GMA DcHA 50 50 -
250 3GA4-9 MEMA GMA DBnA 90 10 -
251 3GA4-7 MEMA GMA DBnA 70 30 -
252 3GA4-5 MEMA GMA DBnA 50 50 -
253 3GA5-9 MEMA GMA MnHA 90 10 -
254 3GA5-7 MEMA GMA MnHA 70 30 -
255 3GA5-5 MEMA GMA MnHA 50 50 -
256 3GA6-9 MEMA GMA cHMA 90 10 -
257 3GA6-7 MEMA GMA cHMA 70 30 -
258 3GA6-5 MEMA GMA cHMA 50 50 -
259 3GA7-9 MEMA GMA BnMA 90 10 -
260 3GA7-7 MEMA GMA BnMA 70 30 -
261 3GA7-5 MEMA GMA BnMA 50 50 -
262 3GA8-9 MEMA GMA MAEPy 90 10 -
263 3GA8-7 MEMA GMA MAEPy 70 30 -
264 3GA8-5 MEMA GMA MAEPy 50 50 -
265 3GA9-9 MEMA GMA Pyrle 90 10 -
266 3GA9-7 MEMA GMA Pyrle 70 30 -
267 3GA9-5 MEMA GMA Pyrle 50 50 -
Monomer (3)Bradley reference Monomer (1)
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268 3GA10-9 MEMA GMA 2-MAPy 90 10 -
269 3GA10-7 MEMA GMA 2-MAPy 70 30 -
270 3GA10-5 MEMA GMA 2-MAPy 50 50 -
271 3GA11-9 MEMA GMA MAn 90 10 -
272 3GA11-7 MEMA GMA MAn 70 30 -
273 3GA11-5 MEMA GMA MAn 50 50 -
274 3GA12-9 MEMA GMA TMEDA 90 10 -
275 3GA12-7 MEMA GMA TMEDA 70 30 -
276 3GA12-5 MEMA GMA TMEDA 50 50 -
277 3GA13-9 MEMA GMA DEMEDA 90 10 -
278 3GA13-7 MEMA GMA DEMEDA 70 30 -
279 3GA13-5 MEMA GMA DEMEDA 50 50 -
280 3GA14-9 MEMA GMA TMPDA 90 10 -
281 3GA14-7 MEMA GMA TMPDA 70 30 -
282 3GA14-5 MEMA GMA TMPDA 50 50 -
283 3GA15-9 MEMA GMA Mpi 90 10 -
284 3GA15-7 MEMA GMA Mpi 70 30 -
285 3GA15-5 MEMA GMA Mpi 50 50 -
286 3GA16-9 MEMA GMA TEDETA 90 10 -
287 3GA16-7 MEMA GMA TEDETA 70 30 -
288 3GA16-5 MEMA GMA TEDETA 50 50 -
289 2GM9 MMA GMA - 90 10 -
290 2GM7 MMA GMA - 70 30 -
291 2GM5 MMA GMA - 50 50 -
292 2GA1-9 MMA GMA DnBA 90 10 -
293 2GA1-7 MMA GMA DnBA 70 30 -
294 2GA1-5 MMA GMA DnBA 50 50 -
295 2GA2-9 MMA GMA DnHA 90 10 -
296 2GA2-7 MMA GMA DnHA 70 30 -
297 2GA2-5 MMA GMA DnHA 50 50 -
298 2GA3-9 MMA GMA DcHA 90 10 -
299 2GA3-7 MMA GMA DcHA 70 30 -
300 2GA3-5 MMA GMA DcHA 50 50 -
301 2GA4-9 MMA GMA DBnA 90 10 -
302 2GA4-7 MMA GMA DBnA 70 30 -
303 2GA4-5 MMA GMA DBnA 50 50 -
304 2GA5-9 MMA GMA MnHA 90 10 -
305 2GA5-7 MMA GMA MnHA 70 30 -
306 2GA5-5 MMA GMA MnHA 50 50 -
307 2GA6-9 MMA GMA cHMA 90 10 -
308 2GA6-7 MMA GMA cHMA 70 30 -
309 2GA6-5 MMA GMA cHMA 50 50 -
310 2GA7-9 MMA GMA BnMA 90 10 -
311 2GA7-7 MMA GMA BnMA 70 30 -
312 2GA7-5 MMA GMA BnMA 50 50 -
313 2GA8-9 MMA GMA MAEPy 90 10 -
314 2GA8-7 MMA GMA MAEPy 70 30 -
315 2GA8-5 MMA GMA MAEPy 50 50 -
316 2GA9-9 MMA GMA Pyrle 90 10 -
317 2GA9-7 MMA GMA Pyrle 70 30 -
318 2GA9-5 MMA GMA Pyrle 50 50 -
319 2GA10-9 MMA GMA 2-MAPy 90 10 -
320 2GA10-7 MMA GMA 2-MAPy 70 30 -
321 2GA10-5 MMA GMA 2-MAPy 50 50 -
322 2GA11-9 MMA GMA MAn 90 10 -
323 2GA11-7 MMA GMA MAn 70 30 -
324 2GA11-5 MMA GMA MAn 50 50 -
325 2GA12-9 MMA GMA TMEDA 90 10 -
326 2GA12-7 MMA GMA TMEDA 70 30 -
327 2GA12-5 MMA GMA TMEDA 50 50 -
328 2GA13-9 MMA GMA DEMEDA 90 10 -
329 2GA13-7 MMA GMA DEMEDA 70 30 -
330 2GA13-5 MMA GMA DEMEDA 50 50 -
331 2GA14-9 MMA GMA TMPDA 90 10 -
332 2GA14-7 MMA GMA TMPDA 70 30 -
333 2GA14-5 MMA GMA TMPDA 50 50 -
334 2GA15-9 MMA GMA Mpi 90 10 -
335 2GA15-7 MMA GMA Mpi 70 30 -
Monomer (3)Bradley reference Monomer (1) Monomer (2)
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336 2GA15-5 MMA GMA Mpi 50 50 -
337 2GA16-9 MMA GMA TEDETA 90 10 -
338 2GA16-7 MMA GMA TEDETA 70 30 -
339 2GA16-5 MMA GMA TEDETA 50 50 -
340 2e9 MMA DEAEMA - 90 10 -
341 2e7 MMA DEAEMA - 70 30 -
342 2e5 MMA DEAEMA - 50 50 -
343 2f9 MMA DMAEMA - 90 10 -
344 2f7 MMA DMAEMA - 70 30 -
345 2f5 MMA DMAEMA - 50 50 -
346 2g9 MMA DEAEA - 90 10 -
347 2g7 MMA DEAEA - 70 30 -
348 2g5 MMA DEAEA - 50 50 -
349 2h9 MMA DMAEA - 90 10 -
350 2h7 MMA DMAEA - 70 30 -
351 2h5 MMA DMAEA - 50 50 -
352 6e9 HPMA DEAEMA - 90 10 -
353 6e7 HPMA DEAEMA - 70 30 -
354 6e5 HPMA DEAEMA - 50 50 -
355 6f9 HPMA DMAEMA - 90 10 -
356 6f7 HPMA DMAEMA - 70 30 -
357 6f5 HPMA DMAEMA - 50 50 -
358 6g9 HPMA DEAEA - 90 10 -
359 6g7 HPMA DEAEA - 70 30 -
360 6g5 HPMA DEAEA - 50 50 -
361 6h9 HPMA DMAEA - 90 10 -
362 6h7 HPMA DMAEA - 70 30 -
363 6h5 HPMA DMAEA - 50 50 -
364 7e9 HBMA DEAEMA - 90 10 -
365 7e7 HBMA DEAEMA - 70 30 -
366 7e5 HBMA DEAEMA - 50 50 -
367 7f9 HBMA DMAEMA - 90 10 -
368 7f7 HBMA DMAEMA - 70 30 -
369 7f5 HBMA DMAEMA - 50 50 -
370 7g9 HBMA DEAEA - 90 10 -
371 7g7 HBMA DEAEA - 70 30 -
372 7g5 HBMA DEAEA - 50 50 -
373 7h9 HBMA DMAEA - 90 10 -
374 7h7 HBMA DMAEA - 70 30 -
375 7h5 HBMA DMAEA - 50 50 -
376 8e9 EMA DEAEMA - 90 10 -
377 8e7 EMA DEAEMA - 70 30 -
378 8e5 EMA DEAEMA - 50 50 -
379 8f9 EMA DMAEMA - 90 10 -
380 8f7 EMA DMAEMA - 70 30 -
381 8f5 EMA DMAEMA - 50 50 -
382 8g9 EMA DEAEA - 90 10 -
383 8g7 EMA DEAEA - 70 30 -
384 8g5 EMA DEAEA - 50 50 -
385 8h9 EMA DMAEA - 90 10 -
386 8h7 EMA DMAEA - 70 30 -
387 8h5 EMA DMAEA - 50 50 -
388 9e9 BMA DEAEMA - 90 10 -
389 9e7 BMA DEAEMA - 70 30 -
390 9e5 BMA DEAEMA - 50 50 -
391 9f9 BMA DMAEMA - 90 10 -
392 9f7 BMA DMAEMA - 70 30 -
393 9f5 BMA DMAEMA - 50 50 -
394 9g9 BMA DEAEA - 90 10 -
395 9g7 BMA DEAEA - 70 30 -
396 9g5 BMA DEAEA - 50 50 -
397 9h9 BMA DMAEA - 90 10 -
398 9h7 BMA DMAEA - 70 30 -
399 9h5 BMA DMAEA - 50 50 -
400 PL6-1 MEMA DEAEMA MA 40 30 30
401 PL6-2 MEMA DEAEMA MA 60 10 30
402 PL6-3 MEMA DEAEMA MA 60 30 10
403 PL6-4 MEMA DEAEMA MA 80 10 10
Monomer (3)Bradley reference Monomer (1) Monomer (2)




 - 158 -
M (1) M (2) M (3)
404 PL6-5 MEMA DEAEA MA 40 30 30
405 PL6-6 MEMA DEAEA MA 60 10 30
406 PL6-7 MEMA DEAEA MA 60 30 10
407 PL6-8 MEMA DEAEA MA 80 10 10
408 PL6-9 MEMA DEAEMA BMA 40 30 30
409 PL6-10 MEMA DEAEMA BMA 60 10 30
410 PL6-11 MEMA DEAEMA BMA 60 30 10
411 PL6-12 MEMA DEAEMA BMA 80 10 10
412 PL6-13 MEMA DEAEA BMA 40 30 30
413 PL6-14 MEMA DEAEA BMA 60 10 30
414 PL6-15 MEMA DEAEA BMA 60 30 10
415 PL6-16 MEMA DEAEA BMA 80 10 10
416 PL6-17 MEMA DEAEMA MEA 40 30 30
417 PL6-18 MEMA DEAEMA MEA 60 10 30
418 PL6-19 MEMA DEAEMA MEA 60 30 10
419 PL6-20 MEMA DEAEMA MEA 80 10 10
420 PL6-21 MEMA DEAEA MEA 40 30 30
421 PL6-22 MEMA DEAEA MEA 60 10 30
422 PL6-23 MEMA DEAEA MEA 60 30 10
423 PL6-24 MEMA DEAEA MEA 80 10 10
424 PL6-25 MEMA DEAEMA DEGMEMA 40 30 30
425 PL6-26 MEMA DEAEMA DEGMEMA 60 10 30
426 PL6-27 MEMA DEAEMA DEGMEMA 60 30 10
427 PL6-28 MEMA DEAEMA DEGMEMA 80 10 10
428 PL6-29 MEMA DEAEA DEGMEMA 40 30 30
429 PL6-30 MEMA DEAEA DEGMEMA 60 10 30
430 PL6-31 MEMA DEAEA DEGMEMA 60 30 10
431 PL6-32 MEMA DEAEA DEGMEMA 80 10 10
432 PL6-33 MEMA DEAEMA THFFA 40 30 30
433 PL6-34 MEMA DEAEMA THFFA 60 10 30
434 PL6-35 MEMA DEAEMA THFFA 60 30 10
435 PL6-36 MEMA DEAEMA THFFA 80 10 10
436 PL6-37 MEMA DEAEA THFFA 40 30 30
437 PL6-38 MEMA DEAEA THFFA 60 10 30
438 PL6-39 MEMA DEAEA THFFA 60 30 10
439 PL6-40 MEMA DEAEA THFFA 80 10 10
440 PL6-41 MEMA DEAEMA THFFMA 40 30 30
441 PL6-42 MEMA DEAEMA THFFMA 60 10 30
442 PL6-43 MEMA DEAEMA THFFMA 60 30 10
443 PL6-44 MEMA DEAEMA THFFMA 80 10 10
444 PL6-45 MEMA DEAEA THFFMA 40 30 30
445 PL6-46 MEMA DEAEA THFFMA 60 10 30
446 PL6-47 MEMA DEAEA THFFMA 60 30 10
447 PL6-48 MEMA DEAEA THFFMA 80 10 10
448 PL6-49 MEMA DEAEMA HEA 40 30 30
449 PL6-50 MEMA DEAEMA HEA 60 10 30
450 PL6-51 MEMA DEAEMA HEA 60 30 10
451 PL6-52 MEMA DEAEMA HEA 80 10 10
452 PL6-53 MEMA DEAEA HEA 40 30 30
453 PL6-54 MEMA DEAEA HEA 60 10 30
454 PL6-55 MEMA DEAEA HEA 60 30 10
455 PL6-56 MEMA DEAEA HEA 80 10 10
456 PL6-57 MEMA DEAEMA HEMA 40 30 30
457 PL6-58 MEMA DEAEMA HEMA 60 10 30
458 PL6-59 MEMA DEAEMA HEMA 60 30 10
459 PL6-60 MEMA DEAEMA HEMA 80 10 10
460 PL6-61 MEMA DEAEA HEMA 40 30 30
461 PL6-62 MEMA DEAEA HEMA 60 10 30
462 PL6-63 MEMA DEAEA HEMA 60 30 10
463 PL6-64 MEMA DEAEA HEMA 80 10 10
464 PL6-65 MEMA DEAEMA A-H 40 30 30
465 PL6-66 MEMA DEAEMA A-H 60 10 30
466 PL6-67 MEMA DEAEMA A-H 60 30 10
467 PL6-68 MEMA DEAEMA A-H 80 10 10
468 PL6-69 MEMA DEAEA A-H 40 30 30
469 PL6-70 MEMA DEAEA A-H 60 10 30
470 PL6-71 MEMA DEAEA A-H 60 30 10
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472 PL6-73 MEMA DEAEMA MA-H 40 30 30
473 PL6-74 MEMA DEAEMA MA-H 60 10 30
474 PL6-75 MEMA DEAEMA MA-H 60 30 10
475 PL6-76 MEMA DEAEMA MA-H 80 10 10
476 PL6-77 MEMA DEAEA MA-H 40 30 30
477 PL6-78 MEMA DEAEA MA-H 60 10 30
478 PL6-79 MEMA DEAEA MA-H 60 30 10
479 PL6-80 MEMA DEAEA MA-H 80 10 10
480 PL6-81 MEMA DEAEMA DMAA 40 30 30
481 PL6-82 MEMA DEAEMA DMAA 60 10 30
482 PL6-83 MEMA DEAEMA DMAA 60 30 10
483 PL6-84 MEMA DEAEMA DMAA 80 10 10
484 PL6-85 MEMA DEAEA DMAA 40 30 30
485 PL6-86 MEMA DEAEA DMAA 60 10 30
486 PL6-87 MEMA DEAEA DMAA 60 30 10
487 PL6-88 MEMA DEAEA DMAA 80 10 10
488 PL6-89 MEMA DEAEMA DAAA 40 30 30
489 PL6-90 MEMA DEAEMA DAAA 60 10 30
490 PL6-91 MEMA DEAEMA DAAA 60 30 10
491 PL6-92 MEMA DEAEMA DAAA 80 10 10
492 PL6-93 MEMA DEAEA DAAA 40 30 30
493 PL6-94 MEMA DEAEA DAAA 60 10 30
494 PL6-95 MEMA DEAEA DAAA 60 30 10
495 PL6-96 MEMA DEAEA DAAA 80 10 10
496 PL6-97 MEMA DEAEMA MMA 40 30 30
497 PL6-98 MEMA DEAEMA MMA 60 10 30
498 PL6-99 MEMA DEAEMA MMA 60 30 10
499 PL6-100 MEMA DEAEMA MMA 80 10 10
500 PL6-101 MEMA DEAEA MMA 40 30 30
501 PL6-102 MEMA DEAEA MMA 60 10 30
502 PL6-103 MEMA DEAEA MMA 60 30 10
503 PL6-104 MEMA DEAEA MMA 80 10 10
504 PL6-105 MEMA DEAEMA St 40 30 30
505 PL6-106 MEMA DEAEMA St 60 10 30
506 PL6-107 MEMA DEAEMA St 60 30 10
507 PL6-108 MEMA DEAEMA St 80 10 10
508 PL6-109 MEMA DEAEA St 40 30 30
509 PL6-110 MEMA DEAEA St 60 10 30
510 PL6-111 MEMA DEAEA St 60 30 10
511 PL6-112 MEMA DEAEA St 80 10 10
512 3e8.5 MEMA DEAEMA - 85 15 -
513 3e8 MEMA DEAEMA - 80 20 -
514 3e7.5 MEMA DEAEMA - 75 25 -
515 3e7 MEMA DEAEMA - 70 30 -
516 3e6.5 MEMA DEAEMA - 65 35 -
517 3e6 MEMA DEAEMA - 60 40 -
518 3e5.5 MEMA DEAEMA - 55 45 -
519 P1 MEMA A-H DEAEMA 85 5 10
520 P2 MEMA A-H DEAEMA 80 5 15
521 P3 MEMA A-H DEAEMA 75 5 20
522 P4 MEMA A-H DEAEMA 70 5 25
523 P5 MEMA A-H DEAEMA 65 5 30
524 P6 MEMA A-H DEAEMA 60 5 35
525 P7 MEMA A-H DEAEMA 55 5 40
526 P8 MEMA A-H DEAEMA 50 5 45
527 P9 MEMA A-H DEAEMA 75 10 15
528 P10 MEMA A-H DEAEMA 70 10 20
529 P11 MEMA A-H DEAEMA 65 10 25
530 P12 MEMA A-H DEAEMA 55 10 35
531 P13 MEMA A-H DEAEMA 50 10 40
532 P14 MEMA A-H DEAEMA 65 15 20
533 P15 MEMA A-H DEAEMA 60 15 25
534 P16 MEMA A-H DEAEMA 55 15 30
535 P17 MEMA A-H DEAEMA 50 15 35
536 P18 MEMA A-H DEAEMA 55 20 25
537 P19 MEMA A-H DEAEMA 50 20 30
538 N1 MEMA A-H DEAEMA 90 5 5
539 N2 MEMA A-H DEAEMA 80 15 5
Monomer (3)Bradley reference Monomer (1) Monomer (2)




 - 160 -
M (1) M (2) M (3)
540 N3 MEMA A-H DEAEMA 70 25 5
541 N4 MEMA A-H DEAEMA 60 35 5
542 N5 MEMA A-H DEAEMA 50 45 5
543 N6 MEMA A-H DEAEMA 50 40 10
544 N7 MEMA A-H DEAEMA 60 25 15
545 N8 MEMA A-H DEAEMA 50 35 15
546 N9 MEMA A-H DEAEMA 60 20 20
547 N10 MEMA A-H DEAEMA 50 30 20
548 N11 MEMA A-H DEAEMA 50 25 25
549 Pg7 MEMA A-H DEAEA 55 5 40
550 Pg4 MEMA A-H DEAEA 70 5 25
551 Pg18 MEMA A-H DEAEA 55 20 25
552 3BAf 6 MEMA A-H DMAEMA 60 10 30
553 Pg15 MEMA A-H DEAEA 60 15 25
554 3BAh 6 MEMA A-H DMAEA 60 10 30
555 Pg3 MEMA A-H DEAEA 75 5 20
556 Pg5 MEMA A-H DEAEA 65 5 30
557 Pg1 MEMA A-H DEAEA 85 5 10
558 Pg10 MEMA A-H DEAEA 70 10 20
559 Pg11 MEMA A-H DEAEA 65 10 25
560 Pg16 MEMA A-H DEAEA 55 15 30
561 Pg8 MEMA A-H DEAEA 50 5 45
562 Pg2 MEMA A-H DEAEA 80 5 15
563 Pg14 MEMA A-H DEAEA 65 15 20
564 3BAf 7 MEMA A-H DMAEMA 70 10 20
565 Pg9 MEMA A-H DEAEA 75 10 15
566 Pg19 MEMA A-H DEAEA 50 20 30
567 Pg6 MEMA A-H DEAEA 60 5 35
568 Pg12 MEMA A-H DEAEA 55 10 35
569 3BAl 6 MEMA A-H DMAPMAA 60 10 30
570 Pg13 MEMA A-H DEAEA 50 10 40
571 Pg17 MEMA A-H DEAEA 50 15 35
572 3BAh 7 MEMA A-H DMAEA 70 10 20
573 3BAl 7 MEMA A-H DMAPMAA 70 10 20
576 P7 MEMA A-H DEAEMA 55 5 40
577 P8 MEMA A-H DEAEMA 50 5 45
523 P9 MEMA A-H DEAEMA 75 10 15
524 P10 MEMA A-H DEAEMA 70 10 20
525 P11 MEMA A-H DEAEMA 65 10 25
526 P12 MEMA A-H DEAEMA 55 10 35
527 P13 MEMA A-H DEAEMA 50 10 40
528 P14 MEMA A-H DEAEMA 65 15 20
529 P15 MEMA A-H DEAEMA 60 15 25
530 P16 MEMA A-H DEAEMA 55 15 30
531 P17 MEMA A-H DEAEMA 50 15 35
532 P18 MEMA A-H DEAEMA 55 20 25
533 P19 MEMA A-H DEAEMA 50 20 30
534 N1 MEMA A-H DEAEMA 90 5 5
535 N2 MEMA A-H DEAEMA 80 15 5
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Appendix III: PhD Activity  
A paten, oral and poster presentations and scientific literature described in this 
section were carried out by the author under the supervision of Prof. Mark Bradley 
for the University of Edinburgh between April 2006 and April 2009.  
 
Patent 
Use of polymer for cell growth (GB 0904834.9). 
 
Oral presentations 
• Bradley group meeting presentation, 7 December 2006, Edinburgh (UK). 
• Postgraduate research seminary, 27 March 2007, Edinburgh (UK). 
• Bradley group meeting presentation, 29 March 2007, Edinburgh (UK). 
• EUROCOMBI 4, 15-18 June 2007, Florence (Italy). 
• INTERNATIONAL SCHOOL OF ADVANCED BIOMEDICINE AND 
BIOINFORMATICS, 1-5 September 2008, Catania (Italy). 
• Istitute of stem cell research (ISCR), 25 September 2008, Edinburgh (UK). 
• Bradley group meeting presentation, 8 November 2008, Edinburgh (UK). 
• MATERIALS RESEARCH SOCIETY CONFERENCE, 26-30 November 
2008, Boston (USA). 
• Postgraduate research seminary, 15 January 2008, Edinburgh (UK). 
• Bradley group meeting presentation, 8 March 2008, Edinburgh (UK). 
• Postgraduate research seminary, 24 November 2008, Edinburgh (UK). 
• Advances in microarray technology, 19-20 May 2009, Stockholm (Sweden). 
 
Poster presentations 
• Firbush Postgraduate Meeting, Screening of Polymer Microarrays for 
Suspension Cell Immobilization and Gene Expression Profiling. 4-6 April 
2008, Firbush (UK). 
• 8th Would Biomaterials Congress. Polymer Microarrays - Fabrication and 
High-Throughput Screening for New Biomaterials. 28 May-1 June 2008, 
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Amsterdam (NL). 
• LabAutomation. Versatile Polymer Microarrays for Selective Cellular 
Control. 25-28 January 2009, Palm Springs, California (USA). 
• 44th Annual Meeting of the European Association for the Study of the Liver. 
A Polymer Matrix Promotes and Stabilises hESC-Derived Hepatocyte 
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